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ABSTRACT OF DISSERTATION

A MOLECULAR-LEVEL VIEW OF THE PHYSICAL STABILITY OF
AMORPHOUS SOLID DISPERSIONS

Many pharmaceutical compounds being developed in recent years are poorly
soluble in water. This has led to insufficient oral bioavailability of many compounds in
vitro. The amorphous formulation is one of the promising techniques to increase the oral
bioavailability of these poorly water-soluble compounds. However, an amorphous drug
substance is inherently unstable because it is a high energy form. In order to increase the
physical stability, the amorphous drug is often formulated with a suitable polymer to
form an amorphous solid dispersion. Previous research has suggested that the formation
of an intimately mixed drug-polymer mixture contributes to the stabilization of the
amorphous drug compound. The goal of this research is to better understand the role of
miscibility, molecular interactions and mobility on the physical stability of amorphous
solid dispersions. Methods were developed to detect different degrees of miscibility on
nanometer scale and to quantify the extent of hydrogen-bonding interactions between the
drug and the polymer. Miscibility, hydrogen-bonding interactions and molecular mobility
were correlated with physical stability during a six-month period using three model
systems. Overall, this research provides molecular-level insights into many factors that
govern the physical stability of amorphous solid dispersions which can lead to a more
effective design of stable amorphous formulations.
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Chapter 1. Introduction

1.1 Pharmaceutical Solids
Solid-state

pharmaceuticals

have

traditionally

been

the

backbone

of

pharmaceutical products since the inception of the modern pharmaceutical industry. The
first synthetic drug, chloral hydrate, a simple organic solid, was introduced in 1869 as a
sedative. The first blockbuster drug, aspirin, was launched in 1899 and is still used today.
Penicillin, first commercially produced in 1942, saved hundreds of thousands of lives
among the allied forces in WWII. All of these drugs were marketed as solid-state
pharmaceuticals. The widespread usage of solid dosage forms can be attributed to several
factors such as a longer shelf life, a lower cost of production and the ease of transport and
handling.
In recent years, however, there has been a challenge in the pharmaceutical
industry. More and more molecules being discovered nowadays belong to Class II of the
Biopharmaceutics Classification System (BCS), characterized by low aqueous solubility.
Poor solubility often leads to low oral bioavailability and inadequate efficacy. Thus, the
effort to increase oral bioavailability has been a focus of research in pharmaceutics in
recent years.
There are many different ways to potentially increase the oral bioavailability of an
active pharmaceutical ingredient, or API, in a solid dosage form, such as micronizatinon,
the use of salts or co-crystals, or the use of amorphous solid dispersions. This research is
focused on amorphous solid dispersions. The following sections introduce the concept of
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crystalline versus amorphous materials and various aspects of amorphous solid
dispersions.

1.2 Crystalline vs. Amorphous Solids
1.2.1

The Crystalline State
Crystalline solids are the most commonly-encountered solid forms for

pharmaceuticals. A crystal is a solid in which molecules are arranged in a highly ordered
fashion, with both short range and long range orders. In an organic crystal, the molecules
are held together by non-covalent interactions. Of these non-covalent forces, hydrogen
bonding is probably the most important.1

1.2.2

Polymorphism
Oftentimes, compounds of the same chemical composition can have different

crystal structures, giving rise to the phenomenon called polymorphism. Polymorphism is
defined by McCrone as the ability of any compound “to crystallize as more than one
distinct crystal species.”2 Due to the differences in molecular packing, polymorphs may
exhibit very different physical and chemical properties. Polymorphs can differ in their
solubility, density, hardness, and crystal shape.1 The most common example is carbon,
with three polymorphs (i.e. diamond, graphite, and fullerenes) all exhibiting different
properties because of their different internal structures. The most well-known example of
the importance of polymorph control in pharmaceutics is probably the incident involving
Ritonavir. This anti-HIV drug was marketed in 1996 as a semi-solid formulation. In 1998,
2

a previously unknown, thermodynamically more stable, and much less soluble crystalline
form (Form II) emerged in production.3 Due to the extremely low solubility of Form II,
the batches produced with this polymorph failed the dissolution test. The inability to
consistently produce Form I finally led to a withdrawal of the product. The drug was
subsequently reformulated into an oral solution. Thus, the control of polymorphism is
very important for pharmaceutical development to avoid changing in dissolution rate,
bioavailability and stability.
A survey of 245 organic compounds showed that 50% exhibited polymorphism.4
Regardless of the statistical number, the prevalence of polymorphism among drug
substances is very high. The often-quoted statement from McCrone says that the number
of polymorphs discovered for each compound is proportional to the time and effort spent
in research on that compound,2 which offers quite some insight on the subject.
At a given temperature and pressure, only one polymorph will have the lowest
free energy and is the most stable polymorph. All other polymorphs are referred to as the
metastable forms. Metastable forms could convert to the most stable form given enough
time or other suitable conditions. Depending on the relationship between thermodynamic
stability and temperature, two polymorphs can be classified as either being monotropic or
enantiotropic. Two polymorphs are said to be monotropic if one form is more stable than
the other form at all temperatures below the melting temperatures of each form. The two
polymorphs are enantiotropic if their relative stability is dependent on temperature.
Figure 1.1 illustrates the energy-temperature relationship of these two systems.

3

Figure 1.1. Free energy diagrams of (a) a monotropic and (b) an enantiotropic system. H
denotes enthalpy, G denotes the Gibbs free energy, and T denotes the temperature.
Subscripts I, II and L denote polymorph I, polymorph II, and the liquid phase,
respectively. Adapted from Burger and Ramberger.5
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1.2.3

The Amorphous State
The word “amorphous” is derived from the Greek term “αορφοϛ”, meaning

“shapeless”.6

Amorphous materials are highly disordered and lack the long-range

molecular order that is typical for crystalline materials. They do, however, possess the
short-range order over a few Ångstroms. The short-range order could be similar to that
found in its crystalline counterpart, such as that due to hydrogen bonding.1
The amorphous state is a thermodynamically metastable state compared to the
crystalline state. Given sufficient time, an amorphous material can transform to the
crystalline for. In fact, the amorphous state can be viewed as an extension of the liquid
phase to temperatures below the melting point of the crystalline solid phase. Figure 1.2
illustrates the thermodynamic relationship between a liquid, an amorphous and a
crystalline state. When a liquid is cooled to below its melting temperature fast enough
and the timescale does not allow adequate rearrangement of the molecules, the material
will fall out of equilibrium and become a supercooled liquid. As temperature continues to
cool and viscosity increases, the material is kinetically “frozen” to form a glass.
An amorphous material exists in the rubbery state above a temperature range
called the glass transition temperature, Tg, whereas it exists in the glassy state below Tg.
As a result of the pseudo second-order phase transition, the glass transition is directly
related to the properties of the material, such as the specific heat, enthalpy, free volume,
viscosity, etc. In the rubbery state, the amorphous material has high molecular mobility,
high free volume and low viscosity, and behaves like a liquid. In the glassy state, the
material has low molecular mobility, low free volume and high viscosity, and behaves
like a solid.
5

With the higher free energy, organic compounds in the amorphous state have
higher dissolution rates and exhibit higher apparent solubilities compared to their
crystalline counterparts. For this reason, using APIs in the amorphous state has become
an effective strategy to increase the bioavailability of BCS class II compounds. However,
to date, there are only a few amorphous formulations on the market.7 One of the major
concerns is the stability. Spontaneous crystallization from the amorphous state during
storage can greatly reduce the bioavailability and render the drug product ineffective. The
following sections of this chapter will examine the theories of crystallization from the
amorphous state and the stabilization of amorphous APIs in solid dispersions.

6

Figure 1.2. Illustration of the enthalpy relationship between the liquid, the amorphous
and the crystalline state as a function of temperature. Adapted from Hancock et al.8
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1.3 Crystallization from the Amorphous State
1.3.1

Nucleation Theory
As mentioned in the previous section, the amorphous state is intrinsically

metastable, and will crystallize given sufficient time. Similar to crystallization from
solution, crystallization from the amorphous state involves nucleation and crystal growth.
According to classical nucleation theory, the free energy change for nucleation includes
two terms, the free energy change to create a surface (ΔGS), and the free energy change
from the amorphous to the crystalline state (ΔGV).9 The relationship can be described as
follows:
4

∆𝐺𝐺 = ∆𝐺𝐺𝑆𝑆 + ∆𝐺𝐺𝑉𝑉 = 4𝜋𝜋𝑟𝑟 2 𝛾𝛾 + 3 𝜋𝜋𝑟𝑟 3 ∆𝐺𝐺𝑣𝑣

(1.1)

where r is the radius of the nucleus, γ is interfacial tension, and ΔGv is the free energy
change of the

transformation per unit volume. Since creating new surfaces is

energetically unfavorable, ΔGS bears a positive sign. On the other hand, the free energy
change from the amorphous to the crystalline state (ΔGV) is energetically favorable, and
bears a negative sign. It is easy to see that the overall free energy change of nucleation
reflects a competition between the energy penalty for creating new surfaces and the
energy gain from forming crystals. As seen in the equation, the energy penalty for
creating new surfaces is a function of r2, whereas the energy gain from crystal formation
is a function of r3. When a nucleus is formed with a very small radius, it will have a high
energy penalty and tend to be unstable. As illustrated in Figure 1.3, when the nucleus
increases to a sufficiently large size as characterized by the critical radius rc, any further
increase in the size of the crystal will reduce the overall free energy, ΔG. Under this
condition, the further increase of nucleus size becomes energetically favorable and a
8

Figure 1.3. The relationship between free energy and nucleus size. Adapted from
Mullin.9
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stable nucleus can be formed. The free energy change at this radius rc is the activation
barrier of nucleation (ΔGcrit).
The energy barrier ΔGcrit can be mathematically obtained by taking the derivative
of the free energy and setting it to zero as shown in the following expression:
𝑑𝑑∆𝐺𝐺
𝑑𝑑𝑑𝑑

= 8𝜋𝜋𝜋𝜋𝜋𝜋 + 4𝜋𝜋𝑟𝑟 2 ∆𝐺𝐺𝑣𝑣 = 0

(1.2)

Therefore,
𝑟𝑟𝑐𝑐 =

−2𝛾𝛾

(1.3)

∆𝐺𝐺𝑣𝑣

From Equation 1.1 and Equation 1.3, we get
16𝜋𝜋𝛾𝛾3

∆𝐺𝐺𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 3(∆𝐺𝐺

(1.4)

2
𝑣𝑣 )

The volume free energy is often estimated by9
∆𝐺𝐺𝑣𝑣 =

∆𝐻𝐻𝑓𝑓 (𝑇𝑇𝑚𝑚 −𝑇𝑇)

(1.5)

𝑇𝑇𝑇𝑇

assuming T is close to Tm, and the enthalpy and entropy changes are independent of
temperature and equal to ΔHf and ΔHf/Tm, respectively. From Equations 1.3, 1.4 and 1.5,
one can see that

and

𝑟𝑟𝑐𝑐 ∝ (𝑇𝑇𝑚𝑚 − 𝑇𝑇)−1

(1.6)

∆𝐺𝐺𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ∝ (𝑇𝑇𝑚𝑚 − 𝑇𝑇)−2

(1.7)
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The above expressions suggest that both the size of the critical nucleus and the
energy barrier decrease with decreasing temperature. This relationship is illustrated in
Figure 1.4.
The rate of nucleation J can be expressed in an Arrhenius form9:
𝐽𝐽 = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴(−∆𝐺𝐺𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 ⁄𝑘𝑘𝑘𝑘)

(1.8)

where A is a pre-exponential constant and k is the Boltzmann constant.
Combining Equations 1.4, 1.5 and 1.8, we can obtain the rate of nucleation in the form:
16𝜋𝜋𝛾𝛾3 𝑇𝑇𝑚𝑚 2
2
2�
𝑓𝑓 (𝑇𝑇𝑚𝑚 −𝑇𝑇)

𝐽𝐽 = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 �− 3𝑘𝑘𝑘𝑘∆𝐻𝐻

(1.9)

Equation 1.9 seems to suggest that the rate of nucleation should increase
indefinitely as the degree of supercooling increases and the temperature decreases from
Tm. Experiments, however, often find that the nucleation rate reaches a maximum as the
supercooling increases and further increases in supercooling cause the rate to decrease.
This behavior was postulated to be caused by the sharp increase in viscosity in the
vicinity of the glass transition temperature.9 Thus the nucleation rate was modified to
include a “viscosity” term in the following expression:
16𝜋𝜋𝛾𝛾3 𝑇𝑇𝑚𝑚 2
2
2
𝑓𝑓 (𝑇𝑇𝑚𝑚 −𝑇𝑇)

𝐽𝐽 = 𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 �− 3𝑘𝑘𝑘𝑘∆𝐻𝐻

+

∆𝐺𝐺′
𝑘𝑘𝑘𝑘

�

(1.10)

where ΔG’ describes the activation energy for molecular motion within the matrix. As
can be seen from the above expression, nucleation reflects a balance between the
thermodynamic driving force and the kinetic motion, where each is favored by different
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temperature regimes. The optimum temperature for nucleation is typically somewhere
above the glass transition temperature.10
The classical nucleation theory describes the process of homogeneous nucleation,
which assumes that there are no foreign particles in the system. In reality, this is rarely
the case. In fact, it is generally accepted that homogenous nucleation is not a common
event.9 Most of the time, heterogeneous nucleation is what is observed in practice. In
heterogeneous nucleation, the activation energy is reduced due to the reduction of
interfacial energy, which depends on the affinity between the crystalline phase and the
foreign solid. The higher the affinity between the two solid phases, the lower the
activation energy. Figure 1.5 shows the schematic of the free energy versus nucleus size
for heterogeneous nucleation in comparison to homogeneous nucleation. In solution,
atmospheric dust or walls of the container often provide the surface of heterogeneous
nucleation. In the case of crystallization from the amorphous state, cracks in the glass can
serve as sites for nucleation. A substantial increase in nucleation rate was observed in
amorphous RS ibuprofen when cracks were intentionally produced in the glassy state.11
The authors pointed out that the crack formation in the glassy state was able to promote
heterogeneous nucleation in a temperature regime (i.e. lower than glass transition
temperature) in which it was difficult to achieve homogeneous nucleation due to the slow
mobility.11
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Figure 1.4. Effects of temperature on the size and free energy of forming a critical
nucleus. Adapted from Mullin.9
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Figure 1.5. Comparison between the homogeneous nucleation and the heterogeneous
nucleation. The free energy for heterogeneous nucleation is substantially lower than that
for homogeneous nucleation. Adapted from Ragone.12
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1.3.2

Crystal Growth Theory
Once stable nuclei are formed, they start growing into crystals. Similar to

nucleation, crystal growth is also governed by two competing mechanisms. At low
degrees of supercooling, the growth rate increases with supercooling as the free energy
difference increases. At high degrees of supercooling, the growth rate decreases with
supercooling as the mobility in the system decreases. The maximum growth rate is
situated in between the glass transition temperature and the melting temperature, and is
typically much higher than the temperature where the maximum rate of nucleation is
found.13 Figure 1.5 shows the schematic of the temperature dependence of these two
processes.
A different mode of fast crystal growth in the glassy state was first noticed by
Greet and Turnbull.14 O-terphenyl crystals were found to grow three to four orders of
magnitude faster than what was expected from the calculations of viscosity near the glass
transition temperature.14 This fast growth phenomenon was studied by Oguni and
coworkers15, 16 and later by Lian Yu’s research group.17-20 The sudden activation of this
growth mode near the glass transition temperature is not limited by molecular diffusion in
the bulk liquid and is termed glass-crystal (GC) growth. Not all organic compounds, and
sometimes not all polymorphs of a given molecular compound are subjected to GC
growth. Sun et al. studied seven polymorphs of 5-methyl-2-[(2-nitrophenyl)amino]-3thiophenecarbonitrile (ROY) and observed four polymorphs showing the fast growth
mode.18 The polymorphs exhibiting the fast growth mode showed changing morphologies
with temperature, from faceted crystals at high temperature, to fiber-like crystals near Tg,
and to compact spherulites in the fast growth mode.18 The polymorphs exhibiting fast
15

growth mode also had higher densities and more isotropic crystal packing, which
suggests that the fast growth may occur if there are sufficient similarities in crystalline
packing between the liquid and the crystalline state.21 Current evidence seems to suggest
that this type of growth mode stems from the solid-state transformations enabled from
local molecular motions native to the glassy state.18
Besides the fast crystal growth in certain organic glasses, a different type of
crystallization at the surface was observed and studied by Yu and coworkers.

22-24

The

crystal growth of indomethacin at the surface was observed to be orders of magnitude
faster than the growth in the bulk.22 In the case of nifedipine, which exhibited the fast
growth mode in the glass, the surface growth rate is even faster than the fast growth mode
in the bulk.23 This type of fast surface growth is postulated to be related to the much
faster surface diffusion compared to that in the bulk21, 25 and high surface mobility.20, 24

16

Figure 1.5. Temperature dependence of nucleation and crystal growth. Adapted from
Gutzow.10
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1.3.3

Factors Influencing the Tendency to Crystallize
As described before, the crystallization process strongly depends on temperature

because both nucleation and crystal growth are temperature dependent events. This
temperature dependency is often coupled with the temperature dependence of molecular
mobility. It is generally accepted that mass transport is one of the most critical factors in
nucleation and growth from the amorphous state.26 Most organic compounds crystallize
at a much faster rate above the glass transition temperature than below the glass transition
temperature, due to the restricted molecular mobility below Tg.
It has been observed that different compounds have shown different
crystallization behaviors, some of which cannot be fully explained by molecular mobility
alone.26 Zhou et al. studied five pharmaceutical compounds and found that the
crystallization tendencies of acetaminophen, sucrose, fenofibrate, ABT-229 and ritonavir
are related to both molecular mobility and configurational entropy.26 Configurational
entropy describes the spatial disposition of particles, rather than the quantum states of
them. Qualitatively, the higher the configurational entropy for a system, the more
orientations the molecules can assume, and the harder it is for them to pack into a specific
crystalline form. The cited work showed that molecules with lower configurational
entropies require less mobility for spontaneous crystallization. Since configurational
entropy is inversely related to the probability that molecules will have the proper
orientation and conformation for crystal formation and the mobility is related to the
number of molecular collisions in a given period of time, both quantities are equally
important to the physical stability of amorphous compounds.26
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1.4 Amorphous Solid Dispersions to Increase Physical Stability
1.4.1

Glass Transition Temperature and Mobility
As discussed earlier in this chapter, the amorphous state is a thermodynamically

meta-stable state and is prone to crystallization. Thus, effective ways to increase the
physical stability and prevent crystallization from occurring are crucial in making
amorphous drugs viable for the market. Most commonly, the amorphous API is mixed
with a suitable polymer to form an amorphous solid dispersion. Typically, the polymer
has a high glass transition temperature and would have an antiplasticization effect on the
drug compound. For an ideally mixed binary mixture, the glass transition temperature can
be estimated by the Gordon-Taylor equation:27
𝑇𝑇𝑔𝑔 =

𝑤𝑤1 𝑇𝑇𝑔𝑔1 +𝑘𝑘𝑘𝑘2 𝑇𝑇𝑔𝑔2

(1.11)

𝑤𝑤1 +𝑘𝑘𝑘𝑘2

where w1 and w2 are the weight fractions of each component, and Tg1 and Tg2 are the glass
transition temperatures of each component. The value k can be estimated as follows,
𝜌𝜌1 𝑇𝑇𝑔𝑔1

𝑘𝑘 ≈ 𝜌𝜌

(1.12)

2 𝑇𝑇𝑔𝑔2

where ρ1 and ρ2 are the densities of each component. If there are very strong interactions
between the drug and polymer, there will be a positive deviation from the predicted Tg
values. Conversely, if the drug and polymer interaction is less than that their self
interactions, there will be a negative deviation from the predicted values.
As implied earlier, an amorphous solid dispersion usually has a higher glass
transition temperature than the drug compound by itself. The increase in the glass
transition temperature of the amorphous system can often result in the amorphous system
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being in the glassy state at room temperature. This effectively reduces the molecular
mobility of the system and the crystallization rate.

1.4.2

Miscibility of Drug and Polymer
To form a more stable amorphous solid dispersion, the amorphous drug and

polymer have to be intimately mixed. Partial miscibility can lead to phase separation of
the system, where drug rich regions exist and could be sites for crystallization. One of the
most common methods to determine whether the drug and polymer are miscible is by
measuring the glass transition temperature of the mixture using differential scanning
calorimetry (DSC). A miscible system is characterized by a single glass transition
temperature intermediate to those of the API and polymer, as opposed to two separate
glass transition temperatures in a phase-separated system. However, it has been
recognized that a single Tg is not an infallible indicator of miscibility.28, 29 Thus, there is a
need to development better understandings and methods to measure phase homogeneity
of these amorphous solid dispersions.

1.4.3

Specific Interactions
Besides molecular mobility, specific interactions between the drug and polymer

play an important role in stabilizing amorphous drugs. Hydrogen bonding is one of the
most important drug-polymer specific interactions in creating stable amorphous solid
dispersions. It has been observed that the stabilization of amorphous indomethacin by
polymers cannot be attributed to the antiplasticizing effect (increase of Tg) alone, and is
20

likely to be related to the ability of the drug to hydrogen bond to the polymer.30, 31 An
example by Khougaz and Clas showed delayed onset of crystallization of MK-0951 in
dispersions with PVP, even in dispersions where the Tg values were lower than that of the
drug by itself.32 The authors ascribed the stabilization effect to ion-dipole interactions
between COO−Na+ of the drug and the cyclic amide group of PVP. Despite the
importance, most of the studies of specific interactions such as hydrogen bonding
interactions are qualitative. Quantitative information pertaining to hydrogen bonding
interactions in amorphous systems has been lacking, mainly due to the limitations of
infrared (IR) or Raman spectroscopy.

1.4.4

Effect of Water
It has been well established that water absorbed by an amorphous solid will act as

a plasticizer and lower the Tg.33 Consequently, sorbed water has been observed to
increase the crystallization rate of amorphous compounds, presumably due to the increase
of molecular mobility.34 The role of water has also been investigated in amorphous solid
dispersions of a hydrophobic drug and a hydrophilic polymer.35, 36 In these studies, water
was thought to form a “cosolvent” with the hydrophilic polymer and decrease the
solubility of the drug in the “cosolvent” system, leading to phase separation. However, it
was noted that some drug-polymer systems remained in one phase even at high relative
humidity, while others phase separated.36 Stronger hydrogen bonding interactions
between the drug and polymer were found in systems that remained in one phase after the
water absorption. The favorable interactions between the drug and polymer were thought
to reduce the mixing enthalpy and help to keep the dispersions in one phase. A caveat of
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this study was that the conclusion was based upon the detection of hydrogen bonding
between the drug and the polymer after the water was removed from the samples. Thus, it
would be interesting to see how sorbed water affects the miscibility of amorphous solid
dispersions in the “as is” condition and, how the physical stability is affected by sorbed
water.

1.5 Overview of Research
This chapter has provided some background on pharmaceutical solids, the reason
to employ amorphous solid as a formulation strategy, and the challenges associated with
it. Some of the issues and gaps in the current literature are identified, including the need
for better measurements of drug-polymer miscibility and quantitative information on
hydrogen bonding interactions in amorphous solid dispersions. Chapter 2 highlights the
fundamentals of solid-state NMR (SSNMR) spectroscopy, with an emphasis on the
experiments and techniques that are pertinent to the study of amorphous systems. Chapter
3 develops a method to determine the miscibility of amorphous solid dispersions using
nifedipine as a model compound and PVP as a polymer. The method employs SSNMR
relaxation time measurements and allows the detection of phase homogeneity on the
order of a few nanometers. In Chapter 4, hydrogen bonding interactions in amorphous
indomethacin and its amorphous solid dispersions are discussed, which involved the
identification and quantitation of various hydrogen bonding species. Chapter 5 focuses on
how molecular mobility and dynamics change in amorphous solid dispersions as a
function of temperature. Dynamics of amorphous systems are examined by twodimensional (2D) exchange NMR spectroscopy. Chapter 6 describes physical stability
22

studies of three different amorphous solid dispersions with varying hydrogen bonding
capabilities under different relative humidity conditions. Correlations with miscibility and
the strength of hydrogen bonding are attempted to explain the differences observed in
crystallization behaviors.

Copyright © Xiaoda Yuan 2015
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Chapter 2. Solid-State NMR Spectroscopy of Pharmaceuticals

2.1 Introduction
Nuclear magnetic resonance was first independently observed in 1945 by Purcell
and others at Harvard and Bloch and others at Stanford.37, 38 For this discovery, the two
were jointly awarded the Nobel Prize for physics in 1952. Since then, solution NMR
spectroscopy has developed into one of the most powerful techniques for the structural
elucidation of organic molecules. In recent years, solid-state NMR spectroscopy has
become a powerful technique in solid-state characterization, and is finding more and
more applications in the analysis of pharmaceuticals. However, there are a few challenges
in producing high-resolution solid-state NMR (SSNMR) spectra due to the unique
characteristics of solids. Many of the challenges have been overcome through techniques
such as magic-angle spinning (MAS), cross polarization and high power 1H decoupling.
This chapter provides an overview of the basic theory of SSNMR spectroscopy and its
applications to the analysis of amorphous pharmaceuticals. For a comprehensive review
of SSNMR theory and its applications to pharmaceuticals, the reader is directed to other
sources.39-41

2.2 Basics of NMR Spectroscopy
The phenomenon of NMR has to do with the nuclei of atoms. All nuclei have a
nuclear spin quantum number I, which takes the values of 0, ½, 1, 3/2, etc. with the units
of h/2π, where h is the Planck’s constant. Nuclei such as 12C and 16O have a spin quantum
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number of zero and are not NMR active. Any nuclei with a non-zero spin quantum
number possesses angular momentum and will generate a magnetic field, which is called
the magnetic moment, μ, as given by Equation 2.1,
𝛾𝛾𝛾𝛾ℎ

𝜇𝜇 =

(2.1)

2𝜋𝜋

where γ is the gyromagnetic ratio, a constant for the particular nucleus.
When nuclei with magnetic moments are placed in an outside magnetic field (B0),
the magnetic moments will orient themselves to certain quantum mechanical states. For a
spin ½ nucleus, such as 1H or 13C, there are two possible orientations, one aligned with (α
state) and one against (β state) the static magnetic field B0, with the β state being the
higher energy state. The population ratio of the two states is governed by the Boltzmann
distribution,
𝑁𝑁𝛽𝛽
𝑁𝑁𝛼𝛼

= 𝑒𝑒 −∆𝐸𝐸/𝑘𝑘𝐵𝐵 𝑇𝑇

(2.2)

where kB is the Boltzmann constant and T is the temperature. ΔE is the energy difference
between the two states and is given by
∆𝐸𝐸 =

𝛾𝛾ℎ𝐵𝐵0

(2.3)

2𝜋𝜋

Since ΔE=hv, resonance can be achieved when the following condition is met,
𝜈𝜈 =

𝛾𝛾𝐵𝐵0

(2.4)

2𝜋𝜋

where ν is the resonance frequency and is often referred to as the Larmor frequency. The
NMR signal originates from the population difference of the two spin states. Calculating
from the above equations, the population difference for 1H nuclei in 7.1 Tesla magnetic
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field is only on the order of 1 in 105. This is the reason why NMR has low sensitivity
compared to IR and UV spectroscopy. We can also easily see from Equations 2.2 and 2.3
that the NMR signal can be boosted at lower temperatures or with higher magnetic fields.
NMR spectroscopy uses a radio frequency (RF) pulse to excite the nuclei of
interest and detect the signal, or free induction decay (FID), when the spins come back to
equilibrium. When placed in a magnetic field B0, electrons circulate and generate an
induced magnetic field in the opposite direction of B0. Thus the effective field
experienced by the nucleus is affected by the local electronic environment. This causes
different nuclei to resonate at slightly different frequencies. Despite changes on the order
of parts per million (ppm), this difference is detectable and is the basis of the NMR
chemical shift.

2.3 Solid-state NMR Spectroscopy
2.3.1

Chemical Shift Anisotropy and Magic Angle Spinning
For a nucleus with a non-spherical electron density, the magnetic field it

experiences will vary with its orientation with respect to the static magnetic field.42 This
is not a problem in solution NMR because the rapid tumbling of the molecules in solution
averages out the effect and the chemical shift is an isotropic value. In solids, however,
molecules are generally not free to move in space and the different orientations that
molecules reside in with respect to the static field result in a distribution of chemical
shifts, known as the chemical shift anisotropy (CSA). This orientation dependence of
chemical shift can be described in terms of the chemical shielding tensor, σ, the
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directionality component of the chemical shift anisotropy. σ can be written in terms of
two components, the isotropic component and the anisotropic component, as in Equation
2.5.
𝜎𝜎 = 𝜎𝜎𝑖𝑖𝑖𝑖𝑖𝑖 + (3𝑐𝑐𝑐𝑐𝑐𝑐 2 𝜃𝜃 − 1)𝜎𝜎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎

(2.5)

As can be seen from the equation, the anisotropic component includes a term
( 3𝑐𝑐𝑐𝑐𝑐𝑐 2 𝜃𝜃 − 1). The anisotropic component can be effectively eliminated if the sample is
spun at an angle θ such that ( 3𝑐𝑐𝑐𝑐𝑐𝑐 2 𝜃𝜃 − 1) = 0. This angle is 54.75° with respect to the

static field, and is called the magic angle.43

If the sample is spun at a rate less than the width of CSA, spinning side bands will
occur at intervals equal to the spinning speed. When high speed is not feasible with some
spinning systems, one remedy is to use a pulse sequence called total suppression of
spinning sideband (TOSS) to eliminate the spinning sidebands.44

2.3.2

Dipolar Coupling and High-power Proton Decoupling
Dipolar coupling is the through-space interaction between the magnetic moments

of two nuclei. This spin interaction is analogous to the interaction of two bar magnets.
1

H-1H homonuclear coupling is much stronger in solids than in liquids, due to the lack of

molecular tumbling in solids. This makes the 1H spectrum of a compound in the solid
state very broad, and generally the spectrum yields little useful information. For this
reason,

13

C is the more commonly detected nucleus for solid-state NMR. Since the

natural abundance of
homonuclear

13

13

C only accounts for about 1.1% of the carbon isotopes,

C-13C coupling is very weak in unlabeled samples due to the low
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probability of two 13C nuclei being spatially close to each other. However, heteronuclear
1

H-13C coupling is still a significant interaction in solids. This interaction is removed by

applying a high decoupling field at the 1H Larmor frequency to rapidly flip the 1H spins
between the α and the β states so that the dipolar interaction is averaged to zero.

2.3.3

Low Sensitivity and Cross Polarization
Since the 13C isotope only accounts for about 1.1% of naturally occurring carbon

isotopes, most of the carbon nuclei in a sample do not yield any NMR signal, which leads
to extremely low sensitivity of

13

C NMR spectra. To mitigate this problem, a technique

called cross polarization (CP) is often implemented.45 In a CP experiment, bulk
magnetization is transferred from the abundant spins (1H) to the dilute spins (13C) and
results in an approximately four-fold signal enhancement. This enhancement ratio is
related to the gyromagnetic ratios of the two spins by a relation of γH/γX, which is
approximately 4/1 for 1H/13C. Another benefit of the CP experiment is that the relaxation
time for the spins to come back to equilibrium before the next acquisition is governed by
the 1H relaxation time instead of

13

C. Since

13

C nuclei have notoriously long relaxation

times compared to 1H nuclei, this technique allows for significantly more acquisitions in
a given period, greatly enhancing the signal to noise ratio and decreasing the amount of
time needed for a high-quality 13C spectrum.

28

2.4 Solid-state NMR Techniques for Amorphous Solid Dispersions
2.4.1

Miscibility and 1H Relaxation Times
Among the various techniques in SSNMR spectroscopy to study amorphous solid

dispersions, relaxation time measurements are one of the most useful techniques and is
also very easy to implement. Generally, the relaxation process in SSNMR describes the
restoration of spins to equilibrium after a perturbation by an RF pulse. The relaxation
process described by the spin-lattice relaxation time T1 or the spin-lattice relaxation time
in the rotating frame T1ρ is achieved through interactions between the spins and their
surroundings. The RF timing and acquisition sequences, which are called pulse sequences,
for measuring 1H T1 and 1H 1ρ used in this work are shown in Figure 2.1
Due to strong dipolar coupling of 1H spins and spin diffusion in the solid state, the
spin-lattice relaxation times of all the 1H spins in the same molecule are usually the same.
The 1H spin-lattice relaxation times of a mixture, on the other hand, are dependent on the
degree of mixing and the spin diffusion length scale. If the length scale of mixing is
shorter than the length scale of spin diffusion, then the magnetization transfer from the
slower to the faster relaxing component is very efficient, and the relaxation times of both
components are equal to the weighted average of the values of the individual component.
If the length scale of mixing is longer than the length scale of spin diffusion, the
relaxation times are those of the individual components. In the case of partial mixing of
the components, the relaxation process may exhibit more complex, multidimensional
decay.46
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Figure 2.1. Solid-state NMR pulse sequences of (a) 1H T1 and (b) 1H T1ρ with
detection. The 1H T1 pulse sequence utilizes the saturation recovery method.

30

13

C

The length scale of spin diffusion L is dependent on the relaxation time t and spin
diffusion coefficient D, and is given by
〈𝐿𝐿〉 = √6𝐷𝐷𝐷𝐷

(2.6)

Commonly D is assumed to be 10-12 cm2/s for organic molecules.46 For a typical 1H T1
value of 5 s, the length scale of the spin diffusion is approximately 50 nm. For a typical
1

H T1ρ value of 50 ms, the length scale of the spin diffusion is approximately 5 nm.
Based on the principal of 1H spin diffusion, 1H T1 and 1H T1ρ relaxation time

measurements can be used to determine the miscibility of an amorphous solid
dispersion.47 Depending on the miscibility and domain size, the following three scenarios
can be differentiated for an amorphous solid dispersion: 1) If the API and the polymer in
a dispersion are miscible on the order of ca. 5 nm (domain size smaller than 5 nm),
common 1H T1ρ and 1H T1 values would be obtained from the API and polymer; 2) If the
components in a dispersion are miscible on the order of 50 nm but not on the order of 5
nm (i.e. the domain size is between ca. 5 nm and 50 nm), the 1H T1ρ values will be
different for each component but the 1H T1 will still be the same; 3) If the components in
a dispersion are not miscible on the order of 50 nm (domain size larger than ca. 50 nm),
both 1H T1ρ and 1H T1 values will be different for each component.
The 1H T1 and 1H T1ρ relaxation time measurements for amorphous solid
dispersions are very important because of the unique ability to probe miscibility on a
small scale. When miscibility is determined by differential scanning calorimetry (DSC),
the detection limit is usually assumed to be 30 nm.48-50 Nano-scale phase separation
smaller than 30 nm can not be distinguished by DSC, but can be distinguished by
SSNMR 1H T1 relaxation measurements.
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2.4.2

Molecular Mobility and Dynamics

2.4.2.1 Variable-Temperature (VT) Relaxation Time Measurement
SSNMR relaxation times can be used to detect motional processes occurring over
a very broad timescale, depending on the nuclei being studied and the types of relaxation
times being measured. 1H relaxation times provide “global” information on molecular
motion, as the strong 1H spin dipolar interactions result in all of the protons having a
common relaxation time.39 On the contrary, relaxation times of

13

C provide the “local”

information since 13C nuclei are sparse and are thus relatively unaffected by homonuclear
dipolar interactions. In this dissertation work, the majority of relaxation times measured
were on 1H nuclei.
The spin-lattice relaxation T1 is sensitive to motions in the MHz region and
usually detects faster motions such as methyl group rotations.42 The rotating frame spinlattice relaxation time T1ρ is sensitive to motions in the kHz region and detects slower
motions such as intermolecular interactions and phase structure. Lubach et al. measured
the 1H T1 relaxation time of crystalline lactose before and after processing.51 Crystalline
lactose α-monohydrate had a 1H T1 relaxation time of 243 s, while compaction reduced
the relaxation time to 79 s with little change in the spectrum. The reduction of 1H T1
relaxation time is an indication of higher mobility resulted from increasing high-energy
sites (crystal defects).
Molecular mobility is affected by temperature and SSNMR relaxation times can
be studied as a function of temperature. Figure 2.2 shows the 1H T1ρ relaxation times of
nifedipine (NIF) and PVP in a 50-50 NIF-PVP amorphous solid dispersion.47 There are
slight decreases in the relaxation times of both compounds as temperature increases from
32

room temperature. As the temperature continues to increase, the decreases in relaxation
times become pronounced. The decrease in relaxation time indicates an increase in
molecular mobility. The large increase of 1H T1ρ relaxation time at temperatures above 60
°C suggests a higher degree of mobility near the glass transition temperature range. This
example highlights the potential of using SSNMR relaxation time to probe molecular
mobility of pharmaceutical solids.
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Figure 2.2. 1H T1ρ relaxation times of nifedipine (NIF) and PVP in the 50-50 NIF-PVP
amorphous solid dispersion as a function of temperature. The error bar indicates 95%
confidence interval of the fit. Adapted from reference. 47

34

2.4.2.2 Two-Dimensional Exchange NMR
Besides relaxation time measurements, two-dimensional (2D) exchange NMR is
another powerful technique for the study of mobility and dynamics, especially for slow
molecular motions. Chemical exchange refers to the dynamic process during which the
magnetization is exposed to two different chemical environments during a specified
period of time.
The basic form of any 2D experiment includes four stages: preparation, evolution,
mixing and detection. The pulse sequence of a 2D 13C exchange experiment is shown in
Figure 2.3. During the preparation stage, transverse magnetization of

13

C is created by

cross polarization. The magnetization is then allowed to evolve under its characteristic
frequency ω1 during t1. This characteristic frequency arises from the nuclear spin
interaction during t1. At the end of t1, the magnetization is restored to the z direction by a
90° pulse on

13

C. During the mixing time, molecules may change orientations or

experience different environments. Last, the magnetization is returned to the observable
transverse plane by another 90° pulse and evolves under the frequency ω2. This evolution
is recorded as a FID during t2. 52
By repeating the experiment for successive values of t1, we can obtain a twodimensional dataset, which, after processing, correlates changes of the molecular
environment during the mixing time. If a change in the molecular environment has
occurred during the mixing time, the frequency after the mixing time ω2 will be different
from the initial frequency ω1 and the 2D spectrum will contain an off-diagonal intensity
at (ω1, ω2). If there is no change in the molecular environment, ω2 will remain the same
as ω1, and the intensity will lie on the diagonal. Since the analysis relies on there being no
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molecular motions during the t1 and t2 periods, the exchange experiment is only suitable
for studying slow molecular motions (approximately 10 ms – 5 s), where tmix >> t1, t2. 52
Figure 2.4 is an illustration of a processed 2D exchange spectrum. The offdiagonal peaks AB and BA suggest that the molecular environment has changed during
the mixing time. The lack of off-diagonal peaks of frequency C suggests that this
frequency has no change in the molecular environment during the mixing time.
2D exchange NMR can be used in combination with the variable temperature
technique to probe molecular dynamics at different temperatures. Chapter 6 will provide
some examples of using this approach to study molecular dynamics of amorphous solid
dispersions.
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Figure 2.3. Pulse sequence of the

13

C 2D exchange experiment to study molecular

motions. The four stages of a 2D experiment are labeled underneath.
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Figure 2.4. Illustration of a processed

13

C 2D exchange spectrum. Frequency A and B

has exchange between each other while frequency C has no exchange with either A or B.

38

2.5 Quantitation
NMR spectroscopy is an inherently quantitative technique, as the amount of
signal observed is directly proportional to the number of nuclei resonating at a given
frequency. There are a number of examples in the literature wherein solid-state NMR has
been used in quantitation. Gao quantified binary mixtures of delavirdine mesylate
crystalline forms using

13

C CPMAS.53 Offerdahl and others successfully quantified

different forms of neotame including the amorphous forms.54 However, a number of
factors have to be considered before a quantitative analysis can be achieved from a
SSNMR spectrum. The considerations mainly involve cross polarization in the solid state,
T1 relaxation and the total sideband suppression (TOSS) sequence prevalently used in
SSNMR.

2.5.1

Cross Polarization Dynamics
Cross polarization (CP) is a widely used technique in SSNMR spectroscopy to

increase the sensitivity of 13C signals. As discussed in a previous section, a rare nucleus
such as 13C has very low sensitivity due to its low natural abundance and long relaxation
time. During a CP process, magnetization is transferred from an abundant spin (1H) to a
rare spin (13C), offering a four-fold increase in sensitivity and fast relaxation time.45
However, the transfer of magnetization generally does not occur at a uniform rate for
each carbon and thus the signal is no longer directly proportional to the number of each
nucleus. So it is generally assumed that the spectra collected with CP are not quantitative
54

.
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The CP transfer process is determined by two rate constants, TCH and T1ρH. The
former determines the rate of increase in the

13

C magnetization, while the latter

determines the rate of decay. The CP dynamic is described in Equation 2.7.

𝐼𝐼(𝜏𝜏) =
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(2.7)

where I(τ) is the intensity or peak area at each contact time τ, M0 is the thermal
equilibrium value of

13

C magnetization, and γH/γC is the gyromagnetic ratio between 1H

and 13C which takes the value of 4.
Figure 2.5 shows the CP dynamics of two forms of naltrexone. The crystalline
form shows slower buildup and longer decay compared to the amorphous form. From
Equation 2.7 one can see that the signal intensity difference between the two forms can
be written as,
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(2.8)

where FA/B is the intensity ratio between the two forms (A=crystalline and B=amorphous)
and all the other parameters are defined the same as in Equation 2.7. For a chosen contact
time of 2 ms, FA/B is calculated to be 1.179. Thus, this value can be used to account for
the signal differences resulted from the CP dynamics of the two forms.
Sometimes, if the species to be quantified come from the same form of a same
molecule, TCH and T1ρH can easily be assumed to be the same for all the species. This is
the case in quantifying the hydrogen-bonding interactions of amorphous indomethacin
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(Chapter 4). The species to be quantified is the carboxylic acid carbon of amorphous
indomethacin in different hydrogen-bonded states. Since all the species to be compared
come from the amorphous form of indomethacin, the CP dynamics can be safely assumed
to be very similar in the analysis.
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Figure 2.5. Evolution of peak area as a function of contact time of a naltrexone
crystalline solvate form and the amorphous form. Carbon 11 is the chosen carbon to be
analyzed. The lines are fitted to Equation 2.7.
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2.5.2

T1 Relaxation Time
In theory, to acquire a quantitative spectrum, signal saturation should be avoided.

Saturation occurs when spins are not allowed enough time to fully relax to equilibrium.
This relaxation process is T1 relaxation. Typically, a pulse delay of at least five times the
T1 of the slowest relaxing species of interest is needed to allow all species to reach
equilibrium. For direct polarization of

13

C, this could mean minutes and even hours of

relaxation delay between each RF pulse, which is usually not feasible. Luckily, with the
CP experiment, the T1 relaxation time of 13C is no longer relevant. The 1H T1 relaxation
(T1H) is the governing relaxation mechanism. Since T1H is typically on the order of
seconds to minutes, the experimental time is greatly reduced for quantitation.
Sometimes, if the species to be quantified have the same T1H, then it is not
necessary to wait five times T1H because the species of interests can not be discriminated
on the basis of their relaxation behavior. A pulse delay of 1.5-2 times of T1H can be
chosen to maximize the signal to noise ratio. The T1H used in Chapter 4 was chosen based
on this idea.

2.5.3

Effect of Sidebands
Magic angle spinning (MAS) is an essential component in modern SSNMR

spectroscopy. In order to get rid of the chemical shift anisotropy and obtain isotropic
chemical shifts, MAS is utilized to split the powder pattern into a series of peaks
separated by spinning speed. When MAS speed is sufficiently high, spinning sidebands
can be eliminated. However, the typical spinning speed of 4 kHz for a 7.5 mm rotor is not
high enough to eliminate all the sidebands, and TOSS44 is often utilized to suppress these
43

sidebands for a cleaner spectrum. If we are only concerned qualitatively about the signal
of a nucleus, the isotropic chemical shift has enough information; if we are concerned
quantitatively about a nucleus, the spinning sidebands also contain a certain portion of the
total signal. When the sidebands are artificially suppressed, this portion of the signal is
lost. The distribution of SSNMR signal in the center band (i.e. isotropic peak) and
sidebands is influenced by the local environment of each nucleus. Therefore, different
nuclei can lead to differences in how much of the total signal resides in the center bands.
Thus, it is sometimes useful to not only compare the center bands but also the center
bands to total signal ratio when performing quantitative analyses. Luckily, in many cases,
the difference of the center band to total signal ratio is negligible among different species
when the spectrum was acquired with a high spinning speed.

Copyright © Xiaoda Yuan 2015
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Chapter 3. Miscibility of Amorphous Solid Dispersions 1
3.1 Introduction
Formulation of oral solid dosage forms using the amorphous form of the active
pharmaceutical ingredient (API) is a strategy used to enhance the oral bioavailability of
poorly water-soluble compounds, as the amorphous API has higher apparent solubility
and faster dissolution rate than its crystalline counterpart.8,

55

However, amorphous

materials possess higher free energies and have the risk of converting to the crystalline
state, which is thermodynamically more stable. To overcome physical instability, a
polymer can be mixed with the amorphous API to form an amorphous solid dispersion,
which has been shown to significantly delay the onset of crystallization.30, 56, 57 The two
main processes that are commonly used to commercially prepare amorphous solid
dispersions are spray drying and hot-melt extrusion. These two methods use different
approaches to prepare stable amorphous dispersions and are most closely mimicked on a
laboratory scale using a mini spray dryer or a melt-quenching approach.
There have been extensive discussions in the literature about the mechanisms of
physical stabilization, including reduction in the thermodynamic driving force towards
crystallization, increase in crystallization energy barrier, disruption/formation of
molecular interactions, and combinations of these factors.58 Regardless of the specific
mechanism, it is generally agreed that molecular-level miscibility is necessary to achieve
maximum stabilization.59,

60

Immiscibility between the drug and polymer has been

reported to have led to increased crystallization rates of amorphous drugs.61, 62 Herein, the
This chapter is adapted with permission from Yuan, X.; Sperger, D.; Munson, E. J. Investigating
miscibility and molecular mobility of nifedipine-PVP amorphous solid dispersions using solidstate NMR spectroscopy Mol. Pharmaceutics 2014, 11, 329– 337. Copyright 2013 American
Chemical Society.
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term miscibility describes a single-phase amorphous system in which the API is
supersaturated in the polymer and the components are intimately mixed at the molecular
level. The API is not necessarily at its equilibrium solubility in the polymer.62
Currently, the most common method to determine whether the API and polymer
are miscible is by measuring the glass transition temperature (Tg) of the mixture using
differential scanning calorimetry (DSC). A miscible system is characterized by a single
glass transition temperature intermediate between those of the API and polymer, as
opposed to two separate glass transition temperatures in a phase-separated system.
However, it has been reported in the literature that it is possible to observe a single Tg in
a phase-separated system

28, 29

and vice versa.63 In addition, Raman mapping has been

used to access phase homogeneity of amorphous solid dispersions.29 The method,
however, is limited by the low spatial resolution as the step size is typically on the micron
scale. Thus, a mixture that appears to be homogeneous using one technique may be found
heterogeneous using another technique with a finer detection limit. For example, when Tg
is used to assess miscibility, a detection limit of about 20 to 30 nm is generally assumed
and domain sizes smaller than that are indistinguishable by DSC.48-50 Thus, a method to
accurately measure the miscibility between the API and polymer at smaller domain sizes
is of great importance to advance our understanding of drug-polymer mixing.
There are many examples in the literature of polymer blends where the length
scale of polymer mixing can be measured via solid-state NMR (SSNMR) 1H T1 and T1ρ
relaxation times.64, 65 If the polymer chains are closer to each other than the length scale
of proton spin diffusion, magnetization transfer from the slower to the faster relaxing
chains is very effective, and the relaxation times of both chains are equal to a weighted

46

average of the values of the individual chains.46 The length scale of spin diffusion L is
given by
〈𝐿𝐿〉 = √6𝐷𝐷𝐷𝐷

(3.1)

where D is the spin diffusion coefficient and t is the relaxation time. Typically, D is
assumed to be 10-12 cm2/s.46, 66 For a typical spin-lattice relaxation time T1 value between
1 and 5 s, the length scale of spin diffusion corresponds to ca. 20 to 50 nm. For a typical
T1ρ value between 5 and 50 ms, the length scale corresponds to ca. 2 to 5 nm. Depending
on the domain size, the following three scenarios can be expected: 1) If the domain size is
smaller than 2-5 nm, a common 1H T1ρ and T1 values should be obtained from the API
and polymer; 2) If the domain size is between the 5 nm and 20 nm range, the T1ρ values
will be different for API and polymer but the T1 will still be the same; 3) If the domain
size is larger than 20-50 nm, both T1ρ and T1 values will be different for API and
polymer.
In recent years, SSNMR has been used to study miscibility of drug and polymer
in amorphous solid dispersions. Aso and coworkers studied miscibility of nifedipine and
PVP using 1H NMR relaxation measurements and found that all three tested compositions
(3:7, 5:5 and 7:3 by weight) were miscible based on the free induction decay (FID)
pattern of T1ρ measurements
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Vogt and coworkers studied several amorphous solid

dispersion systems using 2D SSNMR heteronuclear correlation (HETCOR) experiments
and demonstrated the feasibility of using SSNMR techniques to detect phase separation
and molecular interactions in amorphous solid dispersions.67 Very recently, Van den
Mooter and coworkers studied a hot melt-extruded miconazole and PEG-g-PVA mixture
and found that miconazole (10 wt%) was molecularly dispersed in PEG-g-PVA with an
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average cluster size of 1.6 nm.68 However, in-depth research on miscibility of drugs and
polymers across a large composition range is still lacking and is the focus of this study.
Nifedipine, a dihydropyridine calcium channel blocker is often used as a model
compound to study the stability of amorphous drugs.69, 70 Polyvinylpyrrolidone (PVP), a
common pharmaceutical excipient has been used to form amorphous solid dispersions
with nifedipine.66, 71, 72 It has been reported that nifedipine and PVP formed molecular
level dispersions based on the detection of hydrogen bonding between the drug and the
polymer.72 In this study, we used

13

C SSNMR to evaluate the miscibility of nifedipine-

PVP amorphous solid dispersions of different compositions. The effect of different
preparation methods on miscibility was also investigated.

3.2 Materials and Matheods
3.2.1

Materials
Nifedipine (NIF, minimum purity 98.0 %) was purchased from TCI America

(Portland, OR) and was protected from light whenever possible. Poly(vinylpyrrolidone),
(PVP, Kollidon 25, Mw=28-34 kg/mole) was obtained from BASF (Edison, NJ). PVP was
vacuum dried at 70 °C over night and stored over DrieriteTM at all times. The chemical
structures of nifedipine and PVP are shown in Figure 3.1.

3.2.2

Preparation of Amorphous Nifedipine
Amorphous nifedipine was prepared by melting the drug in a Teflon beaker in an

oven at 180 °C for 10 minutes. The melt was then quench-cooled on a piece of cold metal
block. The resulting sample was lightly ground in a mortar and pestle.
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Figure 3.1. Chemical structures of (a) nifedipine and (b) PVP.

3.2.3

Preparation of Physical Mixture
A physical mixture of amorphous nifedipine (prepared by melt quenching as

described above) and PVP was prepared at a 50:50 ratio (w:w) by mixing in a Turbula
Shaker-Mixer (Glen Mills Inc, Clifton, NJ) at 49 rpm for 30 minutes.

3.2.4

Preparation of Amorphous Solid Dispersions
Amorphous solid dispersions of nifedipine and PVP were prepared in three

different ways: melt quenching in the lab setting, spray drying, and melt quenching in an
NMR rotor while spinning. Amorphous dispersions at ratios of 95:5, 90:10, 75:25, 60:40
and 50:50 nifedipine:PVP (w:w) were prepared by melt quenching in the lab setting. To
prepare the amorphous dispersions via this method, mixtures of drug and polymer were
ball milled for 10 minutes to obtain optimum mixing. The ball-milled mixtures were then
transferred into an oven and heated at 180 °C for 30 minutes. The melted mixtures were
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then quench-cooled on a piece of cold metal block to solidify. The solid dispersions were
vacuum dried at room temperature over night to minimize residual moisture. All solid
dispersions were confirmed amorphous by polarized light microscopy. No chemical
degradation of nifedipine was observed by 1H NMR in solutions of DMSO-d6.
A 90:10 (w:w) nifedipine:PVP amorphous dispersion was prepared by melt
quenching in an NMR rotor while spinning. To prepare amorphous dispersions via this
method, an appropriate mixture of drug and polymer was ball milled for 10 minutes to
obtain optimum mixing. The ball-milled mixture was then transferred into a 7.5 mm
zirconia NMR rotor with Teflon end caps. The rotor was heated in the NMR probe
equipped with a variable-temperature accessory stack (Varian, Palo Alto, CA) at 180 °C
for 30 minutes while spinning at 4000 Hz. The rotor was then rapidly cooled to room
temperature, resulting in the amorphous dispersion.
A 90:10 (w:w) nifedipine:PVP amorphous dispersion was also prepared by spray
drying using a Büchi Mini Spray Dryer B-290 (Büchi, Switzerland) equipped with a 0.7
mm nozzle. Compressed nitrogen gas was used for atomization at a flow rate of 10
L/min. The drug and polymer were dissolved in methanol to form a solution with a total
solid concentration of 13 mg/mL. The feed rate was set at 22.5 mL/min. The inlet
temperature was set at 120 °C and the corresponding outlet temperature was 49 °C. All
amorphous dispersions were stored in glass vials over DrieriteTM in the freezer when not
being analyzed.

50

3.2.5

Modulated DSC
The glass transition temperature (Tg) of nifedipine–PVP solid dispersions was

determined by modulated DSC (MDSC) using a Q2000 differential scanning calorimeter
equipped with an RCS90 refrigerated cooling system (TA Instruments, Newcastle, DE).
Nitrogen gas was used as the purge gas at a flow rate of 50 mL/min. Temperature and
enthalpy were calibrated using indium. Samples (2-5 mg) prepared by melt quenching as
described

above

were

placed

in

TZero™aluminum

pans

and

sealed

with

TZero™aluminum hermetic lids with one pinhole (TA Instruments, New Castle, DE).
Samples were equilibrated at 0°C, and then heated at 1°C/min to 200°C with an
amplitude of ±0.5 °C and a modulation period of 60 s. The glass transition was separated
into the reversing heat flow signal and was determined by half height at midpoint using
the Universal Analysis software (TA Instruments, Newcastle, DE).

3.2.6

Solid-State NMR 1H T1 and T1ρ Relaxation Measurements
All solid-state NMR spectra were acquired using a Tecmag Redstone HF3 2RX

spectrometer (Tecmag, Inc., Houston, TX) operating at 75.48 MHz for 13C (7 Tesla static
magnetic field). Samples were packed into 7.5 mm zirconia rotors and sealed with Teflon
or Kel-F end caps (Revolution NMR, LLC, Fort Collins, CO). Experiments were
performed using a 7.5 mm double-resonance MAS probe (Varian, Palo Alto, CA). All
13

C spectra were acquired under magic angle spinning (MAS) 43 at 4 kHz, using ramped-

amplitude CP,45 total sideband suppression (TOSS) 44 and SPINAL64 decoupling 73 with
a 1H decoupling field of about 62 kHz. A 2 ms contact time was used in all experiments.
3-Methylglutaric acid was used to optimize spectrometer settings and as an external
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standard, with the methyl peak referenced to 18.84 ppm.74 All experiments were
conducted at room temperature if not otherwise specified.
1

through

H T1 relaxation values were measured using the saturation-recovery experiment
13

C observation. The reason to observe

13

C is to provide information on the

relaxation behavior of the protons that belong to each of the individual compounds. A 90°
pulse width of about 4 µs was used in the experiment. In the Fourier-transformed
spectrum, the peak of interest was integrated and plotted against recovery delay times and
the values were fitted to the following equation using GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA)
𝑀𝑀 = 𝑀𝑀0 ∙ (1 − 𝑒𝑒

−

𝜏𝜏
𝑇𝑇1

)

(3.2)

where M is the integrated signal intensity and τ is the recovery delay time. M0 is an
amplitude parameter obtained from the fit and T1 is the obtained spin-lattice relaxation
time.
1

H T1ρ relaxation times were measured by varying the spin-lock duration time

following a 90° pulse. A recycle delay of about 1.5 – 2 times the measured T1 was used
to maximize the signal to noise ratio. A frequency field of about 65 KHz was used for the
spin-lock field. The peak of interest was integrated and plotted against the spin-lock
duration times and the values were fitted to the following equation using GraphPad Prism
(GraphPad Software, Inc., La Jolla, CA)
𝑀𝑀 = 𝑀𝑀0 ∙ 𝑒𝑒

−

𝜏𝜏
𝑇𝑇1𝜌𝜌

(3.3)

where M is the integrated signal intensity and τ is the spin-lock duration time. M0 is an
amplitude parameter obtained from the fit and T1ρ is the obtained spin-lattice relaxation
time in the rotating frame.
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3.3 Results
3.3.1

Modulated DSC
Figure 3.2a shows the MDSC thermograms of NIF, PVP and five compositions of

NIF:PVP amorphous solid dispersions (95:5, 90:10, 75:25, 60:40, 50:50) made by melt
quenching in the lab setting. Only the reversing heat flow is plotted to show the glass
transition event. NIF showed a Tg at 42 °C and a recrystallization event at 78 °C,
followed by melting at 172 °C. The 95:5 and 90:10 dispersions showed similar thermal
events, with Tg, recrystallization and melting all being observed. The thermogram of the
75:25 dispersion was different from the previous three thermograms in that there was no
observable change in the heat capacity above Tg. A small melting peak was observed at
168 °C. The 60:40 and 50:50 dispersions showed no change of heat capacity or melting
peaks above Tg. All five compositions showed single Tg values which was in agreement
with previous reports.72

Figure 3.2b shows the MDSC reversing signal of 90:10

NIF:PVP (w:w) dispersions prepared by all three methods (spray drying, melt quenching
in the NMR rotor during spinning, and melt quenching in the lab). A single Tg was
observed in all three samples and the thermal events were consistent with each other. As
expected, two separate Tg events were observed for the 50:50 NIF:PVP physical mixture,
corresponding to the respective glass transition temperatures of the drug and the polymer
(data not shown).
The Gordon-Taylor equation can be used to estimate the Tg of an ideal binary
mixture,27
𝑇𝑇𝑔𝑔 =

𝑤𝑤1 𝑇𝑇𝑔𝑔1 +𝑘𝑘𝑘𝑘2 𝑇𝑇𝑔𝑔2
𝑤𝑤1 +𝑘𝑘𝑘𝑘2

(3.4)
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where w1 and w2 are the weight fractions of each component, and Tg1 and Tg2 are the
glass transition temperatures of each component. The value k can be estimated by
Equation 3.5,
𝜌𝜌1 𝑇𝑇𝑔𝑔1

𝑘𝑘 ≈ 𝜌𝜌

(3.5)

2 𝑇𝑇𝑔𝑔2

where ρ1 and ρ2 are the densities of each component. The predicted Tg values are plotted
with the experimental Tg values in Figure 3.3. Also shown in Figure 3.3 are the Tg values
obtained by two other preparation methods at the 90:10 NIF:PVP (w:w) ratio. As shown
in the figure, the experimental Tg values agree reasonably well with the Gordon-Taylor
prediction. The small deviation may be due to the presence of a small amount of water or
less than ideal mixing between the two components.
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Figure 3.2. MDSC of (a) NIF, PVP and NIF:PVP amorphous solid dispersions of various
weight ratios and (b) 90:10 NIF:PVP amorphous solid dispersions prepared by three
different methods. The Tg values represent the half-height midpoint values.
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Figure 3.3. Glass transition temperatures of NIF:PVP amorphous solid dispersions. The
circles represent the samples made by melt quenching in the lab setting; the triangle
represents the sample made by melt quenching in the NMR rotor; the cross represents the
sample made by spray drying; the dashed line represents the prediction from the GordonTaylor equation. All experimental Tg values are half-height midpoint Tg values.
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3.3.2

Solid-State 13C NMR of Nifedipine
C CPMAS NMR spectra of two crystalline forms, α and β, and the amorphous

13

form of nifedipine are shown in Figure 3.4. The spectrum of the α form shows narrow
peaks (∆ν1/2 = 28 Hz). There is one peak for each carbon indicating there is one molecule
in each asymmetric unit in the crystalline structure. The peaks between 144 and 150 ppm
showed splitting due to coupling to

14

N. The peaks have been previously assigned by

Apperley et al.75 The spectrum of the β form showed two peaks for most carbons,
indicating there are two molecules in an asymmetric crystalline unit. This agrees with the
crystalline structure of β nifedipine recently solved by Yu and co-workers.76 The line
width of β nifedipine was larger than α (∆ν1/2 ~ 60 Hz). Amorphous nifedipine had much
broader peaks than both crystalline forms (∆ν1/2 ~ 215 Hz). The broader lines are the
result of a wide range of molecular conformations that exist in the amorphous state.
Amorphous nifedipine crystallizes to the β form at temperatures below 42 °C.76 The β
form shown in Figure 4b was obtained by storing the sample over DrieriteTM at 40 °C for
four days. However, a minute amount of α form was also present, indicated by the
shoulders around 19.7 and 170.5 ppm. For all three spectra, the crystalline peaks
overlapped to a large degree with the amorphous peaks, making the identification of
crystalline and amorphous fractions difficult.
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Figure 3.4. 13C SSNMR spectra of (a) α crystalline nifedipine, (b) β crystalline nifedipine
and (c) amorphous nifedipine.
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3.3.3

Miscibility by SSNMR of Samples Prepared by Melt quenching in the Lab
Setting
The 1H T1 and T1ρ relaxation times of the α and β forms of crystalline nifedipine

and amorphous nifedipine are shown in Table 3.1. As seen in the table, the α form had
the longest T1 and T1ρ relaxation times. The β form had shorter relaxation times than the α
form, while the amorphous form had the shortest relaxation times of all the nifedipine
samples. SSNMR relaxation times are usually a reflection of mobility in the solid state
and are generally influenced by structural rigidity, the number of existing ‘relaxation
sinks’ (i.e. methyl or ethyl groups), and the presence of moisture.77,

78

Since both

crystalline forms of nifedipine are packed into crystal lattices with fixed structures, they
are much more rigid than the amorphous form, which can adopt a range of molecular
conformations. As a result, amorphous nifedipine exhibited the shortest relaxation times,
as expected. Among the two crystalline forms of nifedipine, the α form has been shown
to be the stable polymorph,76, 79 which in this case coincided with the relaxation time
measurements.
Also shown in Table 3.1 are the relaxation times of the two components present in
the 50:50 NIF:PVP physical mixture in the amorphous state. As evident in the table,
nifedipine had different relaxation times than PVP in both 1H T1 and T1ρ measurements.
The relaxation times of nifedipine and PVP in the physical mixture were similar to the
values measured in their pure forms. These results showed that the physical mixture of
nifedipine and PVP was not homogeneous on the molecular level.
Because the relaxation times are very sensitive to small changes in water content,
the differences in the relaxation times between nifedipine and PVP were compared, rather
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than their absolute values. Ideally, relaxation time is a weighted arithmetic mean of the
two components in a miscible system. However, water is known to decrease the
relaxation time if present in a system.78
13

C SSNMR spectra of NIF-PVP amorphous solid dispersions prepared by melt

quenching in the lab setting are shown in Figure 3.5. All the spectra had broad peaks,
consistent with the amorphous nature of the samples. For pure amorphous nifedipine (or
PVP), a single proton relaxation time (T1 and T1ρ) was observed regardless of the
resonances used for the integration, as expected due to rapid proton spin diffusion in the
solid state. Thus, any peak from one component that does not overlap with peaks from
the other component can be used to calculate the relaxation times of the component of
interest in the solid dispersion. Thus, the peaks around 175 and 43 ppm were chosen to
calculate the relaxation times of PVP because there was no interference from nifedipine
peaks in the same region. Likewise, the peaks at approximately 167, 148 and 103 ppm
were chosen for nifedipine because they do not overlap with peaks from PVP.
The 1H T1 and T1ρ relaxation times of nifedipine and PVP in the amorphous solid
dispersions prepared by melt quenching in the lab setting are shown in Table 3.2, and the
differences of the relaxation times between nifedipine and PVP are plotted in Figure 3.6.
There were no obvious differences in 1H T1 values between nifedipine and PVP in the
amorphous solid dispersions except for the 95:5 NIF:PVP composition. As shown in
Figure 3.6a, no obvious trend could be seen in the plot of 1H T1 differentials. The similar
1

H T1 relaxation times indicated that nifedipine and PVP were miscible on the 20-50 nm

length scale. This was consistent with modulated DSC measurements that showed single
Tg values for these samples, since DSC generally assumes a distinguishable domain size
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of 30 nm.28 The 95:5 and 90:10 NIF:PVP compositions were on the borderline of being
miscible as the confidence intervals did not or barely touched the zero horizontal line. It
is interesting that the 95:5 and 90:10 compositions were the two that showed the large
recrystallization peaks in the DSC.
1

H T1ρ relaxation times, on the other hand, were different for the drug and

polymer for the 95:5 and 90:10 compositions. There was also a clear trend of decreasing
differentials with increasing PVP content, as shown in Figure 3.6b. The 1H T1ρ relaxation
times indicated that the compositions with 25%, 40% and 50% PVP were miscible on the
2-5 nm length scale. The combination of 1H T1 and 1H T1ρ relaxation times indicated that
the two compositions with higher drug loadings were immiscible on the 2-5 nm length
scale and might be borderline miscible on the 20-50 nm length scale. The three
compositions with lower drug loadings were miscible on the 2-5 nm length scale. The
biggest domain size was estimated to be 4.5 nm for those three miscible compositions
using Equation 3.1 with a 1H T1ρ value of 35 ms. D was assumed to be 10-12 cm2/s.46
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Figure 3.5.

13

C SSNMR spectra of NIF-PVP amorphous solid dispersions prepared by

melt quenching in the lab setting containing 0, 5, 10, 25, 40, 50 and 100% PVP (from top
to bottom).
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Figure 3.6. (a) 1H T1 and (b) T1ρ differential between nifedipine and PVP in the
amorphous solid dispersions prepared by melt quenching in the lab setting as a function
of PVP content. The error bars represent 95% confidence intervals associated with the
fit. Dashed lines represent the zero value.

63

Table 3.1. 1H T1 and T1ρ relaxation times of different forms of NIF, PVP and the 50:50
NIF:PVP physical mixture (PM). The numbers in parentheses indicate the standard errors
associated with the fits.
Nifedipine
α

β

Amorphous

H T1

32.4

13.0

4.2

(s)

(0.5)

(0.4)

H T1ρ

287

(ms)

(6)

1

1

50:50 NIF:PVP PM
PVP
NIF

PVP

2.1

3.6

2.1

(0.1)

(0.04)

(0.07)

(0.04)

190

79.3

27.3

88

16.0

(6)

(0.1)

(0.3)

(3.5)

(0.4)

Table 3.2. Comparison of the measured 1H T1 and T1ρ values for NIF:PVP amorphous
solid dispersions made by melt quenching in the lab setting. The numbers in parentheses
indicate the standard errors associated with the fits.
NIF:PVP Amorphous Solid Dispersions

1

1

95:5

90:10

75:25

60:40

50:50

Nifedipine

4.4 (0.03)

4.4 (0.05)

4.3 (0.2)

4.0 (0.08)

3.7 (0.2)

PVP

3.8 (0.2)

4.0 (0.2)

4.2 (0.2)

4.0 (0.09)

3.6 (0.2)

Nifedipine

94 (2.0)

65 (1.6)

80 (3.1)

42 (0.7)

37 (0.8)

PVP

77 (3.1)

52 (2.3)

73 (1.9)

41 (1.5)

34 (1.2)

H T1 (s)

H T1ρ (ms)
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3.3.4

Miscibility by SSNMR of Samples Prepared by Other Methods
1

H T1 and T1ρ values were also obtained for the 90:10 NIF:PVP amorphous solid

dispersions prepared by two other methods: spray drying, and melt quenching in the
NMR rotor while spinning. The results are shown in Table 3.3. The 1H T1ρ values
suggested that the dispersions made by spray drying and melt quenching in the NMR
rotor during spinning were miscible while the dispersion made by simple melt quenching
in the lab setting was not. The 1H T1ρ values of the dispersion made by melt quenching in
the NMR rotor were large compared to the values of the other two dispersions. This is
due to the dryness of the sample prepared in this method as the sample was heated to high
temperatures while being subjected to a dry environment due to the spinning gas
(dewpoint of -40 ° C). Likewise, the short relaxation times observed for the spray-dried
sample were attributed to residual solvent acting as relaxation sinks which led to short
relaxation times.
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Table 3.3. Comparison of the measured 1H T1 and T1ρ values for 90:10 NIF:PVP
amorphous solid dispersions made by melt quenching in the lab setting (MQ), spray
drying (SD) and melt quenching in the NMR rotor while spinning (MIR). The numbers in
parentheses indicate the standard errors associated with fits.
90:10 NIF:PVP Amorphous Solid Dispersions

1

1

H T1 (s)

H T1ρ (ms)

MQ

SD

MIR

Nifedipine

4.4 (0.05)

3.4 (0.07)

4.5 (0.06)

PVP

4.0 (0.2)

3.4 (0.2)

4.3 (0.1)

Nifedipine

65 (1.6)

34 (0.3)

123 (5.4)

PVP

52 (2.3)

31 (1.6)

123 (5.4)

3.4 Discussion
3.4.1

Miscibility of Nifedipine and PVP
Taylor and co-workers reported that spin-coated films of nifedipine and PVP can

form molecular level dispersions over all compositions based on IR detection of drugpolymer hydrogen bonding involving the nifedipine NH moiety.72 Taylor and coworkers
have also calculated the interaction parameter (χ) between nifedipine and PVP (K12) to
be -3.8 using a melting point depression method.59 The fairly large negative value
indicated mixing was favored; however, the result obtained through this method only
applied to temperatures close to the melting temperature of the drug. This has apparently
limited its practical usage, as storage temperatures are typically much lower than the
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melting point of the drug and the phase behavior of the drug-polymer mixture could be
different at different temperatures.
Hydrogen bonding between nifedipine and PVP has also been studied by Aso and
Yoshioka using 13C NMR spin-lattice (T1) relaxation times.71 It was found that the T1 of
both PVP (carbonyl carbon) and nifedipine (dihydropyridine ring carbon adjacent to
nitrogen) increased in the solid dispersion compared to the polymer or drug alone. The
result suggested reduced motions of these functional groups, which were ascribed to
hydrogen bonding between the PVP carbonyl and nifedipine NH. Interestingly, the
increase of T1 for nifedipine carbons plateaued at about 40% (w:w) PVP, coinciding with
the level of PVP necessary to make miscible dispersions in the present work. It was also
found that the chemical shift of PVP carbonyl carbon increased by about 1 ppm as the
drug content increased,71 which is usually an indication of hydrogen bond formation. In
the present SSNMR spectra, we also observed about a 1 ppm downfield chemical shift
change of the carbonyl carbon of PVP between neat PVP (175.1 ppm) and the dispersion
with up to 95% nifedipine (175.9 ppm) (Table 3.4). The similar chemical shift change
observed in this study indicates that the extent of hydrogen bonding interactions in these
dispersion samples was similar to the samples prepared by Aso and Yoshioka, which in
turn suggests that the existence of hydrogen bonds alone was not enough to demonstrate
complete miscibility. It is likely that in the high drug content dispersions, some
population of the drug was hydrogen bonded with PVP, thus being molecularly dispersed,
while the rest of the drug formed small clusters of roughly 5-20 nm in size.
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Table 3.4. Chemical shift of the carbonyl carbon of PVP in various NIF:PVP amorphous
solid dispersions of different compositions.
NIF:PVP Dispersion

ppm

Neat PVP

175.1

50:50

175.4

60:40

175.6

75:25

175.7

90:10

175.8

95:5

175.9

Hydrogen bonding at the nifedipine NH was also probed using

15

N solid-state

NMR CPMAS. However, no significant change in chemical shift was found among
crystalline NIF, amorphous NIF and the dispersions. It has been reported in the case of
acetaminophen-PVP amorphous dispersions that

14

N SSNMR showed differences in

chemical shift between neat drug and dispersions, while

15

N SSNMR did not show any

difference in chemical shift.80 This finding suggests that
sensitive to hydrogen bonding interactions than

15

14

N chemical shift is more

N in some cases and that same

15

N

chemical shifts may be the same for different hydrogen bonding interactions. Since 14N is
a quadrupolar nucleus with complicated lineshapes, we are currently exploring the
feasibility of performing 14N SSNMR on these systems.
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3.4.2

Effect of Preparation Methods on Miscibility
In this study the main focus was to investigate the melt-quench mixtures prepared

as might be done in a laboratory setting. Because the melting point of crystalline
nifedipine was 173 °C and the Tg of PVP was around 160 °C, it was determined that
heating a ball milled mixture of crystalline nifedipine and PVP to 180 °C for 30 minutes
would result in a uniformly mixed melt. Because PVP was still very viscous at 180 °C,
the concern at higher PVP concentrations was that the drug would not adequately diffuse
into PVP, and so a low limit of 50% drug was used for this study.
It was found in this study that 95:5 and 90:10 NIF:PVP dispersions prepared by
melt quenching in the lab setting were not intimately mixed at the molecular level.
However, 90:10 NIF:PVP dispersions prepared by the other two methods, spray drying
and melt quenching in the NMR rotor during spinning, produced miscible systems as
indicated by the common 1H T1ρ relaxation times. The DSC thermograms of both
dispersions showed recrystallization peaks between 100-115 °C, similar to the
recrystallization behavior of the 90:10 dispersion made by melt quenching in the lab
setting.
It is known that preparation methods affect the crystallization tendency of
amorphous state materials. Strachan and coworkers compared amorphous indomethacin
prepared by melt quenching, spray drying, ball-milling and cryo-milling and found
differences in the recrystallization rates among the samples.81 Our study demonstrated
that on a molecular level, the ability to form a miscible amorphous solid dispersion
depended on the preparation method. It is likely that the 90:10 solid dispersion made by
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melt quenching in the lab setting will phase separate and thus crystallize over time faster
than the other two dispersions of the same composition but prepared differently.

3.5 Conclusions
NIF and PVP amorphous solid dispersions prepared by three different methods
were studied using SSNMR 1H relaxation time measurements. The 95:5 and 90:10
NIF:PVP dispersions prepared by melt quenching in the typical lab setting were found to
be immiscible on the molecular level. Contrary to previous reports that NIF and PVP can
form miscible solid dispersions at all compositions, only the 75:25, 60:40 and 50:50
dispersions were shown to be homogeneous with a domain size of about 4.5 nm using the
above-mentioned preparation method. 90:10 NIF:PVP amorphous dispersions prepared
by spray drying and melt quenching in the NMR rotor with spinning appeared to be
miscible by relaxation measurements. These results demonstrated that different
preparation methods could lead to amorphous systems with different phase
homogeneities undetected by common techniques such as DSC.

Copyright © Xiaoda Yuan 2015
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Chapter 4. Hydrogen Bonding Interactions of Amorphous Indomethacin and its
Amorphous Solid Dispersions

4.1 Introduction
The amorphous form of an active pharmaceutical ingredient (API) has been used
as a strategy to enhance the oral bioavailability of poorly water-soluble compounds, as
the amorphous API has a higher apparent solubility and faster dissolution rate than its
crystalline counterpart.8, 55 However, the amorphous API also has a higher free energy
and could convert to the thermodynamically more stable crystalline state. To minimize
the possibility of crystallization, a polymer is usually mixed with the amorphous API to
form an amorphous solid dispersion, which has been shown to significantly delay the
onset of crystallization.30, 56, 57 Hydrogen bond (HB) formation between the API and the
polymer is often thought to play a significant role in reducing the tendency of amorphous
drugs to crystallize.31, 82
The predominant technique used to identify the existence of hydrogen bonds
between the API and the polymer has been FT-IR.31, 72, 82, 83 Taylor and Zografi detected
the interaction between the carboxylic acid moiety of indomethacin and PVP using FTIR.82 With the same technique, Marsac and others identified the presence of hydrogen
bonds between the drugs nifedipine, felodipine and the polymer PVP in amorphous solid
dispersions.72
High resolution

13

C solid-state NMR has also been used to investigate hydrogen

bonding interactions in the solid state.84 Miyoshi and others found three types of

carboxylic acid groups in blends of poly(acrylic acid) (PAA) and poly(ethylene oxide)
(PEO). They were assigned to: 1) those forming interpolymer hydrogen bonds between
PAA and PEO, 2) those forming hydrogen bonded PAA dimers, and 3) those not forming
hydrogen bonds.85, 86
In addition to experimental methods, molecular dynamics (MD) simulations have
been used to study hydrogen bonding interactions in amorphous systems.87, 88 Xiang and
Anderson probed the structural properties of amorphous drug indomethacin (IMC) using
MD simulations.87 They reported that approximately 79% of simulated IMC formed at
least one hydrogen bond and 21% was hydrogen bond free.87 The authors also performed
MD simulations on amorphous IMC-PVP glasses and found that the overall hydrogen
bonding capability of IMC was not substantially altered in the presence of PVP.88 HBs
between IMC molecules decreased with the addition of PVP and the loss of HBs between
IMC molecules was compensated by the formation of HBs between IMC and PVP.88
Despite the vast number of reports on hydrogen bonding interactions between
amorphous drugs and polymers studied using IR spectroscopy, no experiments, to the
best of our knowledge, have successfully dealt with the question of how much of an
amorphous drug is hydrogen bonded with a polymer excipient at a given composition. In
this chapter, a novel approach is described to identify and quantify the various hydrogen
bonding interactions in the amorphous drug indomethacin and in its amorphous solid
dispersions with PVP and PVP/VA using 13C solid-state NMR spectroscopy. The method
employed single-site

13

C isotopic labeling and spectral subtraction. The quantitative

information obtained from this study was compared with results from MD simulations
reported in the literature. These experiments for the first time quantified hydrogen

bonding interactions in amorphous indomethacin systems. This approach may be useful
in understanding the role of intermolecular drug-excipient interactions on the physical
stability of amorphous formulations.

4.2 Materials and Methods
4.2.1

Materials
Indomethacin (γ form, minimum purity 99%) was purchased from Sigma-Aldrich

(St Louis, MO).

13

C isotopically labeled indomethacin (99%

13

C at the carboxylic acid

carbon) was custom synthesized by Chemtos (Austin, TX). Indomethacin α form was
prepared by precipitation from ethanol solution using deionized water as described by
Kaneniwa et al.89 Polystyrene (average Mw=35 kg/mole) was purchased from SigmaAldrich (St Louis, MO). PVP (Kollidon® 25, Mw=28-34 kg/mole) and PVP/VA
(Kollidon® VA 64, Mw=45-70 kg/mole) were obtained from BASF (Edison, NJ). PVP
and PVP/VA were vacuum dried at 70 °C overnight and stored over DrieriteTM at all
times. The chemical structure of indomethacin, PVP, PVP/VA and polystyrene are shown
in Figure 4.1.

Figure 4.1. Chemical structures of (a) indomethacin, (b) PVP, (c) PVP/VA, and (d)
polystyrene.

4.2.2

Preparation of Amorphous Indomethacin
Amorphous indomethacin samples were prepared by in situ melt quenching in the

spinning NMR rotor. Both natural abundance and 13C isotopically enriched indomethacin
(5% wt 13C-labeled and 95% wt unlabeled) samples were prepared. Samples were packed
into 7.5 mm zirconia NMR rotors with Teflon or Kel-F end caps (Revolution NMR, LLC,
For Collins, CO). The rotors were heated in the NMR probe equipped with a variabletemperature accessory stack (Varian, Palo Alto, CA) at 170 °C for approximately 10
minutes while spinning at 4 kHz. The rotors were then rapidly cooled to room
temperature (over approximately 10 min), resulting in the solidified glasses.

4.2.3

Preparation of Amorphous Solid Dispersions
IMC-PVP and IMC-PVP/VA amorphous solid dispersions were prepared by

cryomilling followed by in situ melt quenching in spinning NMR rotors. Samples of both
natural abundance and

13

C isotopically enriched indomethacin (3% wt

13

C-labeled and

97% wt unlabeled at the carboxylic acid carbon) were prepared. One gram samples at
drug:polymer weight ratios ranging from 9:1 to 1:1 were cryomilled at 10 Hz (SPEX
SamplePrep 6770 Freezer/Mill, SPEX SamplePrep LLC., Metuchen, NJ) for five cycles,
each consisting of 2 minutes of milling and 2 minutes of cooling. Liquid nitrogen was
used as a coolant. The cryomilling procedure was used to ensure optimum mixing of the
drug and polymer prior to melting. The mixtures were then transferred into 7.5 mm
zirconia NMR rotors with Teflon or Kel-F end caps (Revolution NMR, LLC, Fort
Collins, CO). The top end cap had a small hole to allow moisture to evaporate during
heating. The rotors were heated in the NMR probe at 170 °C for approximately 10

minutes while spinning at 4 kHz and then rapidly cooled to room temperature, resulting
in the amorphous solid dispersions.
IMC-polystyrene amorphous solid dispersions were also prepared with low
percentages of IMC (0.2%, 1%, 2% and 5%) that was 13C labeled at the carboxylic acid
carbon. These amorphous solid dispersions were made by solvent evaporation using a
Büchi Rotavapor R-215 (Büchi, Switzerland). The drug and polymer were dissolved in
methylene chloride and the solvent was rotary evaporated at 35 °C. The obtained solids
were subsequently vacuum dried at room temperature overnight to remove residual
solvent.

4.2.4

Solid-State NMR Experiments
All solid-state NMR spectra were acquired using a Tecmag Redstone HF3 2RX

spectrometer (Tecmag, Inc., Houston, TX) operating at 75.48 MHz for 13C. Experiments
were performed using a 7.5 mm double-resonance MAS probe (Varian, Palo Alto, CA).
All

13

C spectra were acquired under magic angle spinning (MAS)43 at 4 kHz if not

otherwise specified, using ramped-amplitude cross polarization,45 total sideband
suppression (TOSS)44 and SPINAL64 decoupling73 with a 1H decoupling field of about
62 kHz. A 2 ms contact time and a pulse delay of 5 s were used in all experiments. A
total of 512 points were acquired with a spectral width of 15 kHz. 3-Methylglutaric acid
was used to optimize spectrometer settings and as an external standard, with the methyl
peak referenced to 18.84 ppm.74 All experiments were conducted at 20 °C if not
otherwise specified. The data were zero-filled to 4096 points with no line-broadening.
Spectra in the region of 160-190 ppm were fitted by Gaussian functions using MATLAB

(MathWorks, Natick, MA). The details of the fitting procedure are explained in the
results section.
The spectra of IMC-polystyrene (PS) amorphous solid dispersions were acquired
using MAS of 5.2 kHz to avoid residual spinning sideband overlap. The spectra of an
amorphous solid dispersion of 1% IMC in PS were also collected as a function of
temperature using a variable-temperature accessory stack (Varian, Palo Alto, CA). Lead
nitrate was used to calibrate the temperature and a linear slope of 0.73 was obtained for
the plot of the chemical shift change versus temperature in the range between -30 and 200
°C, agreeing well with values reported in the literature.90 Samples were equilibrated at
each temperature for at least 15 min before data acquisition. At temperatures above 100
°C, direct polarization was used to acquire the spectra because cross-polarization
efficiency was greatly reduced in the highly mobile environment.
For chemical shift anisotropy tensor analysis, the samples were spun at a low
speed of 1.5 kHz to generate spinning sideband patterns. Both natural abundance and 13C
labeled samples of each composition were used and spectral subtraction was applied to
obtain the signal of the carboxylic acid carbon. The subtracted spectra were deconvoluted
using TNMR (Tecmag, Inc., Houston, TX) and the peaks of interest were analyzed using
the Herzfeld-Berger approach91 with the software HBA.92 For the IMC-PS amorphous
solid dispersion, a dipolar-decoupled sequence was used to suppress polystyrene aromatic
and -CH2 peaks. Since the carboxylic acid peaks in the spectrum did not overlap, the
intensity was used to calculate the tensor elements.

4.3 Results and Discussion
4.3.1

13C

Solid-State NMR of Indomethacin

C CPMAS spectra of two crystalline forms, γ and α, and the amorphous form of

13

indomethacin are shown in Figure 4.2. The spectrum of the γ polymorph shows narrow
peaks (∆ν1/2 = 80 Hz for the methyl carbon). There is one peak for each carbon,
indicating there is one molecule in an asymmetric crystalline unit, which is consistent
with the solved structure of the γ polymorph.93 The spectrum of the α polymorph shows
three peaks for most carbons, indicating there are three molecules in an asymmetric
crystalline unit. This also agrees with the crystalline structure of the α polymorph solved
by Chen and others.94 The line width of the methyl carbon is approximately 40 Hz for
the α polymorph. The peaks of both polymorphs have been previously assigned.75,

95

Amorphous indomethacin has much broader peaks than both crystalline forms (∆ν1/2 =
400 Hz for the methyl carbon).
Figure 4.3 shows the carbonyl region of the three different forms of indomethacin.
γ indomethacin (Figure 4.3a) consists of cyclic dimers between carboxylic acid groups of
two indomethacin molecules.93 The most downfield peak at 179.2 ppm corresponds to the
hydrogen-bonded carboxylic acid carbon. The peak at 167.6 ppm corresponds to the
amide carbon, which is not involved in hydrogen bonding. α indomethacin (Figure 4.3b)
consists of two types of hydrogen bonds, with three crystallographically inequivalent
molecules per unit cell.94 This gives rise to three peaks for each carbonyl carbon and a
total of six peaks in the carbonyl region. The peaks at 181.4 and 179.9 ppm correspond to
the carboxylic acid groups of two of the three molecules that form hydrogen bonded
dimers, similar to what exists in γ indomethacin. The peak at 172.3 ppm corresponds to

the carboxylic acid of the third molecule that is hydrogen bonded to one of the amide
carbonyls of the dimer. This assignment was confirmed by an experiment using α
indomethacin that was 13C isotopically labeled at the carboxylic acid carbon. The peak at
170.9 ppm probably corresponds to the aforementioned amide carbonyl in the dimer that
is hydrogen bonded to the carboxylic acid group. Finally, the two peaks at 166.6 and
167.1 ppm probably correspond to the two non-hydrogen bonded amide carbonyls. The
peak at 167.1 ppm appears as a shoulder which is presumably due to imperfect
crystallization. It was seen as a more defined peak in another report.96 Amorphous
indomethacin (Figure 4.3c) shows very broad peaks in the carbonyl region and the peak
locations seem to be a combination of γ and α forms. However, the exact correlation
between the peaks and carbons is not obvious. A potential mixture of different carboxyl
species might exist due to hydrogen bonding interactions,85,
spectrum.

86

which complicates the

Figure 4.2.

13

C SSNMR spectra of (a) γ crystalline indomethacin, (b) α crystalline

indomethacin, and (c) amorphous indomethacin.

Figure 4.3. Carbonyl region of 13C SSNMR spectra of (a) γ crystalline indomethacin, (b)
α crystalline indomethacin, and (c) amorphous indomethacin.

4.3.2

Hydrogen Bonding Interactions of Amorphous Indomethacin
Indomethacin 13C isotopically labeled at the carboxyl carbon was used at a 5%

level to study the hydrogen bonding interactions of amorphous indomethacin. The
method was used by Munson and co-workers to study stereo-defects in polylactide.97
Figure 4.4 illustrates this process. Figure 4.4a shows the spectrum of

13

C labeled

amorphous indomethacin. Because the labeling is at only one specific carbon, the
carboxyl carbon, the signal of that carbon was significantly enhanced while the signals of
all other carbons were essentially unaltered. The greater intensity between 180 and 170
ppm is the result of the isotopic labeling. Figure 4.4b shows the spectrum of the natural
abundance (i.e. unlabeled) amorphous indomethacin. The unlabeled spectrum was
subtracted from the labeled spectrum while maintaining the same signal intensity for the
aromatic and aliphatic carbon regions of the two spectra (160-0 ppm region). The end
result is a spectrum that only contains the carboxylic acid carbon, as shown in Figure 4.4c.

Figure 4.4.

13

C SSNMR spectra of (a) 13C labeled amorphous indomethacin, (b) natural

abundance amorphous indomethacin, and (c) carboxyl carbon of amorphous
indomethacin.

The spectrum of the carboxyl carbon after the subtraction contains two clear
peaks, with a potential third peak in the middle, as shown in Figure 4.5. The downfield
(high ppm) peak with the highest intensity was assigned to the cyclic dimer, due to its
similar chemical shift compared to the same type of hydrogen bond that exists in the
crystalline forms. The upfield (low ppm) peak was assigned to the carboxylic acid carbon
hydrogen bonded to the amide carbonyl, due to its relatively similar chemical shift
compared to the same type of hydrogen bond that exists in the α form. However, it is
more difficult to assign the peak with the lowest intensity in the middle. The literature
seems to be divided on the assignment of this peak. Miyoshi et al. observed three peaks
for the carboxylic acid carbon in the PAA/PEO polymer complex and assigned the peak
in the center to the free carboxyl group that formed no particular hydrogen bonds.85, 86
Recently, however, Fortier-McGill et al. studied PMAA complexes with a series of
polymers and attributed the resonance in the middle to disordered carboxylic acid chains
through 1H double-quantum MAS NMR.98, 99

Figure 4.5. CPMAS

13

C spectrum of the carboxylic acid of amorphous indomethacin.

Simulated peaks are shown in red to illustrate the potential species. The carbons
highlighted in teal correspond to the carbons in carboxyl groups that are involved in
hydrogen bonds.

Several experiments were conducted using polystyrene to assist in assigning the
peak in the center. Polystyrene is a suitable polymer for this purpose because it can form
an amorphous solid dispersion with indomethacin, yet it has little capability to form a
substantial hydrogen bond with the drug. At sufficiently low concentrations of
indomethacin, some percentage of the indomethacin is likely to be hydrogen-bond free.
Figure 4.6 shows the carboxylic acid region of the

13

C CPMAS spectrum of 1%

indomethacin in an amorphous solid dispersion with polystyrene prepared via solvent
evaporation. Since the indomethacin is labeled at the carboxylic acid carbon, the signals
from other indomethacin carbons are non-observable due to the low concentration of
indomethacin. There are two peaks present in the spectrum in Figure 4.6, one at 179.4
ppm and the other at 170.3 ppm. The peak at 179.4 ppm agrees well with the chemical
shift of the dimer shown in Figure 4.5. The other peak, however, has a chemical shift of
170.3 ppm, significantly different from the upfield resonance in Figure 5 (171.8 ppm).
This suggests that this peak at 170.3 ppm could be a different species and may be the free
carboxylic acid of indomethacin. The broad center resonance in Figure 4.5 could
represent disordered hydrogen bonded chains that are absent when indomethacin
concentration is very low (Figure 4.6). Herein we define disordered chains as carboxylic
acid chains having various lengths. Chain ends may be included, as suggested by FortierMcGill et al.98,

99

and possibly rings larger than dimers could be formed between

carboxylic acids. After cryogrinding, the dispersion showed a decreased intensity of the
peak at 179.4 ppm compared to the peak at 170.3 ppm (spectrum shown in red). This
observation also agrees with the assignment of the 170.3 ppm peak as the free carboxylic
acid as cryogrinding is known to break down molecular interactions and introduce

disorder into the system.51,

100

Consequently, the fraction of free IMC is expected to

increase compared to the dimeric form.
To further confirm our assignments, amorphous solid dispersions with 5%, 2%
and 0.2% indomethacin in polystyrene were investigated. The spectra are shown in
Figure 4.7. It is immediately obvious that the ratio between the two resonances at 179.4
and 170.3 ppm decreased as IMC concentration decreased. This observation supports the
idea that the resonance at 170.3 ppm is associated with the free carboxylic acid of
indomethacin because more free indomethacin molecules are expected on dilution.
Variable-temperature solid-state NMR was also used to investigate the
temperature-dependent behavior of the dispersion. The 1 % indomethacin and
polystyrene amorphous solid dispersion was heated from 20 to 160 °C, and a spectrum
was recorded at each temperature as shown in Figure 4.8. It is anticipated that the ratio
between the carboxylic acid dimer and the free carboxylic acid should decrease as the
temperature increases because of the negative enthalpy for hydrogen bond formation, at
least at temperatures close to and above the glass transition temperature, such that
equilibrium can be achieved. Indeed, this is what is seen in Figure 4.9, which shows the
ratio between the carboxylic acid dimer and the free carboxylic acid as a function of
temperature. As illustrated by the figure, the ratio between the two species decreases as
the temperature increases, further confirming our assignment of the peak at 170.3 ppm as
the free carboxylic acid of IMC.

Figure 4.6.

13

C CPMAS spectrum of the carboxylic acid region of 1% indomethacin in

polystyrene. The spectrum in red is obtained from the sample after cryogrinding.

Figure 4.7. 13C CPMAS spectra of the carboxylic acid region of (a) 5% indomethacin, (b)
2% indomethacin, (c) 1% indomethacin, and (d) 0.2% indomethacin in amorphous solid
dispersions with polystyrene.

Figure 4.8.

13

C spectra of the carboxylic acid carbon of 1% amorphous indomethacin in

polystyrene at (a) 20 °C, (b) 30 °C, (c) 40 °C, (d) 50 °C, (e) 60 °C, (f) 70 °C, (g) 80 °C,
(h) 110 °C, (i) 140 °C, and (j) 160 °C. Spectra a-g were collected by cross polarization.
Spectra h-j were collected by direct polarization.
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Figure 4.9. Peak area ratio between the carboxylic acid dimer and the free carboxylic
acid as a function of temperature. Lines were drawn as a guide to the eye.

Based on this information, four species may contribute to the spectrum in Figure
4.5, namely the carboxylic acid cyclic dimer, disordered carboxylic acid chains, the
carboxylic acid-amide hydrogen bonded complex, and the free carboxylic acid. To
increase the confidence in spectral deconvolution, the IMC spectrum was fitted together
with the spectra of IMC-polymer amorphous solid dispersions. The details will be
discussed in the next section. The fitted spectrum and the fitting parameters are shown in
Figure 4.10 and Table 4.1, respectively. From the deconvolution we can see that the
majority of the IMC molecules appear to be hydrogen bonded through either carboxylic
acid cyclic dimers (59%) or carboxylic acid chains (15%). In addition, 19% of molecules
are hydrogen-bonded through carboxylic acid-amide interactions. The remaining 7% of
molecules are not hydrogen bonded.
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Figure 4.10. Deconvolution of the CPMAS 13C spectrum of the carboxylic acid carbon of
amorphous indomethacin. The experimental spectrum is shown in black; the fitting of the
individual species are shown in red; the sum of the species contributions is shown in
green; the residual difference between the experimental and fitted peaks is shown in blue.

Table 4.1. The fitting parameters for the deconvolution of

13

C SSNMR spectrum of

amorphous indomethacin. a
Chemical Shift
Species
(ppm)
cyclic dimer
179.3 ± 0.006
carboxylic acid chain
176.3 ± 0.02
carboxylic
acid-amide
172.4 ± 0.004
free carboxylic acid
170.4 ± 0.05
a
± indicates the standard error.

Peak Area (%)

Linewidth (Hz)

58.5 ± 0.5
15.2 ± 0.4
18.9 ± 0.4
7.5 ± 0.3

216 ± 0.8
303 ± 5
212 ± 0.6
225 ± 5

4.3.3

Hydrogen Bonding Interactions in Indomethacin Amorphous Solid
Dispersions with PVP and PVP/VA
Amorphous solid dispersions with 10 to 50% PVP or PVP/VA were studied to

quantitatively understand how the addition of polymers may change the HB interactions
in the systems. The spectra of dispersions containing natural abundance IMC were
subtracted from those containing

13

C labeled IMC, as detailed in the previous section.

After subtraction, only the signal from the carboxylic acid carbon of IMC in the
amorphous solid dispersions remains in the spectra. While neat amorphous indomethacin
was previously shown to have four major carboxylic acid species, there are potentially
five or six carboxylic acid species in the amorphous solid dispersions, with the new
species being the carboxylic acid hydrogen bonded to the PVP carbonyl and with the
vinyl acetate carbonyl of PVP/VA. Since indomethacin and PVP each contain an amide
group, it is difficult to differentiate between the carboxylic acid groups that hydrogen
bond with the IMC amide and those that hydrogen bond with the PVP amide. Besides, we
observed that the chemical shift of the IMC carboxylic acid hydrogen bonded to
polyvinyl acetate has a similar chemical shift to that hydrogen bonded to PVP (data not
shown). As a result, the IMC carboxylic acid species that hydrogen bond with either IMC
amide, PVP or PVP/VA were treated as one peak in the deconvolution.
The spectra of amorphous IMC, IMC-PVP and IMC-PVP/VA amorphous solid
dispersions were simultaneously fitted by a combination of four Gaussian functions using
MATLAB (MathWorks, Natick, MA). Each Gaussain function represents a carboxylic
acid species, with varying intensities for each spectrum representing the change of the
species concentration with the composition. The chemical shift and linewidth for each

Gaussian function were shared parameters and fixed across all eleven spectra to reduce
bias in the fitting process. The fitted spectra of IMC-PVP and IMC-PVP/VA amorphous
solid dispersions are shown in Figure 4.11. The fitting parameters are shown in Table 4.2.
It is clear from Figure 4.11a that the carboxylic acid dimers are gradually
disrupted with increasing PVP content. As the polymer concentration increases, the IMC
carboxylic acid chains also decrease. On the other hand, the carboxylic acid-amide
complex increases and gradually dominates the spectra as the polymer concentration
increases. The percentage of free carboxylic acid did not seem to be affected as much as
the other species as the polymer concentration increased. Similar to the IMC-PVP
amorphous dispersion, the carboxylic acid dimer interaction is greatly reduced in the
presence of PVP/VA. The disordered chains also decrease with the increase of PVP/VA
content. On the other hand, the carboxylic acid-polymer complex increases and
dominates the spectrum with high PVP/VA content.

Figure 4.11. CPMAS 13C spectrum of IMC carboxylic acid carbon in (a) IMC-PVP and
(b) IMC-PVP/VA amorphous solid dispersions. From top to bottom: 90% IMC, 80%
IMC, 70% IMC, 60% IMC and 50% IMC (wt %). The experimental spectrum is shown
in black; the fitted peaks representing each species are shown in red; the sum of the fit is
shown in green; the residual difference between the experimental and fitted peaks is
shown in blue.

Table 4.2. The fitting parameters of CPMAS 13C spectra of IMC carboxylic acid carbon
in IMC-PVP and IMC-PVP/VA amorphous solid dispersions.a,b
carboxylic
acid dimer
179.3 ± 0.006
δ (ppm)
216 ± 0.8
Width (Hz)
90-10
Area (%)
28.9 ± 0.4
IMC80-20
Area (%)
9.7 ± 0.3
PVP
70-30
Area (%)
2.5 ± 0.3
Ratio
60-40
Area
(%)
0 ± 0.3
(wt)
50-50
Area (%)
0 ± 0.3
90-10
Area (%)
35.8 ± 0.4
IMC80-20
Area (%)
18.0 ± 0.3
PVP/VA
70-30
Area (%)
6.9 ± 0.3
Ratio
60-40
Area (%)
2.1 ± 0.3
(wt)
50-50
Area (%)
1.7 ± 0.3
a
± indicates the standard error.
parameters

b

carboxylic
acid chain
176.3 ± 0.02
303 ± 5
20.1 ± 0.4
19.1 ± 0.4
14.5 ± 0.4
9.0 ± 0.4
7.2 ± 0.3
19.5 ± 0.4
20.4 ± 0.4
14.8 ± 0.4
8.1 ± 0.3
6.6 ± 0.3

carboxylic
acid complex
172.4 ± 0.004
212 ± 0.6
41.9 ± 0.5
66.5 ± 0.6
81.0 ± 0.7
87.4 ± 0.7
92.6 ± 0.8
38.6 ± 0.4
54.8 ± 0.5
69.4 ± 0.7
83.3 ± 0.8
88.6 ± 0.7

free
170.4 ± 0.05
225 ± 5
8.3 ± 0.3
4.7 ± 0.3
1.6 ± 0.4
3.6 ± 0.4
0.2 ± 0.4
6.0 ± 0.3
6.8 ± 0.3
8.9 ± 0.4
6.5 ± 0.4
3.1 ± 0.4

The chemical shift of free carboxylic acid hits the upper boundary at 170.4 ppm, which

was set based on the chemical shift observed for the free species in polystyrene. When
the boundary is lifted, the fitted chemical shift of this peak moves up to 171.5, which
loses any physical meaning. All other parameters remained within the boundaries set
during the fitting procedure.

There are a few aspects to be noted from the fitting results. First, the spectrum of
amorphous IMC could not be fitted as well as the spectra of the drug-polymer dispersions.
One possible explanation is that the addition of polymer in the amorphous solid
dispersions alters the disordered chain structures resulting in a different distribution in the
types of the disordered species. Thus, the peak shape and position for disordered chains
could be different with and without the polymer. Second, all hydrogen-bonded carboxylic
acid complexes were treated as a single peak in the fitting process, due to the inability of
the present data to differentiate between the different species in the spectra. This
treatment could have led to an underestimation of the errors of the fitted parameters as
fewer parameters were allowed than likely existed. That being said, the most reliable
results obtained are those parameters reflecting the dimer species due to its large
separation from the carboxylic acid complexes. The concentration of the free carboxylic
acid species may be the least certain due to the fact that its chemical shift was restricted
to 170.4. As a result, the true error estimates in the results should be expected to be more
than what is computed.
Figure 4.12 compares the percentages of HB species of IMC plotted as a function
of PVP and PVP/VA percentages. As the plots suggest, the trend for IMC to hydrogen
bond with both polymers is the same. The difference lies in the hydrogen bond accepting
capability of the two polymers. There are fewer carboxylic acid complex forms in the
dispersions of PVP/VA than in the dispersions of PVP. Concomitantly, the fractions of
dimer and disordered carboxylic acid chains in the PVP/VA dispersions are higher than
those in the PVP dispersions at the same polymer weight percentage. This suggests that
PVP/VA is a weaker hydrogen bond acceptor than PVP, probably due to the vinyl acetate

groups in the polymer. This was confirmed by analyzing an IMC-polyvinyl acetate
(PVAc) amorphous solid dispersion with 50% (wt) of IMC, in which approximately 20%
of the IMC carboxylic acids were still existing in cyclic dimers (data not shown).
Matsumoto and Zografi have also studied the hydrogen bonding interactions of
indomethacin with PVP and PVP/VA in amorphous solid dispersions.31 They observed a
distinct loss of the indomethacin dimer peak over the range of 5-30% polymer using IR
spectroscopy. This is in good agreement with our results that the dimer is reduced to a
very small amount with 30% of polymer. The current study, however, is able to detect the
existence of more hydrogen bonding species and also quantify those species.
One unexpected trend observed in Figure 4.12 is that the disordered chain species
seems to be less disrupted than the dimer species, and remains present when the dimer
species completely disappears from the sample. Considering the similar equilibrium of
the formations of dimers and chains, one would assume that the chains disappear at a
similar rate as the dimers. Current data can not explain this phenomenon. One might
speculate that the disordered chain species could contain some species not yet identified.

Figure 4.12. Fraction of IMC carboxylic acid participating in various hydrogen-bonding
interactions in the amorphous solid dispersion with (a) PVP and (b) PVP/VA as a
function of polymer concentration. The error bars indicate the 95% confidence intervals.
Curves are drawn as a guide to the eye.

4.3.4

Investigating Hydrogen Bonds in Amorphous Indomethacin
Chemical shift anisotropy (CSA) tensor was studied in neat amorphous

indomethacin and an amorphous solid dispersion of 1% indomethacin in polystyrene to
gain further understanding of the nature of these different types of hydrogen bonds in
amorphous indomethacin. Generally, the isotropic chemical shift provides an “averaged”
value of the chemical shift, while the CSA tensor provides three-dimensional information
about the local electronic environment at the site of interest. CSA tensor has been used to
study hydrogen bonding in the solid state and has been shown to be very sensitive to the
protonation state and the hydrogen bonding environment of carboxylic acid groups in
amino acids.101-104
Table 4.3 lists the principal components of the CSA tensor of the amorphous IMC
carboxylic acid carbon that participated in various hydrogen bonding states. As seen from
the table, δ11 and δ22 differ by a large degree and shift in opposite directions in the three
carboxyl group species, while δ33 is essentially invariant. This trend is consistent with
literature reports on chemical shift tensor analysis of amino acid carboxylic acid
groups.102,

103

Gu and McDermott surveyed 35 amino acids and correlated the

asymmetries of the carboxylic acid groups to their chemical shift tensors.102 It was found
that the protonation state of the carboxylic acid can be characterized by the asymmetry
function A=δ11+ δ33- δ22. Deprotonated species are characterized by A<185 and
protonated species are characterized by A>195.

In the present study, the peak at

δiso=179.3 ppm clearly falls into the category of deprotonated species (A=164), which
suggests that protons are delocalized in these carboxyl groups, resulting in a high degree
of symmetry. This confirms the assignment of this peak to the cyclic dimer form. The

peak at δiso=172.4 ppm falls into the category of protonated species (A=215), which
suggests a low degree of symmetry in this hydrogen bond. This result is consistent with
the assignment of this peak to the carboxylic acid-amide complex. The peak at δiso=176.3
ppm falls in between the deprotonated and protonated categories, with an asymmetry
function of 185. The protons in these carboxyl groups are neither deprotonated nor
protonated, and are at an “in-between” state. This suggests that these carboxyl groups
may be in carboxylic acid chains including chain ends, where protons are partially
delocalized. The broad nature of this resonance could be partially explained by the
variations in the types and lengths of chains. Rings larger than dimer may also exist.
Table 4.4 lists the principal components of the CSA tensor of the IMC carboxylic
acid carbon in the amorphous dispersion with polystyrene (1% IMC). As expected, the
tensor elements of the cyclic dimer are very similar to those in neat amorphous
indomethacin (Table 4.3). Free indomethacin, on the other hand, showed different
principal components compared to either carboxylic acid chains or carboxylic acid-amide
complexes in neat amorphous indomethacin. This is consistent with the assignment of the
free indomethacin in IMC-PS amorphous solid dispersion as a different species, despite
having an isotropic chemical shift close to that of the carboxylic acid-amide hydrogen
bond. Again, the asymmetric function A equals 207 for the free carboxylic acid, falling
into the category of protonated species with a low degree of symmetry, which is what
would be expected for a free carboxylic acid.

Table 4.3. Principal components of the CSA tensors of the amorphous IMC carboxylic
acid carbon that participates in various hydrogen bonding states.a Free carboxylic acid
was omitted in the analysis due to the small amount present.
cyclic dimer
δiso
179.3
δ11
233 ± 0.8
δ22
187 ± 0.5
δ33
118 ± 0.6
A
164
a
± indicates the standard error.

carboxylic acid chain

carboxylic acid-amide

176.3
238 ± 2.0
173 ± 1.3
120 ± 1.5
185

172.4
248 ± 2.4
151 ± 1.5
118 ± 1.8
215

Table 4.4. Principal components of the CSA tensor of the IMC carboxylic acid carbon in
a 1% IMC amorphous solid dispersion with polystyrene.a
cyclic dimer
free
δiso
179.3
170.3
δ11
231 ± 0.6
231 ± 1.0
δ22
187 ± 0.3
152 ± 0.6
δ33
120 ± 0.5
128 ± 0.8
A
164
207
a
± indicates the standard error.

4.3.5

Investigating the Carboxylic Acid-Amide Hydrogen Bond
As discussed previously, there are two types of carboxylic acid-amide hydrogen

bonds encountered in the present study. Depending on the system, this peak likely
consists of carboxylic acid hydrogen bonded to the IMC amide and that hydrogen bonded
to PVP amides. The chemical shift anisotropy (CSA) tensors of the carboxylic acid
carbons involved in these hydrogen bonds were explored because the CSA tensor is very
sensitive to the local chemical environment as discussed in previous sections. Neat
amorphous indomethacin and the 50-50 IMC-PVP amorphous solid dispersion were
examined because the former represents the carboxylic acid hydrogen bonding with the
IMC amide and the latter predominantly represents hydrogen bonding with PVP amides.
The principal components of the tensors of the carboxylic acid carbon in neat
amorphous IMC and in the 50-50 IMC-PVP amorphous solid dispersion are very similar
(Table 4.5). This similarity suggests that the two types of carboxylic acid-amide
hydrogen bonds are comparable in their strengths and experience very similar electronic
environments. This result indicates that some other mechanisms besides the strength of
the hydrogen bond must exist to favor the PVP amide group as the preferred hydrogen
bond acceptor in the amorphous solid dispersions. One of the contributing factors is the
concentration effect. The molar concentration of PVP monomer is approximately three
times of that of indomethacin for equal weights of the compounds. Thus, every 10% (wt)
increase of PVP is accompanied by a 10% decrease in carboxylic acids available to form
dimers or chains, and a 20% increase in the concentration of amides available to form the
carboxylic acid-amide hydrogen bonds. With 50% PVP, the molar concentration of
amides has doubled, while the molar concentration of carboxylic acids has decreased by

half. The increasing concentration of amides could in part explain the higher percentages
of the IMC carboxylic acid-amide hydrogen bonds when PVP is added.

4.3.6

Thermodynamics of Amorphous Indomethacin Dimerization in a Dilute
System
The indomethacin carboxylic acid dimer and the free carboxylic acid can be

assumed to be in equilibrium in the amorphous state at temperatures above Tg. This
equilibrium can be described by the following equations,
𝐾𝐾𝑒𝑒𝑒𝑒

𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 + 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 �� 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝐾𝐾𝑒𝑒𝑒𝑒 =

[𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑]

(4.1)
(4.2)

[𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓]2

where free denotes the IMC monomer having free carboxylic acid groups, dimer denotes
the carboxylic acid dimer of IMC, and Keq is the equilibrium constant between the free
carboxylic acid and the dimer. The temperature dependence of Keq can be described by
the Van’t Hoff equation,
𝑙𝑙𝑙𝑙 𝐾𝐾𝑒𝑒𝑒𝑒 = −

∆𝐻𝐻°
𝑅𝑅𝑅𝑅

+

∆𝑆𝑆°
𝑅𝑅

(4.3)

where ΔH° is the standard enthalpy of dimerization, ΔS° is the standard entropy of
dimerization, T is the temperature and R is the gas constant. In the amorphous solid
dispersion of 1% IMC with polystyrene, the IMC molecules could be treated as the solute
in a solid solution where polystyrene is the “solvent”. The standard state is defined as the
hypothetical state with unit activity coefficient and 1 molar concentration of IMC in

polystyrene at 25 °C and 1 atmosphere. The reference state is defined as the state with
infinite dilute molar concentration of IMC in polystyrene (unit activity coefficient) at
25 °C and 1 atmosphere.
The weight fractions of the cyclic dimer and free carboxylic acid below the
coalescence temperature can be deconvoluted from the CPMAS spectra as shown in
Figures 4.8 d-f.

The weight fractions of these two species above the coalescence

temperature can be calculated from the chemical shift of the observed coalesced peak
(Figures 4.8 h-j) by the following,
𝛿𝛿𝑜𝑜𝑜𝑜𝑜𝑜 = 𝑤𝑤𝑑𝑑 ∙ 𝛿𝛿𝑑𝑑 + 𝑤𝑤𝑓𝑓 ∙ 𝛿𝛿𝑓𝑓

(4.4)

where δobs is the observed chemical shift of the coalesced peak, δd and δf are the chemical
shifts of the dimer and the free species before coalescence, respectively, and wd and wf
are the weight fractions of two respective species. Since the dimer species contains two
indomethacin molecules and thus double signal intensity for each mole of the species, the
dimer weight fraction was divided in two to convert to the mole fraction. The mole
fractions of the two species were then converted into molar concentrations by the
following,
𝑥𝑥 /𝑚𝑚𝑚𝑚𝐼𝐼𝐼𝐼𝐼𝐼

[𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑] = 0.01/𝜌𝜌𝑑𝑑

𝐼𝐼𝐼𝐼𝐼𝐼 +0.99/𝜌𝜌𝑃𝑃𝑃𝑃

𝑥𝑥 /𝑚𝑚𝑚𝑚𝐼𝐼𝐼𝐼𝐼𝐼

[𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓] = 0.01/𝜌𝜌𝑓𝑓

𝐼𝐼𝐼𝐼𝐼𝐼 +0.99/𝜌𝜌𝑃𝑃𝑃𝑃

(4.5)

(4.6)

where xd and xf are the molar fractions of the dimer and the free species, respectively,
mwIMC is the molecular weight of indomethacin, and ρIMC and ρPS are the densities of
amorphous indomethacin and polystyrene, respectively.

From equations 4.2-4.6, the standard enthalpy and entropy of dimerization were
calculated. The standard dimerization enthalpy (ΔH°) was calculated to be -38 kJ/mol and
the standard dimerization entropy (ΔS°) was calculated to be -83 J/(mol·K). The Van’t
Hoff plot is shown in Figure 4.13.
As seen from Figure 4.13, the Van’t Hoff plot begins to deviate from linearity
below 50 °C. The deviation of the plot from linearity represents the free energy
difference between the real glass and a hypothetical equilibrium state of a fully relaxed
amorphous glass. This free energy difference was calculated to be approximately 2.3
kJ/mol at 25 °C.
The standard dimerization enthalpy of acetic acid has been reported to be between
-31 and -44 kJ/mol in organic solvents such as benzene, CCl4, and n-heptane.105, 106 The
standard dimerization enthalpy of glacial acetic acid was estimated to be -44 kJ/mol.107
Overall, the amorphous IMC carboxylic acid dimerization enthalpy is in very good
agreement with the literature values for acetic acids. The standard dimerization entropy
of acetic acid has been reported to be between -52 and -94 J/(mol·K) in organic solvents
such as benzene, CCl4, and n-hexane.108 The calculated amorphous IMC carboxylic acid
dimerization entropy is also reasonable based on the range of literature reported values.
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Figure 4.13. Van’t Hoff plot of Keq for indomethacin carboxylic acid dimerization in a 1%
solid dispersion in polystyrene.

4.3.7

Hydrogen Bonding Effects on Miscibility and Physical Stability of
Amorphous Solid Dispersions
The miscibilities of IMC-PVP and IMC-PVP/VA amorphous solid dispersions

were studied by SSNMR 1H T1 and T1ρ relaxation times using methods described
previously.47 A common relaxation time for both 1H T1 and T1ρ was found for all solid
dispersions, indicating phase homogeneity. The miscible domain size was calculated to
be less than 5 nm, based on the length scale of 1H spin diffusion
〈𝐿𝐿〉 = √6𝐷𝐷𝐷𝐷

(4.7)

where D, the 1H spin diffusion coefficient, is typically assumed to 10-12 cm2/s for organic
solids,46, 66 and t is the relaxation time. Typical 1H T1ρ relaxation times obtained from
these samples are on the order of 50 ms.
Modulated DSC studies also showed a single glass transition event and no
crystallization or melting peak for all of the amorphous solid dispersions, agreeing with
SSNMR relaxation measurements that they are phase homogeneous. The existence of
strong hydrogen bonds between the drug and the polymer will decrease the enthalpy of
mixing and lower the overall free energy of mixing. This will promote miscibility
between the drug and polymer even when the polymer concentration is relatively low.
Carboxylic acid dimers exist in both known indomethacin polymorphs, indicating
that dimer formation is an important component in the crystallization process. If the
dimer formation is eliminated in the amorphous state, then the drug is less likely to
crystallize. The current study shows that with 40% (wt) PVP, the indomethacin cyclic
dimers are completely disrupted. At this PVP concentration, the majority of the drug is

hydrogen bonded to PVP. Thus, it is reasonable to hypothesize that 40% (wt) of PVP can
effectively inhibit the crystallization of amorphous indomethacin at 20°C for years or
even decades. We are currently testing the stability of several amorphous solid
dispersions to see if this approach can potentially serve as a predictive tool for the longterm physical stability of amorphous solid dispersions.

Table 4.5. Principal components of the chemical shift tensor of the IMC carboxyl carbon
that participates in the carboxyl-amide hydrogen bond. a
amorphous IMC

50-50 IMC-PVP

δ11

248 ± 2.4

250 ± 1.3

δ22

151 ± 1.5

151 ± 0.8

δ33
a

118 ± 1.8
117 ± 1.1
± indicates the standard error.

4.3.8

Comparison of Experimental Data with MD Simulation Results in the
Literature
Xiang and Anderson performed molecular dynamics (MD) simulations on

amorphous IMC and reported that 79% (± 3%) of IMC molecules were hydrogen bonded
with at least one hydrogen bond and 21% (± 3%) of IMC molecules were not involved in
any hydrogen bonds.87 The experiments from the current study found approximately 7%
free IMC in neat amorphous IMC. The MD simulations predicted that of the hydrogen
bonds being formed, 73% were between IMC carboxylic acids. The current experiments
estimated that number to be 79%.
The same authors also reported MD simulations of IMC-PVP amorphous
systems.88 It was found that as PVP concentration increased, IMC self-interactions were
gradually displaced by IMC-PVP interactions.88 The experimental data herein showed the
same trend that the IMC self-interactions were displaced with IMC-PVP interactions. The
MD simulations also identified an almost constant amount of free IMC in all
compositions, although the percentage of free IMC determined in the MD simulations
was greater.
The greater percentage of free IMC found in MD simulations may have been
resulted from the difference in cooling rate for an experimental glass in comparison to
that employed in MD simulations. The cooling rate reported in the MD simulation was 30
K/ns, which is more than 10 orders of magnitude faster than the experimental cooling rate.
At such a rapid cooling rate, the simulated melt of indomethacin fell out of equilibrium at
a considerably higher temperature, resulting in a reported glass transition temperature of
111 °C, which is 65 °C higher than the glass transition temperature determined

experimentally in this study. The discrepancy in the glass transition temperature can lead
to the differences in the amount of free IMC molecules observed by these two methods.
This can be rationalized through the temperature dependence of the equilibrium constant
for IMC dimer formation. Above the glass transition temperature, the amorphous
indomethacin is a supercooled liquid and is expected to follow the solution state
equilibrium. At the temperature of 46 °C, where the experimental amorphous system is
about to solidify into a glass, the equilibrium constant for dimer formation is calculated to
be 70 M-1, whereas at the temperature of 111 °C, where the MD simulated amorphous
system is about to solidify, the equilibrium constant for dimer formation is calculated to
be only 6.3 M-1. Consequently, the percentage of free indomethacin is estimated to be
approximately three times greater in the MD simulated indomethacin glass than in the
experimental samples.

4.4 Conclusions
Amorphous IMC was found to consist mainly of three types of carboxylic acids
from solid-state NMR experiments, representing the carboxylic acid cyclic dimer,
disordered carboxylic acid chains, and the carboxylic acid hydrogen bonded to the amide
carbonyl. Deconvolution revealed that approximately 59% of the IMC molecules form
cyclic dimers, 15% form chains, 19% form carboxylic acid-amide hydrogen bonds, and 7%
remain hydrogen bond free. The standard dimerization enthalpy (ΔH°) and entropy (ΔS°)
of indomethacin were calculated to be -38 kJ/mol and -83 J/(mol·K), respectively, in
amorphous solid dispersions with polystyrene. Adding PVP to IMC created an
amorphous solid dispersion and disrupted the IMC self-interactions. With 40% (w/w)

PVP present, no carboxylic dimers could be detected. The extent of hydrogen bond
formation between IMC and PVP increased as PVP concentration increased. IMC also
formed hydrogen bonds with PVP/VA in a similar fashion as PVP, but less effectively,
due to the weaker hydrogen bonding capability of vinyl acetate groups of the polymer.
The experimental results were compared with previous MD simulations reported
in the literature. The two approaches agreed in their general trends, with the major
difference lying in the greater percentage of free IMC molecules in the MD simulated
glass. This was rationalized by the fast cooling rate employed in the simulations which
resulted in a higher energy state of the simulated amorphous solid. The results from the
current study have practical values in both understanding and designing stable amorphous
solid dispersions as well as providing useful experimental results for improving MD
simulations.
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Chapter 5. Molecular Mobility of Amorphous Solid Dispersions near the Glass
Transition Temperature

5.1 Introduction
In the past two chapters, we have discussed the role of phase homogeneity and
drug-polymer interaction on the physical stability of amorphous solid dispersions. In
addition to these two factors, a number of studies have shown the link between physical
stability and molecular mobility in the amorphous state.58, 109-111 In general, molecular
mobility encompasses both global and local motions. Global mobility reflects cooperative
motions and is the governing motion at temperatures greater than the glass transition
temperature. Historically, global mobility is often described as the α-relaxation. On the
other hand, local mobility reflects noncooperative motions stemming from portions of the
molecule, such as motions of polymer side chains. Local mobility is often termed βrelaxation.
Several techniques have been used to gain information on the molecular mobility
of

amorphous

pharmaceutical

systems,

such

as

DSC,112-114

isothermal

microcalorimetry,115 viscosity measurements,116 dielectric spectroscopy 117, 118 and solidstate NMR.71, 77, 119 Both DSC and isothermal microcalorimetry have been used to study
enthalpy relaxation of amorphous systems during an “aging” process. These two methods
typically do not directly measure the relaxation time, and the relaxation time parameter
extracted from these studies reflects the structural relaxation of the system. Dielectric
spectroscopy has also been used to study molecular mobilities in amorphous systems,
where the relaxation time can be directly measured and reflects the reorientation of
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dipoles under an applied electric field. Typically, the α and/or β relaxation time is
identified by dielectric spectroscopy as a function of temperature. The disadvantage of
this approach is that the relaxation time reflects the average mobility of the entire system,
and is not component specific.
Solid-state NMR spectroscopy can provide information about molecular mobility
through either the direct measurement of relaxation times or through exchange processes.
It is very useful for detecting motions occurring over a very broad frequency range,
depending on the nuclei being studied and the types of motions being probed. One
example is information provided by 1H T1 and T1ρ relaxation times. It is important to note
that 1H relaxation times provide somewhat “global” information on molecular motions,
due to the strong 1H homonuclear dipolar interactions which usually result in all of the
protons in the spin system having a single common relaxation time.39 Because of the fast
proton spin diffusion that averages out 1H relaxation time, the interpretation of mobility
from 1H relaxation time is not very straightforward. On the contrary, relaxation times of
13

C nuclei may often better reflect the motions of the functional groups of interest,

because

13

C nuclei are sparse and are thus relatively unaffected by homonuclear dipolar

interactions. Thus, the motional processes of different regions of the molecules could be
better preserved. The spin-lattice relaxation T1 is known to be sensitive in the MHz
region and usually detects faster motions such as methyl group rotations.42 The rotating
frame spin-lattice relaxation time T1ρ is sensitive in the kHz region and detects slower
motions such as polymer side group motions. 13C T1ρ relaxation times have been shown
to be valuable probes of polymer chain dynamics in the 10-50 kHz region.120
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In addition to relaxation time measurements, exchange NMR spectroscopy is well
suited for studying molecular dynamics of amorphous materials. An extensive body of
literature exists in the study of molecular dynamics of amorphous polymers using twodimensional (2D) exchange NMR.86, 121-123 In a 2D exchange experiment, the change in
the chemical environment of the atoms in a molecule during a specific time period,
known as the mixing time, is translated into a change in frequency afterwards. Off
diagonal peaks correlate the two different frequencies observed before and after the
mixing time and represent the chemical exchange occurring during the mixing time.
Correlation times extracted from 2D exchange experiments have been correlated with
dielectric relaxation times.124 Specific motional processes have also been elucidated in
poly(methyl methacrylate) for the β-relaxation observed with both dielectric and dynamic
mechanical spectroscopy.122
In this chapter, the dynamics of three types of amorphous systems were studied,
namely a pure amorphous API, API-polymer amorphous solid dispersions, and an
amorphous API in very dilute environment with a polymer. Indomethacin was used as the
model hydrophobic API, poly(vinylpyrrolidone) was used as a polymer to form
amorphous solid dispersions with indomethacin, and polystyrene was used to form a
dilute solid solution of indomethacin. This work aims to understand how polymer affects
the motional processes of the API in each of these situations.
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5.2 Materials and Methods
5.2.1

Materials
Indomethacin (IMC, γ form, minimum purity 99%) was purchased from Sigma-

Aldrich (St Louis, MO). 13C isotopically labeled indomethacin (99% 13C at the carboxylic
acid carbon) was custom synthesized by Chemtos (Austin, TX). Polystyrene (PS, average
Mw=35

kg/mole)

was

purchased

from

Sigma-Aldrich

(St

Louis,

MO).

Poly(vinylpyrrolidone), (PVP, Kollidon 25, Mw=28-34 kg/mole) was obtained from
BASF (Edison, NJ). PVP was vacuum dried at 70 °C over night and stored over
DrieriteTM at all times. The chemical structures of indomethacin, PVP, and polystyrene
are shown in Figure 5.1.

Figure 5.1. Chemical structures of (a) nifedipine, (b) indomethacin, (c) PVP, and (d)
polystyrene.
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5.2.2

Preparation of Amorphous Solid Dispersions
Amorphous solid dispersions of indomethacin and PVP were prepared by

cryomilling followed by in situ melt quenching in NMR rotors while spinning.
isotopically enriched indomethacin (3% wt

13

C

13

C-labeled and 97% wt unlabeled at the

carboxylic acid carbon) was used. 1 g samples of drug and polymer in weight ratios of
9:1, 8:2 and 7:3 drug:polymer were cryomilled at 10 Hz (SPEX SamplePrep 6770
Freezer/Mill, SPEX SamplePrep LLC., Metuchen, NJ) for five cycles. Each cycle
consisted of 2 minutes of milling and 2 minutes of cool down. Liquid nitrogen was used
as a coolant. The cryomilling procedure was used to ensure optimum mixing between the
drug and polymer prior to melting. The mixtures were then transferred into 7.5 mm
zirconia NMR rotors with Teflon or Kel-F end caps (Revolution NMR, LLC, Fort
Collins, CO). The top end cap had a small hole to allow moisture to evaporate during
heating. The rotors were heated in the NMR probe at 170 °C for approximately 10
minutes while spinning at 4 kHz and then rapidly cooled to room temperature, resulting
in the amorphous solid dispersions.
Amorphous solid dispersions of indomethacin and polystyrene were prepared by
solvent evaporation using a Büchi Rotavapor R-215 (Büchi, Switzerland). A low level of
indomethacin (1%) that was

13

C labeled at the carboxylic acid carbon were used. The

drug and polymer were dissolved in methylene chloride and the solvent was rotary
evaporated at 35 °C. The obtained solids were subsequently vacuum dried at room
temperature overnight to remove residual solvent.
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5.2.3

Modulated DSC
The glass transition temperatures of the amorphous solid dispersions were

determined by modulated DSC (MDSC) using a Q2000 differential scanning calorimeter
equipped with an RCS90 refrigerated cooling system (TA Instruments, Newcastle, DE).
Nitrogen gas was used as the purge gas at a flow rate of 50 mL/min. Temperature and
enthalpy were calibrated using indium. Samples (2-5 mg) prepared by melt quenching as
described

above

were

placed

in

TZero™aluminum

pans

and

sealed

with

TZero™aluminum hermetic lids with one pinhole (TA Instruments, New Castle, DE).
Samples were equilibrated at 0 °C, and then heated at 1 °C/min to 200 °C with an
amplitude of ±0.5 °C and a modulation period of 60 s. The glass transition was separated
into the reversing heat flow signal and was determined by half height at midpoint using
the Universal Analysis software (TA Instruments, Newcastle, DE).

5.2.4

Solid-State NMR Experiments
All solid-state NMR spectra were acquired using a Tecmag Redstone HF3 2RX

spectrometer (Tecmag, Inc., Houston, TX), operating at 75.48 MHz for

13

C. Samples

were packed into 7.5 mm zirconia rotors and sealed with Teflon or Kel-F end caps
(Revolution NMR, LLC, Fort Collins, CO). Experiments were performed using a 7.5 mm
double-resonance MAS probe (Varian, Palo Alto, CA). All

13

C spectra were acquired

under magic angle spinning (MAS) 43 at 4 kHz if not specified otherwise, using rampedamplitude CP,45 total sideband suppression (TOSS)44 and SPINAL64 decoupling73 with a
1

H decoupling field of about 62 kHz. A 2 ms contact time was used in all experiments. 3-
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Methylglutaric acid was used to optimize spectrometer settings and as an external
standard, with the methyl peak referenced to 18.84 ppm.74
The spectra of IMC-PS amorphous solid dispersions were acquired using MAS of
5.2 kHz to avoid residual spinning sideband overlap. The spectra of IMC-PS amorphous
solid dispersions were collected as a function of temperature using a variable-temperature
accessory stack (Varian, Palo Alto, CA). Samples were equilibrated at each temperature
for at least 15 min before data acquisition. At temperatures above 100 °C, direct
polarization was used to acquire the spectra because cross-polarization efficiency was
greatly reduced in the highly mobile environment.
1

H T1ρ relaxation times of amorphous solid dispersions were determined as a

function of temperature using a variable-temperature accessory stack (Varian, Palo Alto,
CA). Lead nitrate was used to calibrate the temperature prior to the experiment.90 A
linear slope of 0.75 was obtained for the temperature range between 20 and 180 °C,
agreeing very well with the literature reported value.90 Samples were equilibrated at each
temperature for at least 15 min before data acquisition. 1H T1ρ values were determined
between 20 and 120 °C for both nifedipine and PVP in the amorphous solid dispersions,
by varying the spin-lock duration time following a 90° pulse. A recycle delay of about
1.5 – 2 times the measured T1 was used to maximize the signal-to-noise ratio. A
frequency field of about 65 KHz was used for the spin-lock field. The peak of interest
was integrated and plotted against the spin-lock duration times and the values were fitted
to the following equation using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA)
𝑀𝑀 = 𝑀𝑀0 ∙ 𝑒𝑒

−

𝜏𝜏
𝑇𝑇1𝜌𝜌

(5.1)
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where M is the integrated signal intensity and τ is the spin-lock duration time. M0 is an
amplitude parameter obtained from the fit and T1ρ is the obtained spin-lattice relaxation
time in the rotating frame.
2D exchange

13

C NMR spectra were collected with MAS using a hypercomplex

data set.125 Two sets of spectra were collected at each time increment to generate both
real and imaginary components of the spectra. A mixing time of 2 s and a spectral width
of 2000 Hz were used. 40 data points were collected in the direct dimension and 80 were
collected in the indirect dimension. Sine bell apodization was applied to both dimensions
during processing. Symmetrization was performed on the spectra of 70-30 IMC-PVP to
reduce t1 noise.

5.3 Results and Discussion
5.3.1

Molecular Mobility of Amorphous Indomethacin
In this section, studies of the molecular mobility of a pure amorphous compound,

indomethacin, by 2D exchange NMR experiments below and above its glass transition
temperature are reported. Figure 5.1 shows the 2D exchange

13

C NMR spectra of the

carbonyl region of amorphous indomethacin at 20 °C, 40 °C and 50 °C using a 2 s mixing
time. No visible cross peaks were found in the spectrum of amorphous IMC carboxylic
acid carbon at 20 °C and 40 °C (Figure 5.1a and b). The absence of cross peaks suggests
that below the glass transition temperature, which is 46 °C for amorphous indomethacin,
the molecules do not possess a high degree of translational mobility, which is required for
exchange processes to occur. Two clear cross peaks between the dimer and the carboxylic
acid-amide complex can be seen from Figure 5.1c for the spectrum collected at 50 °C.
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The off diagonal peaks suggest that above the glass transition temperature, the dimers are
breaking and forming carboxylic acid-amide complexes, and vice versa. This means the
amorphous IMC is a very dynamic system at 50 °C as the molecules not only have to
break the one type of hydrogen bond but also have to possess enough translational
mobility to form another type of hydrogen bond.
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Figure 5.1. 2D exchange

13

C MAS NMR spectra of the carbonyl region of amorphous

indomethacin at (a) 20 °C, (b) 40 °C, and (c) 50 °C. The sample contained 5%

13

C

labeled indomethacin (carboxyl carbon) and 95% natural abundant indomethacin. A
mixing time of 2 s was used.
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5.3.2

Molecular Mobility of Amorphous Indomethacin in Amorphous Solid
Dispersions with PVP
This section describes the dynamics of indomethacin-PVP amorphous solid

dispersions studied via 2D exchange NMR experiments and how the presence of a
polymer affects the dynamics of the drug. Amorphous solid dispersions with 70-90%
drug loadings were used, representing the higher end of drug/polymer ratios found in
amorphous solid dispersions. Figure 5.2 shows the 2D exchange 13C NMR spectra of the
carbonyl carbon region of a 90-10 IMC-PVP amorphous solid dispersion at 40, 50 and
60 °C. The glass transition temperature of the 90-10 IMC-PVP amorphous solid
dispersion is 53 °C at the midpoint and 48 °C at the onset. No cross peaks were found in
the spectrum collected at 40 °C, indicating limited translational mobility and dynamics
below the glass transition temperature. The spectrum collected at 50 °C shows two cross
peaks between the carboxylic acid dimers and the carboxylic acid-amide complexes. This
suggests that the IMC molecules gained sufficient mobility near the glass transition
temperature so that the carboxylic acid dimers interconverted with the carboxylic acids
that hydrogen bond with the amides. The spectrum collected at 60 °C shows the two
cross peaks with greater intensity, indicating the exchange was faster at temperatures
slightly higher than Tg, where the system was in the rubbery state. The disordered
carboxylic acid species was not found to exchange with either the dimer or the carboxylic
acid-amide complex. Like discussed in the previous chapter, one possible explanation is
that this peak may not repsent entirely the chain species and may contain some unknown
species that do not participate in the exchange. The exact reason is not clear at this point.
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Figure 5.3 shows the 2D exchange

13

C NMR spectra of the carbonyl carbon

region in an 80-20 IMC-PVP amorphous solid dispersion at 50, 60 and 70 °C. Similar to
the 90-10 IMC-PVP, no cross peaks were detected below the glass transition temperature
(Figure 5.3a). The midpoint glass transition temperature for 80-20 IMC-PVP is 64 °C and
the onset glass transition temperature is 60 °C. At close to the glass transition temperature
(60 °C), cross peaks between the carboxylic acid dimers and the carboxylic acid-amide
complexes were seen. Above the glass transition temperature at a temperature of 70 °C,
the intensity of the cross peaks increased. Once again, disordered chains were not found
to exchange with any other species.
Figure 5.4 shows the 2D exchange

13

C NMR spectra of the carbonyl carbon

region in a 70-30 IMC-PVP amorphous solid dispersion at 70 and 80 °C. While the
midpoint glass transition temperature for this system is 73 °C, no cross peaks could be
detected at either 70 or 80 °C. As described in chapter 4, there were essentially no dimers
present in this drug/polymer ratio. The result suggested that the carboxylic acid chains
(176 ppm) did not participate in the exchange with the carboxylic acid-amide complexes
(172 ppm). Similarly, the carboxylic acid chains were not found to participate in
exchange in any other systems investigated, which include the neat amorphous
indomethacin, and indomethacin amorphous solid dispersions with 90% and 80% drug
loadings.
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Figure 5.2. 2D exchange 13C MAS NMR spectra of the carbonyl region of 90-10 IMCPVP amorphous solid dispersions at (a) 40 °C, (b) 50 °C and (c) 60 °C. The sample
contained 3%

13

C labeled indomethacin (carboxyl carbon) and 97% natural abundant

indomethacin. A mixing time of 2s was used.
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Figure 5.3. 2D exchange 13C MAS NMR spectra of the carbonyl region of 80-20 IMCPVP amorphous solid dispersions at (a) 50 °C, (b) 60 °C and (c) 70 °C. The sample
contained 3%

13

C labeled indomethacin (carboxyl carbon) and 97% natural abundant

indomethacin. A mixing time of 2s was used. The spectra were symmetrized.
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Figure 5.4. 2D exchange 13C MAS NMR spectra of the carbonyl region of 70-30 IMCPVP amorphous solid dispersions at (a) 70 °C, and (b) 80 °C. The sample contained 3%
13

C labeled indomethacin (carboxyl carbon) and 97% natural abundant indomethacin. A

mixing time of 2s was used. The spectra were symmetrized.
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5.3.3

Molecular Mobility of Amorphous Indomethacin in a Dilute System
An indomethacin-polystyrene amorphous solid dispersion with 1% drug loading

was investigated as a model system to study the mobility of the drug in a very dilute
environment. Figure 5.5 shows the 2D exchange 13C NMR spectra of the carbonyl region
of the sample at 40 and 50 °C. No cross peaks were detected at 40 °C, but cross peaks
were observed at 50 °C. The onset glass transition temperature of the system is 49 °C and
the midpoint value is 59 °C. The cross peaks suggested interconversion between the
indomethacin cyclic dimers and the free carboxylic acids even in a very dilute
environment in the rubbery state. Since the onset Tg value of the sample is 49 °C, IMC at
50 °C is a glass that is not at the equilibrium. This is exactly what is shown from the 2D
exchange NMR spectra in Figure 5.5. One can recall Figure 4.13 of Chapter 4 where the
Van’t Hoff plot also deviates from linearity at temperatures below 50 °C. These two
studies are in excellent agreement with each other
Besides exchange experiments, mobility can also be studied by spectral line shape.
Figure 5.6 shows the carbonyl region of the 13C spectra of 1% IMC in polystyrene at ten
different temperatures. At low temperatures, the spectra consist of two resolved peaks,
representing the carboxylic acid dimer and the free carboxylic acid. Above the glass
transition temperature, the peaks gradually became broadened. At 80 °C, the two peaks
became so broad that they were indistinguishable. Beyond this temperature, the two
peaks coalesced into a single peak which became narrower again as temperature
increased. The broadening of the peaks and the eventual coalescence are a result of the
overlap between the NMR spectral time scale and the time scale of the interconversion
between the dimer and the free carboxylic acid. The chemical shift of the collapsed single
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peak is given by the mean of the two chemical shifts, weighted by the equilibrium
concentrations of the two species. Thus, a gradual upfield shift towards the free
carboxylic acid species is seen as temperature increases.
Because of the coalensce, it is difficult to measure the extent of spectral
broadening of indomethacin. For this reason, the non-protonated phenyl carbon in
polystyrene was instead investigatead to determine the temperature dependence of the
linewidth. Figure 5.7 shows the linewidth of this carbon as a function of temperature. The
linewidth is invariant below Tg, and starts to increase above Tg. The spectra achieves
maximum broadening at around 353 K, which is approximately 30 K higher than Tg. The
maximum line broadening corresponds to a motional frequency of the molecule that is
equivalent to the line narrowing technique, which is the proton decoupling field or the
magic angle spinning (MAS) rate. To differentiate between the two mechanisims,
experiments were carried out where the sample was spun at 1.5 kHz and 20 °C. Little
difference in linewidth was observed between the two spectra obtained with MAS of 4
kHz and 1.5 kHz, indicating MAS was not the mechanism interfering with the molecular
motions in the systems, but the dipolar decoupling was. Taking the proton decoupling
field of 62.5 kHz, the average correlation time at 353 K can be estimated by
〈𝜏𝜏〉 =

1

𝜔𝜔𝐻𝐻

1

= 2𝜋𝜋𝜋𝜋

(5.2)

where v equals 62.5 kHz. The average correlation time 〈𝜏𝜏〉 is estimated to be 2.5 µs at 353
K. Temperature dependent linewidth broadening has been observed in PEO126 and in a

small molecule amorphous blend127, where the average correlation times were estimated
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to be 2.3 µs at 328 K and 1.9 µs at 325 K using this method. The value obtained in this
study is quite reasonable compared to these results.
It is interesting to see from Figures 5.6 and 5.7 that both indomethacin and
polystyrene achieve the maximum spectral linewidth at the same temperature. This is an
indication that these two components are miscible and undergo the same motional
processes. To investigate the phase homogeneity of the system, 1H T1ρ relaxation times of
the two components were measured at selected temperatures and the results are shown in
Table 5.1. As is seen from the table, indomethacin and polystyrene are intimately mixed
on the nanometer scale at all temperatures investigated, as indicated by the similar 1H T1ρ
relaxation times of the two components. The relaxation times of indomethacin carboxylic
acid protons seem to be closer in value to the polystyrene phenyl ring protons than the
backbone alkyl protons, even though the differences are not very significant. This
observation could indicate that the indomethacin molecules are primarily associated with
the phenyl ring of polystyrene through hydrophobic interactions.
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Figure 5.5. 2D exchange

13

C MAS NMR spectra of the carbonyl region of 1% IMC in

polystyrene at (a) 40 °C, and (b) 50 °C. IMC was
carbon. A mixing time of 2s was used.

132

13

C labeled at the carboxylic acid

Figure 5.6.

13

C spectra of the carboxylic acid carbon of 1% amorphous indomethacin in

polystyrene at (a) 20 °C, (b) 30 °C, (c) 40 °C, (d) 50 °C, (e) 60 °C, (f) 70 °C, (g) 80 °C,
(h) 110 °C, (i) 140 °C, and (j) 160 °C. Spectra a-g were collected by cross polarization.
Spectra h-j were collected by direct polarization.
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Figure 5.7. Temperature dependence of

13

C SSNMR linewidth of the non-protonated

phenyl carbon of polystyrene in the IMC-polystyrene amorphous solid dispersion.
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Table 5.1. 1H T1ρ relaxation times of different species in the IMC-PS amorphous solid
dispersion with 1% IMC.

20 °C

1H

T1ρ
SE

95% CI
40 °C

1H

T1ρ
SE

95% CI
50 °C

1H

T1ρ
SE

95% CI

IMC
(179 ppm)
7.3
0.3
6.684 to
7.974
6.2
0.3
5.557 to
6.806
4.5
0.2
4.034 to
5.062

IMC
(170 ppm)
6.8
0.6
5.412 to
8.220
5.7
0.5
4.480 to
6.961
5.3
0.4
4.418 to
6.264
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PS
(147 ppm)
7.0
0.2
6.590 to
7.436
5.9
0.1
5.726 to
6.173
4.4
0.2
4.014 to
4.852

PS
(128 ppm)
6.6
0.1
6.331 to
6.938
6.1
0.1
5.925 to
6.357
4.2
0.1
3.881 to
4.530

PS
(41 ppm)
6.6
0.1
6.438 to
6.851
6.0
0.1
5.782 to
6.293
3.8
0.1
3.618 to
4.033

5.1 Conclusions
In this chapter, molecular mobilities and dynamics of three types of amorphous
systems were studied using solid-state NMR relaxation times, 2D exchange experiments
and linewidth analyses. The systems under study were neat amorphous indomethacin,
high drug loadings of indomethacin amorphous solid dispersions with PVP, and dilute
dispersions of amorphous indomethacin in polystyrene. Cross peaks between the
carboxylic acid dimers and carboxylic acid-amide complexes were observed near the
glass transition temperature for all systems that exhibited these two species. Cross peaks
between the carboxylic acid dimers and the free carboxylic acid were observed near the
glass transition temperature for the dilute indomethacin system. The cross peaks indicated
exchange processes between dimers and the carboxylic acid-amide complexes or between
dimers and the free carboxylic acids. Disordered chains were not found to exchange with
the other species in all systems. The exact reason for this is unclear.
For the dilute amorphous indomethacin system, spectral line shapes were
analyzed as a function of temperature. The analysis revealed that the motional processes
of indomethacin and polystyrene were coupled above the glass transition temperature.
This is confirmed by the analysis of 1H T1ρ relaxation times of the two components as a
function of temperature. The result also suggested that the system was at equilibrium
above the glass transition temperature.

Copyright © Xiaoda Yuan 2015
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Chapter 6. Impact of Miscibility, Hydrogen Bonding, and Mobility on Physical
Stability of Amorphous Solid Dispersions

6.1 Introduction
Amorphous solid dispersions represent a major enabling technique to increase the
bioavailability of poorly water soluble compounds. This type of amorphous solid
dispersion is an amorphous system where the active pharmaceutical ingredients (APIs) in
the amorphous state are homogeneously dispersed in matrices of polymer or other
excipients. One of the biggest issues concerning this approach is achieving the physical
stability needed for maintaining shelf life. Crystallization during storage often leads to
reduced dissolution rate and bioavailability. Thus, the ability to assess the risk and predict
the physical stability is critical in developing amorphous solid dosage forms.
Crystallization process of an API from an amorphous solid dispersion is very
complicated, as several factors impact the crystallization behavior of an API. These
include: the intrinsic crystallization tendency of the amorphous API,26,

72, 128, 129

miscibility between the API and polymer,62 molecular-level interactions between the API
and polymer,32,

56

and mobility of the amorphous system.57,

111, 130-132

In addition, the

absorption of water has been shown to promote crystallization from amorphous APIs and
amorphous solid dispersions due to the plasticizing effect of water.34, 133, 134
In Chapters 3, a method was established to determine the miscibility of the API
and polymer in an amorphous solid dispersion on the nanometer length scale using solidstate NMR 1H relaxation times. In Chapter 4, it was demonstrated that with a 70% drug
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loading, indomethacin carboxylic acid dimers were almost fully disrupted in amorphous
solid dispersions with PVP, and most of hydrogen bonds were between the drug and the
polymer. In Chapter 5, molecular mobility in indomethacin amorphous systems was
studied using solid-state NMR relaxation times and exchange processes. While
understanding these fundamental interactions is critical to evaluate the molecular
environment in amorphous solid dispersions, it is important to understand how these
interactions impact crystallization of amorphous drugs. In this chapter, the physical
stabilities of three miscible amorphous solid dispersions, each having different degrees of
hydrogen bonding between the API and the polymer under different storage conditions
were studied.
Indomethacin, nifedipine and indomethacin methyl ester were selected as the
three APIs to represent three cases with varying degrees of hydrogen bonding capabilities
with poly(vinylpyrrolidone) (PVP). Among the three different molecules, indomethacin
having a carboxylic acid group will form the strongest hydrogen bond with PVP.
Nifedipine can form an intermediate-strength hydrogen bond with PVP through a
secondary amine. Indomethacin methyl ester, having no carboxylic acid functional group,
cannot form hydrogen bonds with PVP. A drug/polymer weight ratio of 7:3 was selected
for all three systems because this is the ratio corresponding to a near total disruption of
indomethacin dimers. The ratio was kept the same for the other two systems for the
purpose of comparison. Powder X-ray diffraction (PXRD), Raman spectroscopy, and
polarized light microscopy were performed to detect crystallization. Modulated DSC
(MDSC) was performed to detect miscibility. TGA was performed to obtain the water
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content. Solid-state NMR spectroscopy was used to determine miscibility, mobility and
crystallinity of the amorphous solid dispersions.

6.2 Materials and Methods
6.2.1

Materials
Indomethacin (IMC, γ form, minimum purity 99%) was purchased from Sigma-

Aldrich (St Louis, MO). Nifedipine (NIF, minimum purity 98.0 %) was purchased from
TCI America (Portland, OR) and was protected from light whenever possible.
Indomethacin methyl ester was synthesized from indomethacin and methanol. The details
are described in the next section. PVP K25 (Kollidon 25, Mw=28-34 kg/mole) was
obtained from BASF (Edison, NJ). PVP was vacuum dried at 70 °C overnight and stored
over DrieriteTM at all times. Sodium bromide (NaBr) and sodium chloride (NaCl) were
purchased from EMD Chemicals (Gibbstown, NJ). The chemical structures of
indomethacin, nifedipine, indomethacin methyl ester and PVP are shown in Figure 6.1.
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Figure 6.1. Chemical structures of (a) indomethacin, (b) nifedipine, (c) indomethacin
methyl ester, and (d) PVP.
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6.2.2

Synthesis of Indomethacin Methyl Ester
Indomethacin methyl ester was synthesized by refluxing indomethacin and

methanol in the presence of sulphuric acid. 10 grams of γ-indomethacin, 200 ml of
methanol, 0.5 ml of sulphuric acid, and approximately 1 gram of molecular sieves (3Å,
4x8 mesh size) were added into a round-bottom flusk. The molecular sieves acted as a
“water trap” to remove water (water is a product of the reaction) and favor the reversible
reaction towards esterification. The solution was refluxed overnight at 70 °C in an oil
bath with a stirring rate of 100 rpm. When the reaction was stopped, molecular sieves
were filtered out and crystallization occurred immediately as the temperature dropped.
The obtained crystals were washed with methanol and then with MilliQ water several
times before being vacuum dried at room temperature overnight. The obtained product
was pure as determined by thin layer chromatography (TLC). The compound was
characterized by solution 1H NMR, PXRD, 13C solid-state NMR, DSC and TGA.

6.2.3

Preparation of Amorphous Solid Dispersions
Amorphous solid dispersions of IMC-PVP, NIF-PVP and IMC methyl ester-PVP

were prepared via melt quenching. One gram samples of drug and polymer in weight
ratio of 7:3 drug:polymer were cryomilled at 10 Hz (SPEX SamplePrep 6770
Freezer/Mill, SPEX SamplePrep LLC., Metuchen, NJ) for five cycles. Each cycle
consisted of 2 minutes of milling and 2 minutes of cool down. Liquid nitrogen was used
as a coolant. The cryomilling procedure was used to ensure the optimum mixing between
the drug and polymer prior to melting. The cryomilled mixtures were then transferred
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into a Teflon beaker and heated in an oil bath for several minutes until melted. The
mixtures were slightly stirred using a spatula to ensure mixing. The IMC amorphous solid
dispersion was heated at 170 °C, the NIF dispersion was heated at 180 °C, and the IMC
methyl ester dispersion was heat at 160 °C. The mixtures typically melted within 10
minutes of heating. The melted mixtures were then solidified by quench-cooling with
liquid nitrogen. The solid dispersions were vacuum dried at room temperature overnight
to minimize residual moisture. The IMC and NIF amorphous solid dispersions were
ground with a mortar and pestle and sieved using a sieve shaker (Gilson Performer III
SS-3, Gilson Company, Lewis Center, OH). Particles of size between 45-300 μm were
retained. The IMC methyl ester amorphous solid dispersion was not ground or sieved due
to its low glass transition temperature and stickiness at room temperature.

6.2.4

Stability Studies
The IMC-PVP and NIF-PVP amorphous solid dispersions were stored at three

different conditions: 50 °C/0% RH, 40 °C/57% RH, and 40 °C/75% RH. DrieriteTM
desiccants (CaSO4) were used to create the near zero relative humidity. Saturated salt
solutions of sodium bromide and sodium chloride were used to control the relative
humidity levels of 57% and 75% RH, respectively. The IMC methyl ester-PVP
amorphous solid dispersion was stored at 4 °C/0% RH. The reason for choosing 50 °C as
a dry condition for the IMC and NIF dispersions was that these amorphous solid
dispersions had a glass transition temperature of about 70 °C. A temperature of 50 °C is
about 20 °C below their glass transition temperature. Similarly, the IMC methyl ester
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dispersion had a glass transition temperature of about 20 °C and the storage temperature
was about 16 °C below its glass transition temperature. These conditions were chosen to
minimize the effect of glass transition temperature on these different amorphous systems.
Samples were analyzed at time 0, and after storage of 1 week, 2 weeks, 1 month, 2
months, and 6 months by PXRD, MDSC, TGA, Raman spectroscopy, polarized light
microscopy and solid-state NMR spectroscopy. Dissolution tests were conducted at time
0 and after 6 months of storage.

6.2.5

Powder X-ray Diffraction
Crystallization of amorphous solid dispersions was monitored using a powder X-

ray diffractometer (MiniFlex 600, Rigaku Corporation, Japan) with Cu Kα radiation
operating at 40 kV and 15 mA. Samples were scanned from 2θ of 2-42° at the rate of
2°/min and a step size of 0.02°.

6.2.6

Microscopic and Spectroscopic Characterization
Crystallization of the samples was monitored at various time points using a

optical microscope (Olympus BX 51, Olympus America Inc., Center Valley, PA)
equipped with a polarizer (Instec, Boulder, CO) and a first order red compensator (UTP530, Olympus America Inc., Center Valley, PA). Images were captured using a SPOT
Insight digital camera (Diagnostic Instruments, Inc., Sterling Heights, MI).
Crystallization and polymorphic forms of the samples were also studied using
Raman spectroscopy (DXR Raman Microscope, Thermo Scientific, Madison, WI) with a
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780 nm laser source. Spectra were collected with 20 s exposure time and 20 scans,
through a 50x objective and using a 25 μm pinhole aperture. Laser power was typically
set between 1 – 2 mW. Fluorescence was removed from the spectra using baseline
corrections.

6.2.7

Thermal Characterization
The glass transition temperatures of amorphous solid dispersions at various time

points were determined by modulated DSC (MDSC) using a Q2000 differential scanning
calorimeter equipped with an RCS90 refrigerated cooling system (TA Instruments,
Newcastle, DE). Nitrogen gas was used as the purge gas at a flow rate of 50 mL/min.
Temperature and enthalpy were calibrated using indium. Samples (2-5 mg) prepared by
melt quenching as described above were placed in TZero™aluminum pans and sealed
with TZero™aluminum hermetic lids with one pinhole (TA Instruments, New Castle,
DE). Samples were equilibrated at 0 °C, and then heated at 1 °C/min to 200 °C with an
amplitude of ±0.5 °C and a modulation period of 60 s. The glass transition was separated
into the reversing heat flow signal and was determined by half-height at midpoint using
the Universal Analysis software (TA Instruments, Newcastle, DE).
The water contents of amorphous solid dispersions at various time points were
measured using thermogravimetric analysis (TGA Q20, TA Instruments, Newcastle, DE).
Nitrogen gas was used as the purge gas at a flow rate of 40 mL/min for the balance and
60 mL/min for the sample. Temperature was calibrated using a nickel standard and a
magnetic bar for the Curie Point Temperature. Weight was calibrated using standard
weights (200 mg and 1 g). During the experiments, approximately 10 mg of sample was
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placed on a platinum pan and heated at 10 °C/min from room temperature to 200 °C. The
weight loss from room temperature to 120 °C was analyzed for the water content.

6.2.8

Solid-State NMR Spectroscopy
All solid-state NMR spectra were acquired using a Tecmag Redstone HF3 2RX

spectrometer (Tecmag, Inc., Houston, TX), operating at 75.48 MHz for

13

C. Samples

were packed into 7.5 mm zirconia rotors and sealed with Teflon or Kel-F end caps
(Revolution NMR, LLC, Fort Collins, CO). Experiments were performed using a 7.5 mm
double-resonance MAS probe (Varian, Palo Alto, CA). All

13

C spectra were acquired

under magic angle spinning (MAS)43 at 4 kHz, using ramped-amplitude CP,45 total
sideband suppression (TOSS)44 and SPINAL64 decoupling73 with a 1H decoupling field
of about 62 kHz. A spectral width of 15 kHz, a 1H 90° pulse width of about 4.5 µs, a
contact time of 2 ms and a pulse delay of 1.5 – 2 times the measured T1 were used in all
experiments. 3-Methylglutaric acid was used to optimize spectrometer settings and was
used as an external standard, with the methyl peak referenced to 18.84 ppm.74 All
experiments were conducted at -30 °C to avoid crystallization during the experiments.
For samples that did not show crystallization from PXRD and microscope observation, a
total of 512 points were acquired and the FIDs were zero-filled to 4096 points. For
samples that showed crystallization from PXRD and microscope observation, a total of
2048 points were acquired and the FIDs were zero-filled to 16384 points. No linebroadening was used to transform the spectra.
1

through

H T1 relaxation values were measured using the saturation-recovery experiment
13

C observation. For samples that did not show crystallization, a total of 512
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points were acquired and the FIDs were zero-filled to 4096 points with 80 Hz of
Gaussian line-broadening. For samples that showed crystallization, a total of 1024 points
were acquired and the FIDs were zero-filled to 16384 points with 20 Hz of Gaussian linebroadening. In the Fourier-transformed spectrum, the peak of interest was integrated and
plotted against recovery delay times and the values were fitted to the following equation
using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA)
𝑀𝑀 = 𝑀𝑀0 ∙ (1 − 𝑒𝑒

−

𝜏𝜏
𝑇𝑇1

)

(6.1)

where M is the integrated signal intensity and τ is the recovery delay time. M0 is an
amplitude parameter obtained from the fit and T1 is the obtained spin-lattice relaxation
time.
1

H T1ρ relaxation times were measured by varying the spin-lock duration time

following a 90° pulse. A frequency of about 55-60 kHz was used for the spin-lock field.
The acquisition points and Fourier transform conditions are the same as those used in the
1

H T1 experiment. The peak of interest was integrated and plotted against the spin-lock

duration times and the values were fitted to the following equation using GraphPad Prism
(GraphPad Software, Inc., La Jolla, CA)
𝑀𝑀 = 𝑀𝑀0 ∙ 𝑒𝑒

−

𝜏𝜏
𝑇𝑇1𝜌𝜌

(6.2)

where M is the integrated signal intensity and τ is the spin-lock duration time. M0 is an
amplitude parameter obtained from the fit and T1ρ is the obtained spin-lattice relaxation
time in the rotating frame.
In order to quantify the crystallinity of the NIF sample stored at 40 °C/75% RH,
the 163-173 ppm regions in the spectra of these samples were fitted by a linear
combination of three reference spectra (i.e. amorphous, the α form, and the β form) that
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represent the possible components in the sample using least square procedures with
MATLAB (MathWorks, Natick, MA).

6.2.9

Dissolution Studies
Dissolution experiments were carried out using a Pion μDiss Profiler with a fiber

optic detection system (Pion Inc., Billerica, MA). The dissolution medium used was 20
mL of pH 2 HCl buffer for IMC amorphous solid dispersions and 20 mL of 50 mM pH
6.8 phosphate buffer for NIF amorphous solid dispersions. The dissolution media were
chosen to minimize the pH effect of ionizable drugs. Tween 80 (15 μg/mL, below CMC)
was added to the dissolution media to help wet the particles. Calibration stock solutions
for both drugs were prepared in methanol. The stock solution was added into the
respective dissolution medium to construct the calibration curve. Concentration of
indomethacin was measured at 296 nm from the second-derivative spectrum;
concentration of nifedipine was measure at 256 nm from the second derivative spectrum.
The use of the second-derivative spectrum mitigates the particle scattering effect.135, 136
Calibration and dissolution were conducted at 37 °C. Samples weighing 2 mg were used
in the dissolution experiments, equivalent to 70 μg/mL of total drug concentration if fully
dissolved. Sink conditions were not maintained because the dissolution study was
designed to assess supersaturation levels. The dissolution process was monitored over a
period of 4 hours, with data collection every 15 seconds for the first hour and every 2
minutes for the rest.
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6.3 Results
6.3.1

Characterization of Indomethacin Methyl Ester
As a derivative of indomethacin, the indomethacin methyl ester was synthesized

to compare its hydrogen bonding capabilities and the implications on physical stability
with the parent compound, indomethacin. The synthesized molecule was fully
characterized using solution 1H NMR, PXRD, 13C solid-state NMR, DSC and TGA.
The 1H NMR spectrum of indomethacin methyl ester in CDCl3 is shown in Figure
6.2. The chemical shifts are: 2.37 (s, -CH3), 3.65 (s, -CH2), 3.68 (s, -OCH3), 3.82 (s,COOCH3), 6.6 (dd, H-6), 6.83/6.85 (d, H-7), 6.93/6.94 (d, H-4), 7.44/7.45 (d, A2/B2),
7.64/7.65 (d, A2/B2). The chemical shifts are in very good agreement with values reported
in the literature.137
Indomethacin methyl ester crystal has a pale-yellow color and a long needle shape
under the polarized microscope, as shown in Figure 6.3. The crystal was also
characterized by DSC, TGA, PXRD and

13

C solid-state NMR. The compound has a

melting temperature of 91.7 °C as seen in the DSC thermogram (Figure 6.4). The
obtained crystal has a minimal amount of residual solvent as shown from the TGA in
Figure 6.5. Degradation starts to occur at approximately 195 °C. Figure 6.6 shows the
powder X-ray diffractogram, which matches very well with the solved single crystal
structure.138 Figure 6.7 shows the

13

C solid-state NMR spectrum. The methyl ester

carbonyl carbon has a chemical shift of approximately 174 ppm, an upfield shift of 5 ppm
compared to the carboxylic acid carbon in indomethacin (179 ppm). The formation of a
methyl ester is also indicated by the new peak emerging around 54 ppm.
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Figure 6.2. 1H NMR spectrum of indomethacin methyl ester in CDCl3.
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Figure 6.3. Polarized light microscopy image of indomethacin methyl ester.
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Figure 6.4. DSC thermogram of indomethacin methyl ester.
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Figure 6.5. TGA of indomethacin methyl ester.
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Figure 6.7.

13

C CPMAS spectra of (a) indomethacin methyl ester, (b) γ-indomethacin,

and (c) α-indomethacin.
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6.3.2

Analysis of Stability Samples by Various Techniques
Seven samples that underwent the stability studies were analyzed by PXRD,

Raman spectroscopy, polarized light microscopy, MDSC, TGA and solid-state NMR
spectroscopy at each time point. This section is organized by techniques and the results
obtained through each of these techniques will be discussed. Results obtained from solidstate NMR experiments will be discussed in the end in a separate section.

6.3.2.1 Powder X-ray Diffraction
Figures 6.8 - 6.14 show the powder X-ray diffractograms of 70-30 IMC methyl
ester-PVP, 70-30 IMC-PVP and 70-30 NIF-PVP amorphous solid dispersions under
different storage conditions. No crystallization was observed from the PXRD patterns for
the IMC methyl ester-PVP amorphous solid dispersions stored at 4 °C/0% RH for up to 6
months (Figure 6.8). No crystallization was observed in the IMC-PVP amorphous solid
dispersion stored at 50 °C/ 0% RH and that stored at 40 °C/57%RH (Figure 6.9 and 6.10).
The IMC-PVP sample stored at 40 °C/75%RH exhibited minor crystalline peaks after 1
month of storage (Figure 6.11). These peaks grew in intensity at the 2 month and 6 month
time points. The crystalline peaks correspond to the IMC γ polymorph. Similarly, the
NIF-PVP amorphous solid dispersion stored at 50 °C/0% RH and that stored at
40 °C/57%RH exhibited no crystallization for up to 6 months (Figure 6.12 and 6.13).
However, the NIF-PVP sample stored at 40 °C/75%RH exhibited crystallinity after just 1
week of storage (Figure 6.14). The crystalline peaks correspond to the β polymorph.
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Figure 6.8. PXRD patterns of 70-30 IMC methyl ester-PVP amorphous solid dispersions
stored at 4 °C/0% RH. The diffractograms from top to bottom were collected at time 0, 1
week, 2 weeks, 1 month, 2 months and 6 months.
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Figure 6.9. PXRD patterns of 70-30 IMC-PVP amorphous solid dispersions stored at
50 °C/0% RH. The diffractograms from top to bottom were collected at time 0, 1 week, 2
weeks, 1 month, 2 months and 6 months.
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Figure 6.10. PXRD patterns of 70-30 IMC-PVP amorphous solid dispersions stored at
40 °C/57%RH. The diffractograms from top to bottom were collected at time 0, 1 week,
2 weeks, 1 month, 2 months and 6 months.
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Figure 6.11. PXRD patterns of 70-30 IMC-PVP amorphous solid dispersions stored at
40 °C/75%RH. The diffractograms from top to bottom were collected at time 0, 1 week,
2 weeks, 1 month, 2 months and 6 months.
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Figure 6.12. PXRD patterns of 70-30 NIF-PVP amorphous solid dispersions stored at
50 °C/0% RH. The diffractograms from top to bottom were collected at time 0, 1 week, 2
weeks, 1 month, 2 months and 6 months.
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Figure 6.13. PXRD patterns of 70-30 NIF-PVP amorphous solid dispersions stored at
40 °C/57%RH. The diffractograms from top to bottom were collected at time 0, 1 week,
2 weeks, 1 month, 2 months and 6 months.
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Figure 6.14. PXRD patterns of 70-30 NIF-PVP amorphous solid dispersions stored at
40 °C/75%RH. The diffractograms from top to bottom were collected at time 0, 1 week,
2 weeks, 1 month, 2 months and 6 months.
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6.3.2.2 Raman Spectroscopy
Figures 6.15-6.21 show the Raman spectra of the 70-30 IMC methyl ester-PVP,
70-30 IMC-PVP and 70-30 NIF-PVP amorphous solid dispersions under different storage
conditions. Similar to the results obtained by PXRD, no crystallization was observed
from the Raman spectra for the IMC methyl ester-PVP amorphous solid dispersions
(Figure 6.15), the IMC-PVP amorphous solid dispersion stored at 50 °C/0% RH (Figure
6.16) and that stored at 40 °C/57%RH (Figure 6.17), or the NIF-PVP amorphous solid
dispersion stored at 50 °C/0% RH (Figure 6.18) and that stored at 40 °C/57%RH (Figure
6.19) for up to 6 months. Crystallization was seen in the spectrum of the IMC-PVP
amorphous solid dispersion stored at 40 °C/75%RH after 2 months of storage, which is 1
month later than the detection of crystallization by PXRD. This is presumably due to
either sub sampling or a higher detection limit, and could potentially be improved by
sampling more particles and areas of each sample. The peak at 1700 cm-1 corresponds to
the γ polymorph. Similar to what was found using PXRD, crystallization was seen in the
spectrum of the NIF-PVP amorphous solid dispersion stored at 40 °C/75%RH after just 1
week of storage. The peak at 1680 cm-1 is characteristic of the NIF β form. The spectrum
recorded after 2 weeks of storage seemed to show a less extent of crystallization than the
spectrum recorded after 1 week of storage. This is also presumably due to sub sampling
of the dispersion, which is one of the drawbacks of Raman spectroscopy. In general, the
results obtained from the Raman spectra agreed very well with those obtained from
PXRD diffractograms.
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Figure 6.15. (a) Raman spectra and (b) the carbonyl region of the Raman spectra of 7030 IMC methyl ester-PVP amorphous solid dispersion stored at 4 °C/0% RH. From top to
bottom are spectra collected at time 0, 1 week, 2 weeks, 1 month, 2 months, 6 months,
and crystalline IMC methyl ester. No crystallization was observed in any of these
samples.
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Figure 6.16. (a) Raman spectra and (b) the carbonyl region of the Raman spectra of 7030 IMC-PVP amorphous solid dispersion stored at 50 °C/0% RH. From top to bottom are
spectra collected at time 0, 1 week, 2 weeks, 1 month, 2 months, 6 months, and γ-IMC.
No crystallization was observed in any of these samples.
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Figure 6.17. (a) Raman spectra and (b) the carbonyl region of the Raman spectra of 7030 IMC-PVP amorphous solid dispersion stored at 40 °C/57% RH. From top to bottom
are spectra collected at time 0, 1 week, 2 weeks, 1 month, 2 months, 6 months, and γIMC. No crystallization was observed in any of these samples.
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Figure 6.18. (a) Raman spectra and (b) the carbonyl region of the Raman spectra of 7030 IMC-PVP amorphous solid dispersion stored at 40 °C/75% RH. From top to bottom
are spectra collected at time 0, 1 week, 2 weeks, 1 month, 2 months, 6 months, and γIMC. Crystallization was observed in the sample after 2 months of storage.
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Figure 6.19. (a) Raman spectra and (b) the carbonyl region of the Raman spectra of 7030 NIF-PVP amorphous solid dispersion stored at 50 °C/0% RH. From top to bottom are
spectra collected at time 0, 1 week, 2 weeks, 1 month, 2 months, 6 months, and α-NIF.
No crystallization was observed in any of these samples.
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Figure 6.20. (a) Raman spectra and (b) the carbonyl region of the Raman spectra of 7030 NIF-PVP amorphous solid dispersion stored at 40 °C/57% RH. From top to bottom
are spectra collected at time 0, 1 week, 2 weeks, 1 month, 2 months, 6 months, and α-NIF.
No crystallization was observed in any of these samples.
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Figure 6.21. (a) Raman spectra and (b) the carbonyl region of the Raman spectra of 7030 NIF-PVP amorphous solid dispersion stored at 40 °C/75% RH. From top to bottom
are spectra collected at time 0, 1 week, 2 weeks, 1 month, 2 months, 6 months, and α-NIF.
Crystallization was observed in the sample after only 1 week of storage.
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6.3.2.3 Polarized Light Microscopy
Figures 6.22 - 6.28 show the polarized light microscopy images of the 70-30 IMC
methyl ester-PVP, 70-30 IMC-PVP and the 70-30 NIF-PVP amorphous solid dispersion
stored at various conditions. No crystallization was seen in the IMC methyl ester-PVP
sample being stored up to 6 months. Also, no crystallization was seen for the IMC-PVP
sample stored at 50 °C/0% RH. For the IMC-PVP sample stored at 40 °C/57% RH, some
small crystallites were seen on the surface after 6 months of storage. This small amount
of crystallization was not detected by PXRD or Raman spectroscopy. Small crystallites
were noticed for IMC-PVP sample stored at 40 °C/75% RH after 2 weeks of storage,
which is earlier than the detection of crystallization by PXRD or Raman spectroscopy.
Gradually more crystals were seen after 1 month, 2 months and 6 months of storage. For
the NIF-PVP amorphous solid dispersion, no crystallization was seen in the sample
stored at 50 °C/0% RH for up to 6 months. Very limited amount of small crystallites were
spotted on the surface for the sample stored at 40 °C/57% RH for 6 months, which again
was not detected by PXRD or Raman. Extensive crystallization was seen for the NIFPVP sample stored at 40 °C and 75% RH, consistent with the results obtained from
PXRD and Raman spectroscopy.
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Figure 6.22. Polarized light microscopy image of 70-30 IMC methyl ester-PVP
amorphous solid dispersion stored at 4 °C/0% RH at (a) time 0, (b) 1 week, (c) 2 weeks,
(d) 1 month, (e) 2 months, and (f) 6 months of storage.
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Figure 6.23. Polarized light microscopy image of 70-30 IMC-PVP amorphous solid
dispersion stored at 50 °C/0% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e)
2 months, and (f) 6 months of storage.
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Figure 6.24. Polarized light microscopy image of 70-30 IMC-PVP amorphous solid
dispersion stored at 40 °C/57% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e)
2 months, and (f) 6 months of storage.
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Figure 6.25. Polarized light microscopy image of 70-30 IMC-PVP amorphous solid
dispersion stored at 40 °C/75% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e)
2 months, and (f) 6 months of storage.
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Figure 6.26. Polarized light microscopy image of 70-30 NIF-PVP amorphous solid
dispersion stored at 50 °C/0% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e)
2 months, and (f) 6 months of storage.
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Figure 6.27. Polarized light microscopy image of 70-30 NIF-PVP amorphous solid
dispersion stored at 40 °C/57% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e)
2 months, and (f) 6 months of storage.
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Figure 6.28. Polarized light microscopy image of 70-30 NIF-PVP amorphous solid
dispersion stored at 40 °C/75% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e)
2 months, and (f) 6 months of storage.
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6.3.2.4 Modulated DSC
Figures 6.29 - 6.35 show the MDSC thermograms of 70-30 IMC methyl esterPVP, 70-30 IMC-PVP and 70-30 NIF-PVP amorphous solid dispersions under different
storage conditions. Thermograms shown herein were obtained with a pinhole lid;
thermograms obtained with the hermetic lid are not shown for the sake of conserving
space. However, glass transition temperatures are listed in Tables 6.1 - 6.3 for
experiments obtained with both the pinhole and the hermetic lid.
For the sake of brevity, only samples analyzed with hermetic lids/pans are
discussed here, because samples that are hermetically sealed better represent the true
chemical environment of the samples. A gradual increase of the glass transition
temperature of the IMC methyl ester-PVP sample over time can be seen in Table 6.1.
This is presumably due to drying of the sample over desiccant. A small melting peak at
~90 °C was observed for the sample at all time points.
The IMC-PVP sample stored at 50 °C/0% RH also showed a gradual increase in
the glass transition temperature over time. The IMC-PVP sample stored at 40 °C/57% RH
showed a decrease in glass transition temperature after 1 week of storage. There was no
further decrease in the glass transition temperature of this sample upon further storage,
which suggests that the water content was almost fully equilibrated after 1 week.
Similarly, the IMC-PVP sample stored at 40 °C/75% RH showed a decrease in glass
transition temperature after 1 week of storage with no further decrease in temperature
detected. No melting peaks were observed for any of the IMC-PVP samples stored at
these three conditions.
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Similar to the IMC-PVP amorphous solid dispersion, the NIF-PVP sample stored
at 50 °C/0% RH also showed a gradual increase in the glass transition temperature over
time. The NIF-PVP sample stored at 40 °C/57% RH showed a decrease in glass transition
temperature after 1 week of storage. The glass transition temperature seemed to slightly
increase after 1 month of storage, presumably due to a decrease in water content.
However, the reason for this is unclear because crystallization was not observed for this
sample. Compared with the IMC-PVP sample stored at the same condition, the glass
transition temperature of the NIF-PVP sample was lower at the same time point, which is
presumably due to the hygroscopicity of PVP. When PVP is hydrogen bonded with the
drug, it will not have as much capability to hydrogen bond to water as neat PVP.
Considering that the hydrogen bond between NIF and PVP is not as strong as the
hydrogen bond between IMC and PVP, PVP in the NIF-PVP sample would have more
capability to hydrogen bond to water, which leads to lower glass transition temperatures
in the NIF-PVP sample. The NIF-PVP sample stored at 40 °C/75% RH showed an even
larger decrease in glass transition temperature after 1 week of storage. The glass
transition temperature was not observable after 1 month of storage, probably due to the
large extent of crystallization at that time. A melting peak can be observed for all NIFPVP samples stored at three conditions.
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Figure 6.29. MDSC of 70-30 IMC methyl ester-PVP amorphous solid dispersions stored
at 4 °C/0% RH. The thermograms from top to bottom were collected at time 0, 1 week, 2
weeks, 1 month, 2 months and 6 months (pinhole).

Figure 6.30. MDSC of 70-30 IMC-PVP amorphous solid dispersions stored at 50 °C/0%
RH. The thermograms from top to bottom were collected at time 0, 1 week, 2 weeks, 1
month, 2 months and 6 months (pinhole).
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Figure 6.31. MDSC of 70-30 IMC-PVP amorphous solid dispersions stored at
40 °C/57%RH. The thermograms from top to bottom were collected at time 0, 1 week, 2
weeks, 1 month, 2 months and 6 months (pinhole).

Figure 6.32. MDSC of 70-30 IMC-PVP amorphous solid dispersions stored at
40 °C/75%RH. The thermograms from top to bottom were collected at time 0, 1 week, 2
weeks, 1 month, 2 months and 6 months (pinhole).
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Figure 6.33. MDSC of 70-30 NIF-PVP amorphous solid dispersions stored at 50 °C/0%
RH. The thermograms from top to bottom were collected at time 0, 1 week, 2 weeks, 1
month, 2 months and 6 months (pinhole).

Figure 6.34. MDSC of 70-30 NIF-PVP amorphous solid dispersions stored at
40 °C/57%RH. The thermograms from top to bottom were collected at time 0, 1 week, 2
weeks, 1 month, 2 months and 6 months (pinhole).
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Figure 6.35. MDSC of 70-30 NIF-PVP amorphous solid dispersions stored at
40 °C/75%RH. The thermograms from top to bottom were collected at time 0, 1 week, 2
weeks, 1 month, 2 months and 6 months (pinhole).
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Table 6.1. Glass transition temperatures of 70-30 IMC methyl ester-PVP amorphous
solid dispersions stored at 4 °C/0% RH at different time points.

Time 0
1 week
2 weeks
1 month
2 months
6 months

Hermetic (°C)
19.4
19.2
21.1
22.5
24.1
24.1

Pinhole (°C)
22.9
16.0
16.9
20.5
25.4
21.3

Crystallization
No
No
No
No
No
No

Table 6.2. Glass transition temperatures of 70-30 IMC-PVP amorphous solid dispersions
stored at various conditions at different time points.

Time 0
1 week

50 °C/0% RH
Hermetic Pinhole Crystal
(°C)
(°C)
lization
No
62.4
74.0
No
71.7
74.7

2 weeks

71.4

75.3

1 month

70.7

75.9

2 months

73.0

76.8

6 months

74.3

78.3

No

40 °C 57%RH
Hermetic
Pinhole Crystal
(°C)
(°C)
lization
No
62.4
74.0
No
52.7
74.1
52.8

No

74.4

51.8

No

74.6

50.4

No

74.4

52.0

75.0
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No

40 °C 75%RH
Hermetic Pinhole Crystal
(°C)
(°C)
lization
No
62.4
74.0
No
41.4
74.9
41.1

No

75.2

41.3

No

74.3

39.9

No

76.6

43.7

74.7

No

Yes
Yes
Yes

Table 6.3. Glass transition temperatures of 70-30 NIF-PVP amorphous solid dispersions
stored at various conditions at different time points.

Time 0

50 °C/0% RH
Hermetic Pinhole Crystalli
(°C)
(°C)
zation
63.9
73.4
No

40 °C 57%RH
Hermeti Pinhole Crystalli
c (°C)
(°C)
zation
63.9
73.4
No

40 °C 75%RH
Hermetic Pinhole Crystalli
(°C)
(°C)
zation
63.9
73.4
No

1 week

67.2

73.9

No

44.3

74.4

No

35.3

75.4

Yes

2 weeks

69.0

74.0

No

44.3

74.5

No

35.2

Yes

1 month

70.0

74.8

No

46.1

74.4

No

-

2 months

71.7

76.0

No

46.4

74.9

No

-

63.59/
121.46
124.1

Yes

6 months

72.1

77.6

No

48.3

76.0

No

-

129.3

Yes
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Yes

6.3.2.5 Water Content Determined by TGA
Tables 6.4 - 6.6 list the water contents of the 70-30 IMC methyl ester-PVP, 70-30
IMC-PVP and 70-30 NIF-PVP amorphous solid dispersions under different storage
conditions at different time points. The water content of the IMC methyl ester-PVP
amorphous solid dispersion decreased slightly over time, presumably due to the storage
over desiccants. The same trends were observed for IMC-PVP and NIF-PVP amorphous
solid dispersions stored over desiccants. These results are consistent with the
observations of slightly increased glass transition temperatures over storage time for
these samples. The IMC-PVP and NIF-PVP amorphous solid dispersions stored in
humidity chambers showed various degrees of water absorption; the amount of water
absorption is consistent with the humidity levels in each chamber. As discussed in the
previous section, the NIF-PVP amorphous solid dispersions absorbed more water than the
IMC-PVP amorphous solid dispersions at each time point under the same storage
condition, indicating lesser degree of hydrogen-bonding interactions in NIF-PVP
amorphous solid dispersions compared with IMC-PVP amorphous solid dispersions.
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Table 6.4. Water content of 70-30 IMC methyl ester-PVP amorphous solid dispersion at
various time points.

Time 0
1 week
2 weeks
1 month
2 months
6 months

Weight Loss (%)
1.5
1.6
0.9
0.8
0.4
0.4

Table 6.5. Water contents of 70-30 IMC-PVP amorphous solid dispersions stored at
different conditions at various time points.

Time 0
1 week
2 weeks
1 month
2 months
6 months

50 °C dry
0.8
0.2
0.3
0.0
0.1
0.2

40 °C 57%RH
0.8
2.0
1.8
1.8
1.9
1.9

40 °C 75%RH
0.8
3.2
3.2
3.4
3.5
3.0

Table 6.6. Water contents of 70-30 NIF-PVP amorphous solid dispersions stored at
different conditions at various time points.

Time 0
1 week
2 weeks
1 month
2 months
6 months

50 °C dry
0.8
0.4
0.5
0.4
0.3
0.3

40 °C 57%RH
0.8
3.2
3.1
2.9
2.7
2.6
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40 °C 75%RH
0.8
4.6
5.2
5.8
4.5
5.4

6.3.3

Analysis of Stability Samples by Solid-State NMR Spectroscopy
Figures 6.36 - 6.42 show the CPMAS NMR spectra of the 70-30 IMC methyl

ester-PVP, 70-30 IMC-PVP and the 70-30 NIF-PVP amorphous solid dispersions stored
at various conditions. Similar to the results obtained from PXRD, no crystallization peaks
were seen in the spectra of IMC methyl ester-PVP amorphous solid dispersions, the IMCPVP amorphous solid dispersion stored at 50 °C/0% RH and that stored at 40 °C/57%RH
for up to 6 months. However, polarized light microscopy suggested that there might be a
limited amount of crystallites on the surface of the particles for the sample stored at
40 °C/57%RH for 6 months. For this reason, a CPMAS spectrum was collected with a 1H
T1ρ filter of 40 ms to selectively detect more crystalline signals. This spectrum is shown
in Figure 6.43. There are no obvious crystalline peaks in the spectrum (Figure 6.43b),
suggesting the crystallinity is too low for the detection of solid-state NMR, or that the
crystallites had a shorter 1H T1ρ value that was similar to the amorphous form.
Crystallization peaks were seen as shoulders at 179.7 ppm, 136.5 ppm, 113 ppm
and 98 ppm in the IMC amorphous solid dispersion after storage at 40 °C/75%RH for 2
and 6 months. Crystallization was observed after 1 month of storage from the PXRD
diffractogram. This might suggest that PXRD is a better technique in detecting
crystallization, however, a CPMAS spectrum collected with a 1H T1ρ filter of 40 ms
revealed crystallization in the sample after storage of 1 month (Figure 6.44). Figure 6.44b
shows crystalline peaks in the dispersion that corresponds to those in γ-indomethacin.
Peaks at 43 ppm and 32 ppm are residual signals from PVP.
No crystallization peaks were seen in the CPMAS NMR spectra of the NIF
amorphous solid dispersions stored at 50 °C/0% RH and at 40 °C/57%RH for up to 6
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months, agreeing with the PXRD data. Since polarized light microscopy suggested that
there might be a limited amount of crystallites on the surface of the particles for the
sample stored at 40 °C/57%RH for 6 months, a CPMAS spectrum was collected with a
1

H T1ρ filter of 40 ms to selectively detect more crystalline signals. This spectrum is

shown in Figure 6.45. The narrow peaks at 170.5 ppm, 168.6 ppm, 103.4 ppm, 101.8 ppm
and 19.7 ppm indicated crystallinity in the sample. As is seen from Figure 6.45e, two
small crystalline peaks at 170.5 ppm and 168.6 ppm in the carbonyl region corresponded
to the α polymorph. This was not detected by PXRD or the regular CPMAS NMR
spectrum.
Crystallization peaks were seen in the spectrum of the NIF amorphous solid
dispersion stored at 40 °C/75%RH for just 1 week. The carbonyl region of the spectrum
showed that the crystalline peaks were a mixture of the α and β polymorphs (Figure 6.46).
The spectra between 163 and 173 ppm of all time points were fitted by a linear
combination of reference spectra of the amorphous, the α and the β forms using least
square procedures with MATLAB (MathWorks, Natick, MA). The obtained relative
amount of each species was plotted as a function of the time points and is shown in
Figure 6.47. The figure reveals that both the α and the β forms emerged in the beginning.
The α form steadily increased as the storage time increased, whereas the meta-stable β
form peaked at about 2 weeks of storage time and then converted to the α form. The
overall crystallinity seems to reach a plateau of approximately 90% after 2 months of
storage. A small amount (~ 7%) of the β form was still observed at the end of the 6
months stability study.
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The 1H relaxation times of the three amorphous solid dispersions stored at various
conditions were determined and the differences between the APIs and the polymers were
calculated and normalized with respect to the relaxation times of the APIs. The
normalized differences for each sample are shown in Figures 6.48-6.54.
As suggested by both 1H T1 and T1ρ relaxation time differentials in Figure 6.48,
IMC methyl ester and PVP were intimately mixed when stored up to six months at 4 °C/0%
RH. The 1H T1ρ relaxation times showed differences after 2 months and 6 months that
were close to the 95% confidence intervals, which may suggest the system was
experiencing some degree of immiscibility. The

1

H T1 and T1ρ relaxation time

differentials of the IMC dispersion stored at 50 °C/0% RH were small and within the 95%
confidence intervals, indicating miscibility up to six months of storage (Figure 6.49).
Figure 6.50 shows the normalized relaxation time differentials of the IMC
dispersion stored at 40 °C/57% RH, where the sample seemed to be miscible the entire
storage time as indicated by 1H T1 and T1ρ relaxation times. However, sorbed water can
increase the molecular mobility of amorphous systems and has been shown to possess a
high degree of translational mobility in glassy matrices.77 Thus, sorbed water can act as a
plasticizer and a relaxation sink, resulting in a decrease in 1H relaxation times. Indeed,
this is what is observed for the 1H T1ρ relaxation times in the IMC-PVP amorphous solid
dispersions plotted as a function of water content, as shown in Figure 6.55a. The 1H T1
relaxation time differentials did not change significantly in the range of water content
studied (Figure 6.55b). In the ternary system consisting of IMC, PVP and water, the 1H
T1ρ relaxation of either IMC or PVP is reduced by water, which exists in the vicinity of
both IMC and PVP as loosely bound molecules that have a considerably high degree of
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mobility. The relaxation times of the drug and the polymer essentially reflect the
relaxation times of the drug-water and polymer-water micro domains.
Taylor and coworkers have shown that a 75-25 IMC-PVP amorphous solid
dispersion did not phase separate upon exposure to 94% RH for 84 days at 25 °C.36
However, the conclusion was based on the detection of hydrogen bonding between IMC
and PVP after the moisture was removed from the sample. The result does not necessarily
reflect miscibility with water present. It is known that hydrogen bond formations
generally change as a function of water content in the system, so the hydrogen bonding
interactions between IMC and PVP could be different with and without water.
Nonetheless, the present data show one glass transition temperature and nearly constant
water content for the entire time of storage, indicating a good chance of miscibility in the
system, as phase separation is known to lead to higher water vapor sorption in some
amorphous dispersion systems including the IMC-PVP system.139
Figure 6.51 shows the normalized 1H relaxation time differentials of the IMC
dispersion stored at 40 °C/75% RH. Crystallization of this system was detected after 1
month of storage, which means there had to be some degree of phase separation at that
point. However, the 1H T1 relaxation time seems to suggest miscibility for the entire
storage period, while the 1H T1ρ relaxation times suggest possible immiscibility in the
sample after 1 and 2 months of storage, and definite immiscibility after 6 months of
storage. The detection of immiscibility is most likely due to the fact that crystalline
indomethacin has a much longer relaxation time.
Figure 6.52 shows the normalized 1H relaxation time differentials of the NIF
amorphous solid dispersions stored at 50 °C/0% RH. Similar to the relaxation behaviors
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of the IMC amorphous solid dispersion stored in the same condition, both 1H T1 and T1ρ
relaxation time differentials indicate miscibility for this NIF system. For the NIF system
stored at 40 °C/57% RH, the 1H T1 relaxation time differentials indicated miscibility and
the T1ρ relaxation time differentials indicated borderline miscibility for the entire storage
period (Figure 6.53). Since the NIF amorphous solid dispersion stored at 40 °C/75% RH
showed substantial crystallization after just one week of storage, both 1H T1 and T1ρ
relaxation time differentials for this sample were quite large indicating phase separation
as expected (Figure 6.54).
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Figure 6.36.

13

C CPMAS spectra of 70-30 IMC methyl ester-PVP amorphous solid

dispersion stored at 4 °C/0% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e) 2
months, and (f) 6 months of storage. No crystallization is observed in any spectra.
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Figure 6.37. 13C CPMAS spectra of 70-30 IMC-PVP amorphous solid dispersion stored
at 50 °C/0% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e) 2 months, and (f)
6 months of storage. No crystallization is observed in any spectra.
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Figure 6.38. 13C CPMAS spectra of 70-30 IMC-PVP amorphous solid dispersion stored
at 40 °C/57% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e) 2 months, and (f)
6 months of storage. No crystallization is observed in any spectra.
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Figure 6.39. 13C CPMAS spectra of 70-30 IMC-PVP amorphous solid dispersion stored
at 40 °C/75% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e) 2 months, and (f)
6 months of storage. Crystallization is observed in (e) and (f).
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Figure 6.40. 13C CPMAS spectra of 70-30 NIF-PVP amorphous solid dispersion stored at
50 °C/0% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e) 2 months, and (f) 6
months of storage. No crystallization is observed in any spectra.

197

Figure 6.41.

13

C CPMAS spectra of 70-30 NIF-PVP amorphous solid dispersion stored

at 40 °C/57% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e) 2 months, and (f)
6 months of storage. No crystallization is observed in any spectra.
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Figure 6.42. 13C CPMAS spectra of 70-30 NIF-PVP amorphous solid dispersion stored at
40 °C/75% RH at (a) time 0, (b) 1 week, (c) 2 weeks, (d) 1 month, (e) 2 months, and (f) 6
months of storage. Crystallization is observed in (b), (c), (d), (e) and (f).
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Figure 6.43.

13

C CPMAS spectra of (a) 70-30 IMC-PVP amorphous solid dispersion

stored at 40 °C/57% RH for 6 months, (b) ) 70-30 IMC-PVP amorphous solid dispersion
stored at 40 °C/57% RH for 6 months collected with a 40 ms 1H T1ρ filter, (c) γindomethacin, and (d) α-indomethacin.
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Figure 6.44.

13

C CPMAS spectra of (a) 70-30 IMC-PVP amorphous solid dispersion

stored at 40 °C/75% RH for 1 month, (b) ) 70-30 IMC-PVP amorphous solid dispersion
stored at 40 °C/75% RH for 1 month collected with a 40 ms 1H T1ρ filter, (c) γindomethacin, and (d) α-indomethacin.
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Figure 6.45.

13

C CPMAS spectra of (a) 70-30 NIF-PVP amorphous solid dispersion

stored at 40 °C/75% RH for 1 month, (b) ) 70-30 NIF-PVP amorphous solid dispersion
stored at 40 °C/75% RH for 1 month collected with a 40 ms 1H T1ρ filter, (c) α-nifedipine,
(d) β-nifedipine, and (e) carbonyl region of (b).
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α polymorph

Figure 6.46.

13

β polymorph

C CPMAS spectrum of the carbonyl region of 70-30 NIF-PVP amorphous

solid dispersion stored at 40 °C/75% RH after 1 week.
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Figure 6.47. Crystallization of amorphous NIF in the 70-30 NIF-PVP amorphous solid
dispersion stored at 40 °C/75% RH as a function of time. The circle represents
amorphous NIF; triangle represents the α polymorph; square represents the β polymorph;
and cross represents the total crystallinity (sum of α and β polymorphs).
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Figure 6.48.

Normalized differences of (a) 1H T1 and (b) 1H T1ρ relaxation times

between IMC methyl ester and PVP in the 70-30 IMC methyl ester-PVP amorphous solid
dispersion a function of storage time at 4 °C/0% RH.
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Figure 6.49. Normalized differences of (a) 1H T1 and (b) 1H T1ρ relaxation times between
IMC and PVP in the 70-30 IMC-PVP amorphous solid dispersion a function of storage
time at 50 °C/0% RH.
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Figure 6.50. Normalized differences of (a) 1H T1 and (b) 1H T1ρ relaxation times between
IMC and PVP in the 70-30 IMC-PVP amorphous solid dispersion a function of storage
time at 40 °C/57% RH.
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Figure 6.51. Normalized differences of (a) 1H T1 and (b) 1H T1ρ relaxation times between
IMC and PVP in the 70-30 IMC-PVP amorphous solid dispersion a function of storage
time at 40 °C/75% RH.
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Figure 6.52. Normalized differences of (a) 1H T1 and (b) 1H T1ρ relaxation times between
NIF and PVP in the 70-30 NIF-PVP amorphous solid dispersion a function of storage
time at 50 °C/0% RH.
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Figure 6.53. Differences of (a) 1H T1 and (b) 1H T1ρ relaxation times between NIF and
PVP in the 70-30 NIF-PVP amorphous solid dispersion a function of storage time at
40 °C/57% RH.
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Figure 6.54. Differences of (a) 1H T1 and (b) 1H T1ρ relaxation times between NIF and
PVP in the 70-30 NIF-PVP amorphous solid dispersion a function of storage time at
40 °C/75% RH.
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Figure 6.55. Dependence of (a) 1H T1ρ relaxation time, and (b) 1H T1 relaxation time on
water content for the 70-30 IMC-PVP amorphous solid dispersion.
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6.3.4

Dissolution Studies
Dissolution profiles of the IMC-PVP and NIF-PVP amorphous solid dispersions

at time 0 and after 6 months of storage are shown in Figures 6.56 and 6.57. As shown in
Figure 4.56, the fresh IMC amorphous solid dispersion exhibited a very quick
supersaturation and achieved a concentration of approximately 8 μg/mL before
precipitation occurred. The final concentration after 4 hours was 4.5 μg/mL. The
dispersion after 6 months of storage at 50 °C/dry achieved a lower supersaturation value
of about 6 μg/mL before declining to about 3.4 μg/mL. The dispersion after 6 months of
storage at 40 °C/57% RH achieved a much lower supersaturation value of 3.4 μg/mL
before precipitation and had a final concentration of 2.4 μg/mL. The dispersion after 6
months of storage at 40 °C/75% RH did not exhibit prominent supersaturation but the
final concentration was 3.1 μg/mL.
Comparing Figure 6.57 with 6.58, we can see that the NIF amorphous solid
dispersions did not exhibit any super saturation expected from the dissolution of an
amorphous solid dispersion. This could be due to the slow wetting of the particles. It is
observed that the particles floated on top of the dissolution medium for a longer period of
time compared with the IMC amorphous solid dispersions. The amorphous solid
dispersions of NIF achieved a final drug concentration equivalent to that of dissolution of
the crystalline α form. This suggests that the rate limiting step in this dissolution process
was probably wetting of the particles, which also explains why the there was no
difference in the dissolution profiles among all the samples including the sample that was
mostly crystalline (sample stored at 40 °C/75% RH for six months).
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Figure 4.56. Dissolution profiles of 70-30 IMC-PVP amorphous solid dispersion at time
0 and after storage for 6 months. The shaded area represents the standard deviation (n=3).
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Figure 6.57. Dissolution profiles of 70-30NIF-PVP amorphous solid dispersion at time 0
and after storage for 6 months. The shaded area represents the standard deviation (n=3).
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6.3.5

Implications of Miscibility, Hydrogen Bonding and Mobility on Physical

Stability
Out of the three different amorphous systems and seven total conditions under
study, all three systems stored in the dry condition remained completely amorphous after
6 months. The storage temperatures corresponded to, on average, 18 °C, 22 °C, and 20 °C
below their respective midpoint glass transition temperatures. Also, all three systems
were miscible by MDSC and solid-state NMR 1H relaxation time measurements. The
IMC and NIF systems stored at 40 °C/57% RH also remained amorphous after 6 months
as detected by PXRD and regular CPMAS NMR spectra. However, the NIF system
stored at 40 °C/57% RH for 6 months did show a very small amount of crystallization as
detected by a CPMAS spectrum with a 1H T1ρ filter. These storage temperatures
corresponded to 12 °C and 6 °C below the respective midpoint glass transition
temperatures. The IMC and NIF systems stored at 40 °C/75% RH are the only two
samples that showed significant crystallization at some points during storage. Their
storage temperatures before substantial crystallization occurred corresponded to 1 °C
below and 5 °C above the respective midpoint glass transition temperatures. The IMC
system was first observed to crystallize after 1 month of storage, while the NIF system
was first observed to crystallize after only 1 week of storage and it also exhibited higher
degree of crystallinity.
From the above observations, a few conclusions can be drawn. First, miscible
systems with limited mobility are relatively stable for long periods of time. This is
demonstrated by all three systems stored in the dry conditions, despite their differences in
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forming hydrogen bonds between the API and the polymer. A number of studies have
demonstrated the correlation between the crystallization rates or onsets of amorphous
pharmaceuticals and their molecular mobilities.111,

132, 140

Kothari et al. showed a

correlation between the crystallization rates of three model systems and their α-relaxation
times measured by dielectric spectroscopy.140 The present data also suggest good physical
stability in amorphous systems with limited translational mobilities.
Second, molecular mobility gained by the absorption of water vapor negatively
influences the physical stability of amorphous solid dispersions. The IMC and NIF
systems that were stored close to or above their respective glass transition temperatures
(40 °C/75% RH) crystallized within 1 month of storage. Sorbed water has shown to
markedly increase the molecular mobility of amorphous excipients such as PVP.77
Combined with the plasticizing effect, sorbed water increased the molecular mobilities of
the samples stored at 40 °C/75% RH in the current study and resulted in crystallization of
these samples.
Third, the physical stabilities of systems that are initially miscible but gain
considerable mobility via water sorption during storage are influenced by the specific
interactions between the API and the polymer. This is demonstrated by the IMC and NIF
systems stored at 40 °C/75% RH, where a stronger hydrogen bonding interaction exists
between IMC and PVP than that between NIF and PVP, and the NIF system crystallized
at a much faster rate. Drug-polymer interaction has been found to enhance the inhibition
of crystallization of amorphous drugs.141,

142

Mistry et al. correlated the delay of

crystallization onset temperature of ketoconazole solid dispersions with reduced
molecular mobilities and stronger drug-polymer interactions.142 In the present study, the
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stronger interaction between IMC and PVP is also reflected in the differences in water
vapor sorption behaviors of the two systems, where the IMC system adsorbed less water
and showed higher glass transition temperatures compared to the NIF system. A stronger
API-polymer interaction is expected to result in a reduced water vapor sorption for a
hydrophobic API, due to a decrease in the availability of the percentage of the polymer
that can uptake water. Physical mixtures have been shown to adsorb considerably higher
amounts of water compared to their amorphous solid dispersions for this reason.139

6.4 Conclusions
In this study, miscible amorphous solid dispersions of 70-30 IMC-PVP, 70-30
NIF-PVP and 70-30 IMC methyl ester-PVP were studied under three different storage
conditions by a combination of techniques. All three amorphous systems that were stored
dry and about 20 °C below their respective glass transition temperatures remained
miscible and completely amorphous after 6 months. The IMC system stored at 40 °C/57%
RH remained miscible and did not crystallize after 6 months, but the system stored at
40 °C/75% RH crystallized after 1 month of storage. The NIF system stored at 40 °C/57%
RH seemed to be borderline miscible for the entire storage period, and showed a very
small amount of crystallinity after 6 months of storage. The crystallization was not
detected by PXRD but was detected by a CPMAS NMR spectrum acquired with a 1H T1ρ
filter. The NIF system stored at 40 °C/75% RH crystallized after only 1 week. The study
showed that both molecular mobility and hydrogen bonding interactions played a role in
the physical stability of miscible amorphous solid dispersions. While storage below the
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glass transition temperature is very important, strong hydrogen bonding interactions can
delay the onset of crystallization.

Copyright © Xiaoda Yuan 2015
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Chapter 7. Conclusions and Future Directions

Amorphous solid dispersions have emerged as one of the leading enabling
strategies to increase the oral bioavailability of poorly water-soluble compounds in
pharmaceutical development. However, one reservation about the use of amorphous solid
dispersions is their long-term physical stability. Crystallization of the amorphous API can
occur during storage if not properly stabilized, resulting in lowering of bioavailability.
For the amorphous API to be properly stabilized, it has to form a miscible, single phase
amorphous system with a suitable excipient. Specific interactions between the API and
the excipient will contribute to the miscibility of the two components and the overall
physical stability of the system against phase separation and crystallization.
Phase homogeneity is a prerequisite in forming stable amorphous solid
dispersions. Conventional methods such as DSC often fail to adequately determine the
miscibility and phase homogeneity. In this research, a method that can detect miscibility
on the nanometer scale using solid-state NMR 1H relaxation times was tested on
nifedipine and PVP amorphous systems (Chapter 3). This method successfully
differentiated miscible, partially miscible and immiscible systems, where DSC was
unable to determine any differences between them.
Specific interactions such as hydrogen bonding interactions of amorphous
pharmaceuticals have been proposed as a way of stabilizing amorphous solid dispersions.
Previous studies using IR spectroscopy have detected interactions between drugs and
polymers, but not at a quantitative level. Quantitative understanding of molecular-level
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interactions in amorphous solid dispersions is of great interest both intellectually and
practically, because when such interactions exist between the API and the excipient,
better miscibility between the two may result. In Chapter 4, a novel method was
developed to identify and quantify various hydrogen bonding interactions in a model
amorphous API indomethacin and its amorphous solid dispersions using
NMR spectroscopy. The method employed single-site

13

13

C solid-state

C isotopic labeling, spectral

subtraction and simultaneous spectral fitting. The study of amorphous indomethacin
unraveled new information regarding the molecular interactions of this well-studied
molecule, identifying the existence of carboxylic acid cyclic dimers, disordered
carboxylic acid chains and carboxylic acid-amide complexes. The relative percentages of
these species were determined to be 59%, 15% and 19%, respectively. The remaining 7%
was ascribed to free indomethacin molecules not involving in any hydrogen bonds.
Indomethacin monomer and dimer were found to be at equilibrium above 50 °C in a 1%
(wt) dispersion with polystyrene. Thermodynamic parameters of indomethacin
dimerization through the carboxylic acids were calculated. The study also quantitatively
tracked the percentage of each species when different concentrations of polymer PVP or
PVP/VA were present in the amorphous solid dispersions. At between 30% and 40% (wt)
PVP, no carboxylic acid dimers and very few carboxylic acid chains could be detected.
The result provides evidence of the predictive power of this approach, since cyclic dimers
are present in both crystalline forms and the elimination of this species in the amorphous
state would effectively inhibit nucleation and crystallization if molecular mobility is
being limited.
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Besides miscibility and specific interactions, molecular mobility adds another
dimension important for physical stability of amorphous solid dispersions. Mobility plays
a crucial role in nucleation and crystal growth from the amorphous state. For this reason,
a supercooled liquid above Tg typically sees a much higher crystallization rate than a
glass. In Chapter 5, molecular motions of amorphous indomethacin and indomethacin
amorphous solid dispersions were studied via 2D exchange NMR experiments.
Indomethacin carboxylic acid cyclic dimers were found to exchange with carboxylic
acid-amide complexes or free carboxylic acids in these systems. Disordered carboxylic
acid chains were not found to exchange with the other species. Despite an increase in
molecular mobility above the glass transition temperature, the API and the polymer were
found to undergo similar motional processes in a 1% (wt) indomethacin-polystyrene
amorphous solid dispersion.
Using the analytical tools and knowledge developed from Chapters 3, 4 and 5, the
physical stabilities of three miscible amorphous solid dispersions with different degrees
of hydrogen bonding capabilities between the API and the polymer were tested at various
storage conditions that reflect different molecular mobilities. All three amorphous
systems, when stored in a condition that limited their molecular mobilities, remained
completely amorphous after 6 months despite the varying hydrogen bonding capabilities
among them. The two amorphous systems stored at 40 °C/75% RH, which allowed a
higher degree of molecular motions within the system, both crystallized but at different
times. The nifedipine-PVP system crystallized after only 1 week of storage, while the
indomethacin-PVP system crystallized after 1 month of storage. Besides their different
intrinsic crystallization tendencies, the ability to form stronger hydrogen bonds between
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indomethacin and PVP is likely the reason for the delayed onset of crystallization
observed.
Due to the complexity and the vast scope of amorphous pharmaceutical systems,
many avenues of possible research were left unexplored in this dissertation. In particular,
how do solid-state NMR relaxation times relate to the other techniques that can measure
relaxation processes, such as dielectric spectroscopy or dynamic mechanical analysis?
Granted that each of these techniques measures different relaxation processes, the
ultimate goal is to infer a physical meaning from these relaxation parameters. In this
dissertation, the solid-state NMR relaxation times being studied were 1H T1 and T1ρ
relaxation times, which are suitable for detecting phase homogeneities but less useful in
measuring molecular mobilities, due to the fast 1H spin diffusion that averages out all
motional processes. 13C T1ρ, on the other hand, is less affected by motional averages and
is likely to provide more information on the local motions of an amorphous system. It
would be very interesting to compare 13C T1ρ relaxation times with other techniques, and
use it to study the mobility of amorphous pharmaceutical systems in the glassy state,
which is most relevant to the physical stability of practical concern because most
amorphous formulations will be stored as glasses.
Another important question relating to amorphous pharmaceutical systems is how
water affects the physicochemical properties of the system, including the API and the
excipients. The ubiquitous nature of water makes it a very important factor to consider
when dealing with amorphous systems. The preliminary studies included in the
appendices showed that different types of API-water interactions were likely to exist in
an amorphous solid dispersion. 1H T2 relaxation time is thought to be very sensitive to
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water and has been used to elucidate the dynamics of water in food materials. It would be
a very valuable tool if applied to pharmaceutical amorphous dispersion systems to help
understand the interactions with water, and eventually the physical stability with water
present.

Copyright © Xiaoda Yuan 2015
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Appendix A. Investigate the Effects of Water on Hydrogen Bonding Interactions of
Indomethacin-Poly(Vinylpyrrolidone) Amorphous Solid Dispersions

A.1 Introduction
The ubiquitous nature of water makes it an important factor to consider in
pharmaceutical development, especially in amorphous solid dosage forms. It is well
known that water absorbed by amorphous solids can act as a plasticizer and lower the
glass transition temperature of the system.33 Consequently, sorbed water has been shown
to increase the crystallization rates of neat amorphous drugs and amorphous drugs in
solid dispersions with polymers.34, 35, 134 Taylor and co-workers studied the drug-polymer
interactions of several drug-polymer systems in the presence of moisture using IR
spectroscopy and found that sorbed water disrupted the drug-polymer interactions in
some systems but not others.36 Thus it was hypothesized that crystallization of
amorphous drugs in solid dispersions in the presence of moisture can occur from either a
one-phase miscible system or a moisture-induced, phase-separated system.
Previously in Chapter 4, a method was developed to quantify various hydrogen
bonding interactions between a model compound indomethacin and PVP using solid-state
NMR spectroscopy. Thus, it is of interest of this chapter to quantitatively investigate the
effect of sorbed water on the hydrogen bonding interactions between indomethacin and
PVP in amorphous solid dispersions.
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A.2 Materials and Methods
A.2.1 Materials
Indomethacin (minimum purity 99%) was purchased from Sigma-Aldrich (St
Louis, MO).

13

C isotopically labeled indomethacin (99%

13

C at carboxyl carbon) was

custom synthesized by Chemtos (Austin, TX). PVP (Kollidon® 25, Mw=28-34 kg/mole)
was obtained from BASF (Edison, NJ). The polymers was vacuum dried at 70 °C
overnight and stored over DrieriteTM at all times. Potassium carbonate (K2CO3) was
purchased from Alfa Aesar (Wardhill, MA). Sodium bromide (NaBr) and sodium
chloride (NaCl) were purchased from EMD Chemicals (Gibbstown, NJ). The chemical
structures of indomethacin and PVP are shown in Figure A.1.

Figure A.1. Chemical structures of (a) indomethacin and (b) PVP.

A.2.2 Preparation of Amorphous Samples with Different Water Contents
Amorphous solid dispersions of indomethacin and PVP were prepared by
cryomilling followed by melt quenching with liquid nitrogen. Samples of both natural
abundance and 13C isotopically enriched (3% wt) were prepared. 1 g of drug and polymer
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in the weight ratio of 8:2 and 7:3, respectively, was cryomilled at 10 Hz (SPEX
SamplePrep 6770 Freezer/Mill, SPEX SamplePrep LLC., Metuchen, NJ) for five cycles.
Each cycle contained 2 minutes of milling and 2 minutes of cool down. Liquid nitrogen
was used as coolant. The cryomilling procedure was used to ensure the optimum mixing
between drug and polymer prior to melting. The amorphous solid dispersions were
prepared by melting the aforementioned cryomilled mixtures of indomethacin and PVP in
an oil bath at 170 °C for approximately five minutes until melt. The sample was stirred
during heating with a spatula to ensure mixing. The sample was then quench cooled using
liquid nitrogen. The solidified glass was ground with mortar and pestle. It was then
sieved and particles with a size range of 45-300 μm were retained.
The prepared amorphous samples were stored over various saturated salt solutions
to achieve various water contents. Saturated salt solutions of potassium carbonate (43%
RH), sodium bromide (60% RH) and sodium chloride (75% RH) were used to control the
relative humidity. The amorphous solid dispersion sample was stored over the saturated
salt solutions for a period of 5-16 days at 4 °C. The water content was determined using
TGA (Q50, TA Instruments, New Castle, DE). Solid-state NMR experiments of these
samples were conducted at -20 °C.

A.2.3 Solid-State NMR Experiments
All solid-state NMR spectra were acquired using a Tecmag Redstone HF3 2RX
spectrometer (Tecmag, Inc., Houston, TX), operating at 75.48 MHz for 13C. Experiments
were performed using a 7.5 mm double-resonance MAS probe (Varian, Palo Alto, CA).
All

13

C spectra were acquired under magic angle spinning (MAS)43 at 4 kHz, using
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ramped-amplitude CP,45 total sideband suppression (TOSS)44 and SPINAL64
decoupling73 with a 1H decoupling field of about 62 kHz. A 2 ms contact time was used
in all experiments. 3-Methylglutaric acid was used to optimize spectrometer settings and
was used as an external standard, with the methyl peak referenced to 18.84 ppm.74 A
pulse delay of 5 s was used. All experiments were conducted at -20 °C. The data were
zero-filled to 4096 points with no line-broadening.
Spectral subtraction was performed between the labeled and natural abundant
samples as detailed in Chapter 4. After the subtraction, spectra of each dispersion system
(80-20 IMC-PVP and 70-30 IMC-PVP) in the region of 160-190 ppm were fitted
simultaneously by appropriate number of Gaussian functions, each representing a
carboxylic acid species using MATLAB (MathWorks, Natick, MA). The details of the
fitting procedure are explained in the results section.

A.3 Results and Discussion
In Chapter 4, the 80-20 IMC-PVP amorphous solid dispersion were fitted with
four peaks, namely the dimer, chain, the carboxylic acid-amide complex and the free
carboxylic acid. Besides those species, the 80-20 IMC-PVP amorphous solid dispersion
with sorbed water should in theory has at least one more peak representing the carboxylic
acid-water interaction. Since the free carboxylic acid only accounted for a very small
percentage, it was neglected in the analysis. Thus, the spectra were fitted by four peaks,
each representing the dimer, chain, the carboxylic acid-amide complex and the carboxylic
acid-water complex. The chemical shifts and linewidths of the dimer, chain and the
carboxylic acid-amide complex were fixed to the values obtained in Chapter 4. A new
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peak was allowed to be determined from the simultaneous fitting to represent the
carboxylic acid-water interactions. This peak was fitted with a chemical shift of 173.8 ±
0.04 ppm and a linewidth of 211 ± 5 Hz. The fitted spectra are shown in Figure A.2.
Since the 70-30 IMC-PVP amorphous solid dispersion was determined to be
consisted mostly of carboxylic acid chains and the carboxylic acid-amide complexes
(Chapter 4), the 70-30 IMC-PVP amorphous solid dispersions with sorbed water were
fitted with these two species and a new species representing the carboxylic acid-water
interaction. However, three peaks were not adequate to described all of features of the
spectra. As a result, two peaks had to be used to adequately fit the spectra. The chemical
shifts and the linewidths of the carboxylic acid chain and the carboxylic acid-amide
complex were fixed to the values obtained in Chapter 4. The chemical shifts and the
linewidths of the two new fitted peaks are 173.1 ± 0.09 ppm and 208 ± 7 Hz, and 174.3 ±
0.09 ppm and 443 ± 4 Hz, respectively. The peak at 173.1 ppm is ascribed to the
carboxylic acid hydrogen bonded to both an amide and a water molecule, while the peak
at 174.3 is ascribed to the carboxylic acid hydrogen bonded to water. The former type of
interaction is named Type I interaction and the latter Type II interaction. Some of the
possible arrangements for these two types of carboxylic acid-water interactions are
illustrated in Figure A.4.
Figure A.5 shows the percentages of the indomethacin hydrogen bonding species
in 80-20 and 70-30 IMC-PVP amorphous solid dispersions as a function of water content.
The general trend observed is that the carboxylic acid-amide complex decreases as the
water content increases. The dimer and chain are not influenced as much as the
carboxylic acid-amide complex. At the same time the carboxylic acid-water interaction
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increases. For the 70-30 IMC-PVP amorphous solid dispersions, the Type I carboxylic
acid-water interaction seems to reach a plateau at approximately 1.6 (wt) % of water,
while the Type II carboxylic acid-water interaction continues to increase as water content
increases.
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Figure A.2. CPMASS 13C spectrum of IMC carboxylic acid carbon in a 80-20 IMC-PVP
amorphous solid dispersion with (a) 0.2 % water, (b) 1.2 % water and (c) 1.6% water
(wt %). The experimental spectrum is shown in black; the fitted peaks representing each
species are shown in red; the sum of the fit is shown in green; the residual difference
between the experimental and fitted peaks is shown in blue.
231

Figure A.3. CPMASS 13C spectrum of IMC carboxylic acid carbon in a 70-30 IMC-PVP
amorphous solid dispersion with (a) ~0% water, (b) 0.7% water, (c) 1.7% water, (d) 2.5%
water and (e) 3.6% water (wt %). The experimental spectrum is shown in black; the fitted
peaks representing each species are shown in red; the sum of the fit is shown in green; the
residual difference between the experimental and fitted peaks is shown in blue.
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a

b

Figure A.4. Illustrations of (a) carboxylic acid-amide-water (Type I) and (b) carboxylic
acid-water (Type II) interactions.
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Figure A.5. Fraction of IMC carboxylic acid participating in various hydrogen-bonding
interactions in the (a) 80-20 IMC-PVP and (b) 70-30 IMC-PVP amorphous solid
dispersion as a function of water content. The error bars indicate the 95% confidence
intervals. Curves are drawn as a guide to the eye.
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A.4 Conclusions
Indomethacin was found to interact with sorbed water in the amorphous solid
dispersions with PVP. The carboxylic acid-amide complex was found to be displaced by
the carboxylic acid-water complex as the water content increased in the 80-20 IMC-PVP
amorphous solid dispersions. In the 70-30 IMC-PVP amorphous solid dispersions, two
possible types of carboxylic acid-water interactions were identified. One type involved
indomethacin interacting with both an amide and the water molecule(s). The other type
only involved the indomethacin and water. Similar to the 80-20 IMC-PVP system, it was
found that the carboxylic acid-amide complex was gradually displaced by the two types
of carboxylic acid-water interactions as the water content increased in the 70-30 IMCPVP system.

Copyright © Xiaoda Yuan 2015
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